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ABSTRACT 
The increasing demand for organs has stimulated the necessity in xenotransplantion, 
which promises an unlimited supply of organs for clinical use. However, 
coagulopathy of xenografts remains a major hurdle to successful pig-to-primate 
xenotransplantation. The ability to generate pigs expressing a human complement-
regulatory protein (hCRP) and/or pigs in which the α1,3-Galactosyltransferase gene 
has been knocked-out (GT-KO) has largely overcome the barrier of hyperacute 
rejection (HAR) of a pig organ transplanted into a primate. However, acute humoral 
xenograft rejection (AHXR), presenting as microvascular thrombosis with/without 
consumptive coagulopathy (CC), ensures and results in graft failure. 
 
The causes of coagulopathy were believed to be humoral response-dependent. 
Xenoreactive antibodies (Abs) and activation of complement provoke porcine 
endothelial cells (ECs) from an anticoagulant to a procoagulant phenotype. In this 
study, I demonstrated that recipient platelets and monocytes were activated to express 
tissue factor (TF), an initiator of the coagulation cascade, after incubation with porcine 
ECs through humoral immune response-independent process. These observations 
were mirrored in the animal studies. Kidneys or livers from GT-KO pigs that express 
a hCRP transplanted into nonhuman primates were not susceptible to HAR. 
Nevertheless, most recipients developed CC, even when the grafts were still 
functioning. Activation of graft ECs and the measurable immune response were 
minimal. TF expression on recipient platelets plays a pivotal role in initiating CC. 
Therefore, understanding the interactions between porcine ECs and primate platelets 
may be crucial to prevent coagulopathy. On the other hand, the generation of GT-KO 
pigs has directed interest to the role of anti-nonGal Abs in intravascular thrombosis. 
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My study revealed that anti-nonGal Abs activated porcine ECs to express TF, 
independent of complement activation. 
 
I also demonstrated that anti-P-selectin and vWF Abs and some anti-platelet agents, 
such as clopidogrel and eptifibatide, prevented TF expression on platelets after 
incubation with porcine ECs. Porcine ECs from pigs that expressed tissue factor 
pathway inhibitor (TFPI) were resistant to the activation induced by primate serum 
even with high titre anti-nonGal Abs. Atorvastatin not only inhibited this activation of 
platelets but also prevented the activation of porcine ECs induced by primate serum.  
 
Coagulopathy is increasingly recognized as barriers to successful xenotransplantation, 
many mechanisms of which are not associated with humoral immune response. 
Further manipulation of the immune response alone, with the risk of inducing 
infection and other complications, does not appear likely to resolve the challenge of 
xenograft coagulopathy. My results provide evidence for further genetic manipulation 
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CHAPTER 1 
                 INTRODUCTION 
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1.1 ORGAN SHORTAGE  
 
1.1.1 Progress of organ transplantation         
Since the first kidney transplantation was performed in 1954 between identical twins 
(Merrill et al., 1956), organ transplantation has emerged as a definite treatment for many 
end-stage organ diseases. In the past decades, the 5-year survival rates of patients 
increased to over 80% in kidney, and 70% in liver and heart transplantation in the USA 
(Sayegh and Carpenter, 2004). At the end of 2002 in the USA, 150,000 people lived with 
functioning solid-organ allografts, up from 62,000 in 1993 (www.ustransplant.org). 
  
1.1.2 Organ demand and shortage  
The success of organ transplantation has dramatically increased the discrepancy between 
organ demand and supply. In the USA, the number of patients on the waiting list for 
transplantation increased from 37,252 to 98,236 between 1993 and 2007. At the same 
time, the number of donors just increased from 14,638 to 28,231 (www.ustransplant.org). 
In Asian countries, the gap is more critical because the organ donation rate is much lower 
than that in western countries (de Villa et al., 2003). The ever-growing deficiency of 
donors has stimulated the necessity of alternative organ resources, such as living donors, 
marginal donors, or organs from other species.          
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1.1.3 Expanded organs (marginal organs) 
One innovative way to increase the number of deceased donors is to use the organs from 
expanded criteria donors or donors after cardiac death. However, these transplants are 
often associated with inferior outcomes and higher costs. Moreover, although a great 
effort has been devoted to maintain the organs after cardiac arrest, organs from donors 
after cardiac death still remain scarce (D'Alessandro et al., 2008). Another way is to use 
deceased donors with certain types of infections, such as hepatitis B and C.  This also puts 
the recipients in a risk of overwhelming infection and even mortality. The expanded use 
of marginal organs raises potential ethical considerations about appropriate recipient 
selection and the high cost of medical care (Pomfret et al., 2008). 
1.1.3.1  Living donors   
The use of kidneys from living donors significantly shortens the waiting time and 
provides better patient and graft survivals, compared to deceased donor transplantation 
(Davis and Delmonico, 2005). In the USA, the number of live kidney donors has 
surpassed the number of deceased donors. However, in the areas where deceased donors 
are few, most centres perform kidney transplantation from live donors. Similarly, living-
donor liver transplantation has rooted from Asian countries .In experienced centres; liver 
transplantation from live donors reduces the waitlist mortality. Post-transplant patient and 
graft survivals are equivalent to those from deceased donors (Chen et al., 2003).  
 
However, living donor donation has entailed a risk to healthy donors.  The mortality rate 
of hepatic lobe donor for liver transplantation is around 0.15-0.2% and the overall 
complication rate is up to 38% although the reasons are not definitely related to donor 
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surgery (Olthoff et al., 2005; Trotter et al., 2006). The overall percentage of live donor 
liver transplants peaked at 10% of the total number of liver transplants performed in 2001. 
Since then, the percentages have reduced to 5% of the total, about 320 each year in the 
USA (www.ustransplant.com).  
 
1.1.4 The necessity of xenotransplantation  
No matter how great an effort has been dedicated, the gap between demand and supply of 
organs is burgeoning and is predicted to remain so. The use of animal organs, 
xenotransplantation, if the immunologic barriers and associated problems could be solved, 
may provide an unlimited alternative to allografts. In the last century, some attempts were 
made to transplant kidneys or livers from primates or non-primate mammals into human. 
The longest survivals of kidney, heart and liver from primate donors were 9 months, 20 
days, and 70 days, respectively (Appel et al., 2002). However, the results from non-
primate organs were dismal, surviving hours rather than days.   
 
1.2 PIGS AS SOURCES OF DONORS  
 From the immunologic perspective, non-human primates would be preferable organ 
donors. However, many of them are endangered species, and the time and expense of 
breeding these animals are also prohibitive. Therefore, the UK Department of Health 
Advisory Group on the Ethics of Xenotransplantation recommended that “it would be 
ethically unacceptable to use primates as source animals for xenotransplantation”. 
Secondly, concerns about the transmission of infectious agents from nonhuman primates 
to humans have been raised, particularly since most non-human primates are either wild-
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caught or have been housed under colony conditions for relatively few generations. 
Furthermore, there is no experience in generating genetically-modified primate animals. 
Instead of primates, pigs are thought the most suitable animals as a source of xenografts 
for human.  
 
1.2.1 Physiology of pig and human  
Pigs emerge as the most suitable source of xenograft organs. They are easily bred with 
sexual maturity within 9 months, gestation of 3.5 months, and litters of 6-16 piglets. 
Furthermore, the physiology and anatomy of organs in adult pigs are similar to adult 
human with life expectancy of approximate 30 years. The hematological and chemistry 
profiles are compatible with those in adult humans and non-human primates (Figure 1.2-




140.1±55.2642±198Alkaline phosphatase (ALP) (U/L)
56.9±42.853.5±13.3Gamma glutamyl transferase (GGT) (U/L)
42.8±15.338.7±15.6Aspartate aminotransferase (AST) (U/L)
75.9±19.234.5±15Alanine aminotransferase (ALT) (U/L)
291± 106297±73Platelets (PLT) (×103/µl) (U/L)
26.6± 3.938.0± 3.3Hematocrit (Hb) (%) 
9.4± 1.112.5±1.0Hemoglobulin (Hb) (mg%)
15.0± 7.18.5±4.4White blood cells (WBC) (×103/µl)
5.1± 0.85.1±0.4Red blood cells (RBC) (×106/µl)
Pigs Baboon Parameters 
 
Figure 1.2-1 Normal values of biochemistry and hematology in baboons and pigs. 
The data were based on 25 baboons and pigs (provided by Dr Echeverri and Ekser). 
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1.2.2 Concerns of zoonosis   
Since the organs from other species are directly implanted into recipients during 
xenotransplantation, pathogens may bypass the natural defenses of hosts, such as skin and 
mucosa, and become infectious to humans. Importantly, the recipients of human require 
receiving extensive immunosuppressive regimens and will become more susceptible to 
pathogens.  These immuno-compromised recipients will serve the seeds for human-to-
human transmission. Some porcine viruses have been identified as pathogens in human.  
One of the most concerns is porcine endogenous retroviruses (PERVs), which are able to 
infect human cell lines in vitro (Patience et al., 1997). Fortunately, recent retrospective 
studies showed no evidence of infection, expression or replication of PERVs in human 
recipients who had exposed to short-term extracorporeal porcine kidney or to porcine 
fetal islets. Recently, a study also revealed there was no evidence by infection of PERVs 
in clinical staff who were involved with the care of patients undergoing extracorporeal 
liver perfusion (Levy et al., 2007).   
 
1.2.3 Genetic modification of pigs  
In order to minimize the immune response between different species, the modification of 
donors that supply xenografts to human offers a unique way to solve the problems which 
are encountered in xenotransplantation. Advances in transgenic manipulation and cloning 
in swine has fulfilled the reality of genetically-modified organs from pigs. Pigs 
overexpressing human complement-regulatory proteins (hCRP) such as CD59, or human 
decay-accelerating factor (DAF, CD55) have suggested that to further modification of 
swine is a practical way to overcome the barriers between swine and primates.  
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1.2.4 Ethics of xenotransplantation  
Non-human primates, such as chimpanzees, have intellectual and social natures, similar to 
humans. They are considered as endangered species as well. Hence, using non-human 
primates as donors raises ethical concerns. In contrast, from the point of view of ethics, 
pigs as xenograft donors raise minimal issues. There are still some other ethical issues 
associated with xenotransplantation. For example, whether the transfer of organs or 
tissues from animals is natural and whether to kill animals to benefit human beings is 
justified remain controversial points.  Nevertheless, the shortage of organs leaves patients 
desperate. This demand stimulates progress in xenotransplantation from the scientific 
point of view.   
 
Taken together, the aforementioned issues indicate that pigs are currently considered the 
most suitable sources of xenografts (Cooper et al., 1993; Elliott et al., 2000; Heneine et al., 
1998) although clinical application of this technique still requires ethical, regulatory, and 
legal frameworks to provide guidelines and to establish a consensus.   
 
1.3 HYPERACUTE REJECTION  
Although pigs are relative ideal animals as donors of xenografts, vigorous immunologic 
rejection by the host’s immune system ensues due to differences between species, 
especially the existence of natural antibodies (Abs). Various types of immunologic 
rejection are categorized according to their reactive times, including hyperacute rejection 
(HAR), acute humoral xenograft rejection (AHXR), and cellular rejection.  
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The most devastating immunologic response faced in pig-to primate xenotransplantation 
is HAR, which is induced by the binding of preformed Abs to the xenograft vascular 
endothelial cells (ECs) within minutes to hours (Perper and Najarian, 1967). The binding 
of xenoreactive Abs (XNA) to donor ECs activates the recipient’s complement system, 
which consequently results in the deposition of C3 and terminal membrane attack 
complex (MAC) on ECs. This reaction leads to shape change and the formation of gaps in 
the absence of cytolysis (Saadi and Platt, 1995).   The loss of integrity of ECs exposes the 
underlying subendothelial matrix, in which there are many potent ligands and substances, 
to trigger the coagulation cascade and platelet aggregation (Yang and Sykes, 2007). 
Meanwhile, the MAC activates ECs to become procoagulant because of increased 
cytosolic calcium and nonlytic secretion of high molecular weight multimers of von 
Willebrand factor (vWF) from intracellular storage granules (Hamilton et al., 1990) and 
the loss of natural anticoagulant properties. These changes trigger the coagulation cascade 
and the activation of platelets to form thrombi.   
 
1.3.1 Loss of anticoagulant properties  
In HAR, the injured ECs become thrombogenic even when they are still alive. C5b-9 
proteins induce vesiculation of ECs and thereby expose a catalytic surface for the 
prothrombinase enzyme complex, contributing to fibrin deposition associated with 
immune EC injury (Hamilton et al., 1990). Moreover, activated ECs lose the capacity of 
natural anticoagulation (Robson et al., 2000). These anticoagulant molecules include 
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thrombomodulin (Ogawa et al., 1990), antithrombin, CD39, and heparan sulfate 
proteoglycan.  
 
Dowregulation of thrombomodulin and antithrombin has been recognized in discordant 
xenografts (Blakely et al., 1994). In vitro studies showed that exposure of porcine aortic 
endothelial cells (PAECs) to human serum caused cleavage and release of proteoglycans 
dependent on activation of the classical complement pathway (Platt et al., 1990).  A few 
years later, an additional thromboregulatory factor, ecto-nucleoside ATP 
diphosphohydrolases (ecto-NAPDases), which is also expressed by quiescent ECs, and 
has the capacity to degrade the extracellular inflammatory mediators, adenosine 
triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate 
(AMP) is lost after ECs are activated. This change promotes platelet activation and 
aggregation and may be crucial for the progression of vascular injury (Robson et al., 
1997). In addition, murine tissue factor pathway inhibitor (TFPI) expression was also 
down-regulated in cytokine-induced peritonitis models (Shimokawa et al., 2000).  
  
These detrimental procoagulant and inflammatory environments result in microvascular 
thrombosis, intravascular occlusion, and ultimate graft loss within minutes to hours after 
reperfusion.  
 
1.3.2 Gal antigen  
The main cause of HAR results from the existence of XNA. The most important one is 
the Ab against the Galα1–3Galβ1–4GlcNAc (Gal) epitope, which accounts for over 85% 
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(Cooper et al., 1993; Galili et al., 1984). The Gal epitope is a common carbohydrate 
structure found in many mammals, and this epitope has been reported to be expressed on 
glycoproteins and glycolipids of different species. In 1988, Galili investigated Gal epitope 
expression in mammals by immunostaining with anti-Gal Abs, and correlated this with 
binding of the lectin Griffonia (Bandeiraea) simplicifolia-IB4 (GS-IB4), which interacts 
with Gal residues. Many cells of non-primate mammals, prosimians and New World 
monkeys are readily bound by both anti-Gal Abs and the GS-IB4 lectin. The Gal epitope 
is synthesized by the enzyme α1,3-galactosyltransferase (α1,3GT) using N-
acetyllactosamine as the sugar acceptor and uridine diphosphate-Gal as the sugar donor. 
However, humans, apes and Old World monkeys (monkeys of Asia and Africa) only 
possess the pseudogene for this enzyme; therefore, they carry anti-Gal Abs that are raised 
in response to antigenic stimulation by Gal epitopes expressed in gastrointenstinal tract 
bacteria (Galili et al., 1987a; Galili et al., 1987b; Galili, 1993). 
 
1.3.3 Depletion of xenoreactive antibodies  
Since Gal Abs play a pivotal role in the pathogenesis of HAR, the activation of XNA 
interaction is critical to avert HAR. Removal of the natural Abs by plasmapheresis is 
effective in preventing HAR but entails some disadvantages, such as marked depletion of 
complement and coagulation proteins. The use in the peri-transplant period therefore is 
limited (Fischel et al., 1990). Nonspecific Ig-binding columns were designed to result in 
90.5 and 86.0% reduction in total IgG and IgM, with the preservation of albumin and 
coagulation proteins. They resulted in prolonged xenograft function in ex-vivo perfusion 
systems (Kroshus et al., 1995) and averted HAR in kidney xenotransplantation models 
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(Leventhal et al., 1995). Gal-specific affinity columns also effectively removed anti-Gal 
Abs and minimized hypogammaglobulinemia in spite of the requirement of multiple 
absorptions (Kozlowski et al., 1998; Watts et al., 2000). However, these modalities can 
only be used temporarily because they require vascular access, real-time separation of 
blood and plasma. Importantly, the production of anti-Gal Abs continues, and near-
normal levels of Abs return rapidly after cessation of immunoabsorption, which leads to 
graft loss. 
 
Another approach is neutralizing anti-Gal Abs by continuous intravenous infusion of 
large amounts of soluble antigens, such as Gal sugar (e.g. GAS914 and TPC) (Katopodis 
et al., 2002; Schirmer et al., 2004; Teranishi et al., 2002). Nevertheless, despite the 
delayed return, anti-Gal Abs are never eliminated and graft rejection is delayed but not 
abrogated.  
 
1.3.4 Genetic engineering to decrease Gal antigen expression  
Since there are a large number of Gal epitopes on pig cells (35×106/cell), the removal or 
inhibition of anti-Gal Abs in primate serum could not effectively prevent humoral 
rejection for a long period of time. The advantage of xenotransplantation is the 
opportunity to modify the donors by genetical engineering.  The ideal way to eliminate 
the Gal antigen in pigs is to generate pigs that lack the expression of Gal epitopes by 
targeting the donor genome.  
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Pigs that express human α 1, 2-fucosyltransferase (H-transferase, HT) were generated in 
an attempt to reduce the expression of Gal epitopes. HT expression modifies the cell 
surface carbohydrate phenotype on pig cells, resulting in the expression of the universal 
donor O antigen and a concomitant reduction in the expression of the antigenic Gal 
epitopes. The significant reduction in the expression of the Gal epitopes reduced XNA 
reactivity, and increased resistance to complement-dependent cytotoxicity (Costa et al., 
1999). Similarly, pigs that expressed the human beta-d-mannoside beta-1,4-N-
acetylglucosaminyltransferase III (GnT-III) gene reduced serum reactivity to Gal epitopes 
by changing the configuration of glycoproteins. EC studies from the GnT-III transgenic 
pigs revealed a significant down-regulation in antigenicity, including the Hanganutziu-
Deicher antigen, and dramatic reductions in both the complement- and natural killer cell-
mediated pig cell lyses. In addition, the effect of GnT-III in down-regulating the 
xenoantigen expression in pig heart grafts was evidenced in an animal study (Miyagawa 
et al., 2001). However, this resulted in only partial reduction in epitope numbers and 
failed to substantially extend graft survival in primate recipients. 
 
1.3.5 GT-KO pigs     
The development of nuclear transfer technology has provided a means for locus-specific 
modification of large animals. It allowed for the development of pigs in which the gene of 
α1,3GT is deleted. By cloning fetal fibroblast cells, which are used as nuclear donors for 
embryos reconstructed with enucleated pig oocytes, heterogenous GT-KO pigs have been 
generated in the early period of this decade (Dai et al., 2002; Lai et al., 2002). To date, 
homozygous GT-KO pigs are available for pig-to-primate animal studies by some groups 
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(Phelps et al., 2003; Sharma et al., 2003). It is worth noting that the deletion of Gal from 
donor organs has been recognized as a major step toward the clinical application of 
xenotransplantation. Transplanting hearts from GT-KO pigs into baboons, the medium 
survival of xenografts was extended up to over 70 days with a co-stimulatory pathway 
blockade-based immunosuppressive regimen (Kuwaki et al., 2005). Meanwhile, in the 
kidney model, the longest survival was extended up to 83 days with the tolerance-
inducing regimens by co-transplantation of vasculized thymic tissue (Yamada et al., 
2005).  
 
The production of homozygous pigs is based on a disruption in the α1,3GT gene, which 
encodes Gal epitope. The concerns have arisen regarding GT-KO pigs as to whether the 
Gal epitope is exclusively produced by the α1,3GT gene. Isoglobotrihexosylceramide 
(iGb3) synthase was shown to be another candidate that synthesizes Gal epitope (Milland 
et al., 2006; Taylor et al., 2003).   Low levels of Gal are still expressed in GT-KO mice in 
the form of a lipid (iGb3), which is produced by iGb3 synthase. Similarly, GT-KO cells 
in pigs have been demonstrated to synthesize the Gal antigen at 1 to 2% of the level of 
control heterozygous cells by flowcytometry (Sharma et al., 2003).  Although GT-KO 
pigs do avert HAR and prolong graft survival, the presence of secondary enzymes, such 
as iGb3 synthase may possibly have implications for long-term graft survival in pig-to 
primate xenotransplantation using GT-KO organs.  
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1.3.6 Complement pathway  
HAR is caused by the rapid binding of terminal complement complexes to the cell 
membranes of the endothelial lining of blood vessels in the donor organ (Cascalho and 
Platt, 2001).  The complement system consists of more than 30 proteins in plasma and on 
cell surfaces. Complement proteins in plasma amount to more than 3g/L and constitute 
approximately 15% of the globulin fraction (Walport, 2001). Complement is part of the 
innate immune system, serves as one of the main effector mechanisms of Ab-mediated 
immunity, and forms the nexus of the innate and adaptive immune systems. Three 
biochemical pathways activate the complement system: the classical complement 
pathway, the alternative complement pathway, and the mannose-binding lectin pathway 
(Figure 1.3-1). 
C las s ic al pathway L ec tin pathway Alternative pathway 
Immune c omplex
Non immune ac tivator 
C 1 (C 1q,C 1r, C 1s ) 
C 4 C 4b C 4b2a
C 2
C 2a
C 3 C 3b













F ac tor BP roperdin




Terminal lytic pathway 
 
Figure 1.3-1 The pathway of complement activation and regulation.  
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(Adapted from Walport MJ, NEJM 2001. Blue: activation; red: regulator and inhibition; 
MBL: mannose-binding lectin; MCP: membrane cofactor protein; DAF: decay-
accelerating factor)   
 
The classical pathway is activated mainly by the immune response and other apoptotic 
cells or pathogens (Walport, 2001). Ab-mediated complement activation is initiated by 
the activation of C1 (which is composed of C1q, C1r and C1s) after the interaction of IgG 
or IgM bound to antigen epitopes. The C1q-binding capacity of human IgG subclasses is 
IgG3, IgG1, IgG2 and IgG4, in decreasing order. Conformational changes in C1q then 
allow cleavage of C1r, and activated C1r cleaves and activates C1s, which is the enzyme 
that activates C2 and C4.  
 
C4 is cleaved by C1s into C4a and C4b. C4b combines with the enzymatically-active 
fragment C2a to form C4b-C2a, which is known as the classical pathway C3 convertase. 
After C3-convertase formation, the classical pathway leads to the common step of C3 
activation, and cleavage to C3a and C3b. When a C3b molecule is covalently deposited in 
the vicinity of the C3 convertase, the form of C5 convertase C4b-C2a-C3b is generated. 
Cleavage of C5 then releases the bioactive peptides C5a, and C5b. C5b initiates formation 
of the MAC (membrane-bound C5b–C6–C7–C8–C9, denoted as C5b–C9), which causes 
cell lysis.  
 
The mannose-binding lectin pathway is initiated by binding of the complex of mannose-
binding lectin, which is found on the surface of some bacteria, yeasts and fungi. This 
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pathway activates the complement by interaction with mannose-binding lectin–associated 
proteases (MASP1, MASP2, MASP3 and small MAP). MASP2 acts in a fashion similar 
to that of C1s to lead to the formation of the C3 convertase enzyme C4b2a. MASP1 may 
be able to cleave C3 directly.  Activation of C3 triggers the alternative pathway loop and 
the formation of MAC (Fujita, 2002). The activation of the alternative pathway does not 
require sensitization and Abs. This pathway involves the participation of C3, factor B, 
factor D and properdin.  In this pathway, C3 undergoes spontaneous cleavage and induces 
binding between factor B and C3b. The C3bB complex is cleaved by factor D, releasing 
the factor B amino-terminal fragment (Ba), and activating the serine protease domain in 
the remaining C3bBb complex. The C3bBb complex can be recognized and stabilized by 
properdin. Dissociation of convertases leads to the irreversible deactivation of the 
catalytic site (Kemper and Hourcade, 2008).  
 
1.3.7 Regulators of the complement system 
Such a powerful complement system requires tight regulation; therefore, cells are 
resistant to complement-mediated lysis. At least three different mechanisms of regulation 
are known (Figure 1.3-1). CD46 was formerly called membrane cofactor protein (MCP) 
and exists ubiquitously, except on erythrocytes (Astier, 2008). Its primary function is to 
protect autologous cells from complement attack. Indeed, it binds to C3b and C4b and 
acts as a cofactor for the protease factor I, allowing the proteolytic cleavage of C3b and 
C4b (Seya and Atkinson, 1989). CD55 (DAF) inhibits formation of the C3 convertases 
through binding to C3b and C4b. It also binds the alternate pathway convertase C3bBb, 
the classical pathway convertase and C4b2a to accelerate their decay (Nicholson-Weller 
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and Wang, 1994). CD59 protects cells from complement-mediated lysis through binding 
C9, inhibiting its incorporation into the C5b-9 complex and preventing the terminal 
polymerization of MAC in plasma membranes (Lachmann, 1991). 
 
1.3.8 Complement system and hyperacute rejection   
Knowledge of the importance of complement and the activation and regulation of its 
pathway shed light on developing strategies to overcome HAR in xenotransplantation. 
The activation of complement resulting in HAR can be attributed to the classical and 
alternative pathway. Depletion of complement by cobra venom factor (CVF) (Leventhal 
et al., 1993) or inhibition by soluble complement receptor type 1 prevents HAR (Pruitt et 
al., 1994). Furthermore, C6-deficiency in rabbits and rats prevents HAR of cat and guinea 
pig kidneys (Zhow et al., 1990). These observations suggested activation of complement 
in HAR is via the classical pathway as a consequence of endothelial binding of XNA.  
However, other studies have demonstrated that HAR could be induced by the 
complement system in the absence of XNA (Johnston et al., 1992), implicating 
involvement of the alternative pathway of complement (Forty et al., 1992). For example, 
in the mouse to human ex vivo combination by depleting C1q or factor D, both the 
classical and alternative pathway was related to the activation of complement to HAR 
(Romanella et al., 1997).  Similar results were also reported in the pig-to-human in vitro 
model (Zhao et al., 1994). 
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1.3.9  Animal studies using a complement inhibitor  
Understanding of the activation of complement leading to HAR encouraged in vivo 
animal studies.  Direct inhibition of complement activity by administering anti-
complement agents to the recipients has been attempted, including sCR1, CVF, FUT-157, 
K76, C3-binding peptide, and anti-C5 monoclonal Abs. The most promising agents are 
sCR1 and CVF.  
 
sCR1 acts to inhibit human complement receptor 1 and has proven to be effective in 
preventing HAR in small animal studies. Based on immunosuppressive therapy with 
cyclosporine, cyclophosphamide and steroid, the addition of sCR1 prolonged the survival 
of porcine cardiac grafts to 11-32 days in monkey, in comparison with 38min in the 
control group (Davis et al., 1996).  CVF is purified from the snake Naja naja kaouthia and 
acts as a complement activating protein to form stable C3/C5 convertase and exhaust the 
complement system.  In the pig-to-primate cardiac xenograft model, CVF extended 
survival from less than 1 hour to medians of 5 days and 12 days, depending on whether 
splenectomy was performed. Dense deposition of IgM and, to a lesser extent, IgG and 
IgA, were seen on the ECs, but only trace levels of complement deposition were present 
in CVF-treated recipients (Kobayashi et al., 1997).  
 
1.3.10  Genetic engineering for expression of a complement-regulatory protein 
Despite the effectiveness of complement inhibitors, their effects are offset because of the 
cost, side-effects and potential compromise of the recipient’s innate immune defenses. To 
avert the side-effects from systemic administration of a complement inhibitor, direct 
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surface targeting of hCRP by genetic modification was proposed. These include MCP 
(CD46), DAF (CD55) and protectin (CD59). As shown in Figure 1.3-1, CD59 limits 
formation of the terminal MAC. CD55 and CD46 may be the most useful because they 
not only inhibit the production of C3b but also limit the production of the 
proinflammatory peptides C3a, C4a and C5a. CD55 is generally considered to control the 
classical complement activation pathway more effectively and CD46 the alternative 
activation pathway (Christiansen et al., 1996; Loveland et al., 1993). However, CD46 is 
very effective at protecting cells against complement-mediated lysis by both the classical 
and alternative pathways, and its recognized ability to control alternative pathway 
activation suggested that for long-term graft survival, where innate immune responses 
might be important, it may be preferred over CD55 (Brodbeck et al., 2000).   
 
The generation of pigs that express a hCRP, including CD46, CD55, and CD59 became 
possible and provided a major advance in xenotransplantation. CD59 transgenic pigs were 
first generated and high-level cell surface expression of CD59 was achieved in a variety 
of porcine cell types, most importantly on both large vessel and capillary ECs (Fodor et 
al., 1994). CD55 transgenic pigs were tested in cardiac xenograft models with 
immunosuppressants; the grafts escaped from HAR (McCurry et al., 1995). The grafts 
from CD46 transgenic pigs did not succumb to HAR, and survival extended for up to 23 
days with the immunosuppressants of cyclosporine, steroids and cyclophosphamide 
(Diamond et al., 2001). 
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Another issue of debate concerned whether pig CRPs can regulate human complement as 
effectively as the human counterparts. The pig analogues of hCRPs are comparable to the 
human proteins in their capacity to inhibit human complement. The effectiveness of CRPs 
to protect xenografts depends on an increase in the number of CRPs expressed on the 
transgenic tissue (Morgan et al., 2005). 
 
1.4  ACUTE HUMORAL XENOGRAFT REJECTION 
Although several strategies have been developed to overcome the problems of HAR and 
prolong graft survival, the grafts are still lost within weeks or months due to another form 
of humoral rejection. This type of rejection is characterized by ECs activation, 
progressive infiltration of inflammatory cells, microvascular thrombosis, and ischemic 
changes.  
 
AHXR, designated as delayed humoral xenograft rejection (DXR) or acute vascular 
rejection (AVR), usually occurs after 24 hours to within weeks after transplantation, 
causing the development of a consumptive coagulopathy and graft failure. Like its 
terminology, this phase of rejection is a heterogeneous phenomenon and the factors 
involved in this rejection remain undefined. The presumed mechanism for AHXR is Ab-
mediated rejection with possible involvement of complement and /or infiltration of 
polymorphonuclear granulocytes. The factors contributing AHXR could be natural (Gal 
or non-Gal) or elicited XNA (Gollackner et al., 2004).  AHXR is associated with the 
deposition of Abs and could be completely inhibited if the preformed Abs is depleted 
completely and elicited Abs production and complement activation are significantly 
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suppressed by using severely toxic immunosuppressants (Lin et al., 1998). On the other 
hand, the role of complement in AHXR remains controversial. In the pig-to-primate 
model using complement-regulator transgenic pigs, grafts undergoing complement-
dependent rejection showed pathophysiologic mechanisms similar to HAR, with a 
prominent infiltration of inflammatory cells. In contrast, grafts succumbing to 
complement-independent AHXR contained almost no infiltration of lymphocytes, 
macrophages or NK cells. Therefore, a clear understanding of the role of complement in 
AHXR has significant therapeutic implications (Lin et al., 1998; Waterworth et al., 1998).  
 
1.5 CELLULAR AND CHRONIC REJECTION  
Acute cellular xenograft rejection occurs later after transplantation and appears to be 
similar to allograft rejection, but stronger. The mechanisms of cell-mediated rejection 
have less intensely been investigated because the strength and immediacy of AHXR has 
made it difficult to keep discordant recipients surviving long enough to study cell-
mediated rejection until recently. Several cell types have emerged to be associated with 
cell-mediated xenografts rejection, such as CD4 T cells, NK cells, and other 
inflammatory cells (Auchincloss and Sachs, 1998).   
   
Taken together, when transplanting pig organs into primates, activation of PAECs is 
initiated by the immunologic response and develops procoagulant characteristics 
compared with anticoagulant features in the quiescent condition. These activated PAECs 
play an essential role in a deleterious chain reaction during xenograft rejection and 
emerge as a major barrier for successful xenotransplantation.  
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1.6 ENDOTHELIAL CELL (EC) ACTIVATION  
The EC surface in an adult human is composed of approximately 1 to 6 × 1013 cells, 
weighs approximately 1 kg, and covers a surface area of approximately 1 to 7 m2 
(Augustin et al., 1994). They have been found to operate several active functions rather 
than just provide physical separation between blood flow and tissue, which was thought 
in the earlier age. The ECs serve as a dynamic, heterogeneous, disseminated organ that 
possesses vital secretory, synthetic, metabolic, and immunologic functions (Cines et al., 
1998). The ECs exist in two states: quiescent and activated. When confronted by an 
inflammatory stimulus, ECs modify their phenotype and become an activated phenotype 
to promote adhesion, activation, and transmigration of circulating leucocytes, platelets 
and other cells (Cines et al., 1998; Pober and Cotran, 1990). This process is accomplished 
primarily via the up-regulation of a series of proinflammatory genes such as E-selectin, P-
selectin, inter-cellular adhesion molecule 1 (ICAM-1, CD54), and vascular cellular 
adhesion molecule 1 (VCAM-1, CD106). The expression of these genes is regulated 
primarily at the transcriptional level through the activation of the transcription factor NF-
B (Wrighton et al., 1996). 
 
Of relevance to xenotransplantation, the donor ECs of grafts are the first site of contact 
between the recipients’ blood and transplanted organ, and on which the inflammatory and 
immunologic response occur during HAR and AHXR. Therefore, they are divided into 
two phases, according to the timeframe of activation.  
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1.6.1 Type I activation  
Type I activation of ECs, independent of protein synthesis, occurs within seconds to 
minutes, and has been postulated to be the underlying cause of HAR (Bach et al., 1995). 
Type I activation is typically mediated by ligands that bind to the extracellular domains of 
heterotrimeric G-protein-coupled receptors (GPCRs) and an elevated plateau of cytosolic 
Ca2+ levels, which usually last for 10–20 minutes, after which the receptors become 
desensitized, preventing restimulation (Pober and Sessa, 2007).  Recipient XNA and 
complement result in the activation of porcine ECs, leading to retraction of endothelium 
and capillary leakage with consequent hemorrhage and exposure of subendothelial matrix. 
Collagen and vWF on the subendothelial matrix, combined with P-selectin and vWF on 
porcine ECs adhere to platelets via the receptor glycoprotein Ib (GPIb) on the platelets. In 
addition, activated platelets increase the expression of P-selectin and GPIIbIIIa by 
inflammatory mediators to recruit platelets and promote thrombosis. The intensity and 
rapidity of HAR is catastrophic, resulting in the thrombosis of the graft, which limits 
further consumption of platelets and coagulation factors, therefore averting systemic 
coagulopathy. 
  
1.6.2 Type II activation  
Type II activation of ECs requires transcription and translation of new proteins; hence 
needs longer time to be initiated compared with type I activation (hours as opposed to 
minutes).  This type of activation is respondent to the stimulation of the mediators such as 
tumor necrosis factor (TNF) and interleukin-1 (IL-1). In spite of being through different 
signaling pathway, they activate the same transcriptional factor, nuclear factor-κB (NF-
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κB), and activator protein 1 (AP1)(Martin and Wesche, 2002). After activation, ECs 
synthesize adhesion proteins, cytokines, chemokines and procoagulant factors (Collins et 
al., 1995). Adhesion molecules such as selectins, ICAM and VCAM promote the 
adhesion and infiltration of leucocytes, which is much more effective following type II 
activation than type I activation. Initially, neutrophil recruitment is triggered by the 
synthesis and display of chemokines. The expression of adhesion molecules favors a 
transition from neutrophil-rich infiltrates to mononuclear cell-rich infiltrates, which 
typically occurs between 6 and 24 hours after cytokine-mediated activation (Munro et al., 
1989).  During AHXR, progressive accumulation of NK cells and macrophages, 
associated with the up-regulation of P-selectin and E-selectin is found in the grafts 
(Blakely et al., 1994).   
 
Of importance, this type of activation causes ECs to become procoagulant, resulting in 
thrombosis. The de novo synthesis of TF initiates the coagulation cascade by binding to 
factor VIIa (FVIIa). Moreover, activated ECs lose thromboregulatory mechanisms such 
as the action of the ecto-NTPDases, thrombomodulin, heparan sulfate, contributing to the 
prothrombotic environments.   
 
In xenotransplantation, AHXR was considered to be related with type II activation of ECs 
(Bach et al., 1995). The mechanisms that could result in type II activation still remain 
perplexing. Primate serum induces type II activation of PAECs (up-regulation of selectins 
or VCAM-1), dependent on the presence of complement (Solvik et al., 2001). This type 
of activation is associated with the binding of the IgG3 subclass of anti-Gal Abs (Saethre 
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et al., 2002) or anti-nonGal Abs (albeit less contributory) (Saethre et al., 2006). However, 
direct targeting of the Gal epitope by agonist could evoke type II EC activation in the 
absence of complement activation (Palmetshofer et al., 1998). Another study also showed 
induction of IL-8 and plasminogen activator inhibitor-1 (PAI-1) in PAECs after activation 
with XNA without the involvement of complement (Vanhove and Bach, 1993). On the 
other hand, whether type II activation of ECs is attributed to factors other than Abs or 
complement remains under investigation. It is speculated that platelets activated by 
retracted PAECs secrete chemokines to recruit and activate host monocytes and NK cells.  
The latter activated mononuclear cells secrete further cytokines, such as TNF-α, 
interleukin 1, and interferon-γ (IFN-γ). These then provide a stimulus for EC activation, 
with consequent coagulation and inflammation.  
 
1.7  HAEMOSTASIS   
Haemostasis is the process that maintains the integrity of a closed, high-pressure 
circulatory system after vascular damage. Vessel-wall injury and the extravasation of 
blood from the circulation rapidly initiate thrombosis in the vessel wall that seals the 
breach. Physiologically, this process requires circulating platelets and the coagulation 
system. Platelets are recruited to the site of injury, where they become a major component 
of thrombus and the coagulation cascade culminates in the generation of thrombin and 
fibrin (Furie and Furie, 2008).  
 
During injury, platelets establish adhesive interactions with exposed subendothelial 
structures and are activated to become the reactive surface for continuing platelet 
deposition.  Thrombus formation is initiated by platelet adhesion to extracellular matrix 
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and augmented by subsequent aggregation via the engagement of receptors of platelets 
(Ruggeri, 2000). Blood coagulation is initiated by TF to form thrombin and fibrin strands, 
which strengthen the platelet plug and serve as another potent stimulator to platelets via 
protease-activated receptor 1 (PAR1) in human and PAR4 in mice(Shrivastava et al., 
2007). These occur concomitantly and are controlled by regulatory mechanisms, which 
are activated to terminate clot formation and commence fibrinolysis, temporally 
containing the thrombus formation.  When pathologic processes disrupt the balance, 
excessive quantities of thrombin form and initiate thrombosis. 
 
1.7.1 Coagulation pathways  
The coagulation cascade consists of a series of proteolytic reactions, converting inactive 
pro-enzymes (zymogen) into active enzymes, resulting in the precise and balanced 
generation of thrombin, the main effective enzyme of the coagulation cascade. Most of 
them are serine proteases except factor V (FV) and factor VIII (FVIII), which are 
glycoproteins and Factor XIII (FXIII), a translutaminase.  
 
The coagulation cascade has two pathways: the contact activation pathway (formerly 
known as the intrinsic pathway) and the TF pathway (formerly known as the extrinsic 
pathway). The intrinsic pathway begins with the formation of the primary complex on 
collagen by high-molecular weight kininogen (HMWK), prekallikrein, and factor XII 
(FXII, Hageman factor). The extrinsic pathway is initiated by TF. Both converge to the 
common pathway at the activation of FX, which converts prothrombin to thrombin 
(Figure 1.7-1).  
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The extent of the haemostatic response is controlled by the action of inhibitory pathways, 
which ensure that thrombin activity and the spread of the haemostatic plug is limited to 
the site of vessel damage. The inhibitory pathway is operated by regulators such as TFPI, 
anti-thrombin or thrombomodulin.  
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Figure 1.7-1 The cascade theory of  coagulation pathway  
A.  Intrinsic and extrinsic pathways. 
B. Regulators of coagulation pathway. 
Red dashed line: inhibitor of coagulation. AT: antithrombin, TBM: thrombomodulin 
TFPI: tissue factor pathway inhibitor. (Adapted from Mackman N, Arterioscler Thromb 
Vasc Biol2 007; Black line: stimulatory; red line: inhibitory)  
   
1.7.2 Tissue factor (TF)  
TF is a 47-kDa integral transmembrane protein and is considered to be the most important 
initiator of intravascular coagulation. When exposed to the blood stream, TF binds the 
coagulation factor VIIa (FVIIa), and the complex TF-FVIIa is a powerful activator of 
both FX and FIX, thereby initiating thrombin and fibrin formation (Mackman, 2004).  
 
TF is constitutively expressed by certain cells within the vessel walls and cells 
surrounding blood vessels, such as vascular smooth muscle cells, pericytes, and 
adventitial fibroblasts (Mackman et al., 2007). Thrombosis may result from a pathologic 
response to vessel wall injury. Under physiological conditions, vascular cells that are in 
contact with blood do not express TF. However, pathologic conditions lead to induced TF 
expression by a variety of vascular cells and this expression plays an important role in 
thrombosis even without exposure of blood to the subendothelium.   
 
For example, TF protein was observed on ECs in the aorta of septic baboons (Lupu et al., 
2005).  TF antigen has also been observed on circulating ECs in patients with sickle cell 
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disease and on ECs of the pulmonary vein in a mouse model of sickle cell disease 
(Solovey et al., 1998; Solovey et al., 2004). Furthermore, in a rodent septic model 
induced by systemic lipopolysaccharide, transgenic mice expressing TFPI or 
anticoagulant hirudin on endothelium were resistant to intravascular thrombosis and 
consumptive coagulopathy (Chen et al., 2004a). This observation suggests ECs are 
inducible to express TF activity by pathologic conditions.  
 
TF expression has been shown to contribute to disseminated intravascular coagulation 
(DIC) in baboon and rodent models of sepsis. A key cell type that can be induced to 
express TF is the monocytes (Pawlinski et al., 2004; Semeraro and Colucci, 1997; Taylor 
et al., 1991). Although there have been some debates, several studies demonstrated robust 
TF expression on neutrophils in the different diseases (Higure et al., 1996; Maugeri et al., 
2006). 
 
Whether or not platelets express TF has been controversial. Platelets were demonstrated 
to confer TF activity through a process in which monocyte-derived microparticles bind to 
activated platelets, and activated platelets themselves release TF-positive microparticles 
(Falati et al., 2003; Rauch et al., 2000).   However, other evidence shows that resting and 
activated platelets express TF activity and contribute to the pool of circulating TF 
(Losche, 2005; Siddiqui et al., 2002; Schwertz et al., 2006).   
 
Microparticles are small membrane fragments released from activated or apoptotic 
vascular cells such as leucocytes, ECs, platelets and smooth muscle cells. They contribute 
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to the circulating TF activity because TF antigen levels have been detected in human 
platelet-free plasma (Misumi et al., 1998). Importantly, levels of TF-positive 
microparticles are elevated in patients with a variety of diseases, including cardiovascular 
disease, diabetes, cancer, sickle cell disease, and endotoxemia (Mackman et al., 2007).  
 
Although negatively-charged phospholipids enhance the association of FVIIa with TF, 
they are not essential for complex formation of TF-FVIIa (Wildgoose et al., 1992). TF-
FVIIa complex may enhance Vmax of the reaction to catalyze the conversion of factor X to 
factor Xa, then subsequently shortening the clotting time. The explanations for this 
condition are that the exposure of phospholipids may change the structure of TF-FVIIa 
complex and enhance its function, or phospholipids induce a change in shape of TF-FVIIa 
complex can increase the number of active catalytic sites (Bach, 2006).  
 
Under normal conditions, most membrane TF expose at the cell surface is encrypted. 
Recently, in addition to an initiator of blood thrombosis dubbed the procoagulant form of 
TF, TF was found to have another form (cryptic) because of disulfide isomerization 
(Ahamed et al., 2006). The surface-accessible, extracellular Cys186–Cys209 disulfide bond 
of TF is critical for coagulation. When the disulfide bond of TF is cleaved by protein 
disulfide isomerase, TF also binds FVII to cleave and activate PAR2, the only receptor of 
PAR family that is not activated by thrombin and to exert as cell signaling. These 
signaling functions of TF-FVII in concert with thrombin elicit the cellular response to 
coagulation activation.  
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1.7.3 Thrombin  
Following the initiation phase, the limited quantities of FXa that are generated catalyze 
the conversion of trace quantities of prothrombin to thrombin. Albeit in trace quantities, 
thrombin enables the feedback activation of FVIII and FV, non-enzymatic cofactors in 
the intrinsic pathway of the coagulation cascade. The complex activates further FX and, 
as a result, bypasses the reliance on TF·FVIIa as a source of FXa generation. 
Consequently, this allows the explosive generation of thrombin that enables this serine 
protease to fulfill its myriad functions, including the deposition of fibrin (Lane et al., 
2005). Once generated, thrombin plays a central role in the regulation of thrombosis and 
termination of coagulation. 
 
A primary function of thrombin is to catalyze the conversion of fibrinogen to fibrin. 
During this reaction, fibrin monomer is first generated and spontaneously polymerizes to 
form protofibrils which can undergo lateral aggregation. Together with activated platelet 
plugs, the local deposition of fibrin forms an extensive meshwork to form a stabilized clot 
that seals the site of vascular injury.  
 
Thrombin is also a potent stimulator to activate platelets. During normal haemostasis, 
platelets are specifically recruited to the site of vascular injury by exposure of collagen 
and the actions of vWF. This forms the primary platelet plug. Thrombin specifically 
activates platelets by binding PAR1 receptor (Coughlin, 2005). Distinct to procoagulant 
function, thrombin also participates in the interaction of anti-coagulant function and 
inhibition of fibrinolysis, via thrombin-antithrombin complexes.  
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Of importance, evidence demonstrated that thrombin is involved in proinflammatory 
reactions and vascular neogenesis apart from coagulation. In peritonitis and the xenograft 
heart transplantation model, thrombin facilitates the generation of local monocyte 
chemoattractant protein (MCP)-1, which is needed to recruit natural killer cells via PAR1 
receptor (Chen et al., 2008a; Chen et al., 2008b).  
 
1.7.4 Coagulation inhibition 
The activation of the coagulation cascade and platelets efficiently allows maintaining the 
integrity of the circulatory system. However, if unregulated, this cascade has the potential 
to generate overwhelming clot deposition and organ damage. Endogenous inhibitors 
ensure the balanced formation of thrombus, including TFPI, thrombomodulin/activated 
protein C and heparan sulfate.  
 
In the initiation phase, TFPI is the principal inhibitor of TF-initiated coagulation, which 
binds and inhibits TF·FVIIa in a FXa-dependent manner (Bajaj et al., 2001). By targeting 
the initiating procoagulant stimulus, TFPI ensures that a small procoagulant stimulus does 
not induce the uncontrolled generation of thrombin. Since only a small quantity of FXa 
and thrombin is generated in this phase, this process is strongly influenced by the 
inhibitory activity of TFPI (Mann et al., 2003).  During this propagation period, the 
thrombin facilitates fibrin deposition that stops extravasation of blood. The inhibitory 
actions of protein C and antithrombin pathways become more prevalent in controlling 
thrombin generation.  
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1.7.5 Tissue factor pathway inhibitor (TFPI) 
TFPI is normally expressed by many cells; the major site is on ECs, which constitutively 
express the protein under normal conditions (Bajaj et al., 1990; Crawley and Lane, 2008). 
It has been reported that a proportion of TFPI is stored close to the membrane surface of 
cultured endothelial cells. This cellular fraction can be released in response to different 
agonists (eg, heparin, thrombin, shear forces.   On secretion from endothelial cells, a small 
amount of TFPI may associate ionically with the cell surface proteolglycans via K3 and its 
basic carboxy terminus. Such an ionic interaction might explain the, albeit limited, 
competitive release of TFPI from the endothelial surface by heparin. The mobilization of 
intracellular/cell surface–associated TFPI into plasma contributes to the anticoagulant 
effect of heparin administration. Heparin not only induces TFPI secretion into plasma, it 
also upregulates TFPI gene expression leading to elevation of both cellular and plasma 
TFPI pools(Crawley and Lane, 2008).  
 
The anticoagulant effect is mainly operated by TFPIα. The mature TFPIα is a 276 amino 
acid protein with three Kunitz-type domains (Wun et al., 1988). The first domain (K1) 
binds to the active site of FVIIa in the FVIIa/TF complex (Girard et al., 1989). The 
second  (K2) binds and inhibits FXa (Petersen et al., 1996).The third Kunitz domain (K3) 
has no described inhibitory function, but may mediate the ionic binding of TFPIα to cell 
su rfaces. The β isoform of TFPI-1, generated by alternative splicing, contains only K1 
and K2 and is directly attached to ECs by a GPI linkage (Zhang et al., 2003). 
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TFPI secreted by endothelial cells circulates in plasma at a concentration of 2.5 nmol/L 
but fluctuates temporally in humans because of their natural circadian rhythms.  Plasma 
levels are increased 1.5- to 3-fold after administration of heparin. The majority of the 
plasma pool circulates in association with low-density lipoproteins (LDL), and as a 
consequence confer markedly reduced inhibitory potential toward FXa and TF·FVIIa. 
LDL levels seem to correlate with plasma TFPI concentration. Only about 10% of plasma 
TFPI circulates in a full-length free 43-kDa form (Novotny et al., 1991). 
 
1.7.6 Thrombomodulin and protein C activator  
Thrombomodulin is expressed predominately on the vascular ECs and is widely 
distributed in the endothelium of arteries, veins, capillary and lymphatics (Maruyama and 
Majerus, 1987). It is a glycosylated transmembrane molecule of 557 amino acids and 
does not possess intrinsic enzymatic activity. When thrombin binds to thrombomodulin, 
the procoagulant activity of thrombin is altered. Protein C activation takes place by way 
of interaction of two receptors between the thrombomodulin–thrombin complex and the 
endothelial protein C receptor on endothelium (Figure 1.7-2). The binding of thrombin 
and thrombomodulin activates protein C much more efficiently (greater than 1,000-fold) 
(Dittman and Majerus, 1990). Activated protein C, together with cofactor protein S, 
provides an essential anticoagulant mechanism that prevents the amplification of 
thrombin generation via proteolysis of activated coagulation FVa and VIIIa.  
 
 As a result, it blocks the thrombin-mediated conversion of fibrinogen into fibrin and 
inhibits the binding of thrombin to other cellular receptors on platelets and inflammatory 
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cells. Recently, thrombomodulin was found to have important functions of fibrinolysis, 
inflammation and embryogensis. For example, thrombomodulin is also a critical cofactor 
for the activation of thrombin-activatable fibrinolysis inhibitor, which inhibits plasmin 
formation (Weiler and Isermann, 2003). 
 
      
         
 
Figure 1.7-2  Endothelial activation of coagulation and protein C pathway  
Coagulation is initiated by TF and other coagulation-factor complexes on the surface of 
endothelial cells. Thrombin is generated to form a complex with thrombomodulin. Protein 
C activation takes place by way of interaction between the thrombomodulin–thrombin 
complex and the endothelial protein C receptor (adapted from Faust SN, et.al. NEJM, 345: 
408, 2001). 
 
1.7.7   Heparan sulfate and antithrombin      
Heparan sulfate achieves its anticoagulant activity by interacting with antithrombin, a 
serine proteinase inhibitor (serpin). After interaction, antithrombin is activated via a 
conformation change to inhibit blood coagulation. Antithrombin is a 58 kDa, 432 amino 
acid glycoprotein synthesized in the liver, with a half-life of 3 days (Johnson et al., 2006). 
Antithrombin inhibits all of the other proteolytic coagulation factors, but the 
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predominance of its anticoagulant activity is focused on the regulation of FXa, FIXa and 
thrombin.  
 
Heparan sulfate is found on the surface of ECs and subendothelium.  In vivo, form of 
heparan sulfate and antithrombin maintain a normal, non-thrombogenic nature (Quinsey 
et al., 2004). Antithrombin is expressed as both an α-form and  a β-form. The α-form 
represents 90% of antithrombin.  While comprising only 10% of antithrombin, β-form 
antithrombin has a higher affinity for heparin and is thought to exert an overall larger 
anticoagulant effect (McCoy et al., 2003). 
 
1.8 MOLECULAR INCOMPATIBILITIS BETWEEN SWINES AND 
PRIMATES  
Because of evolutionary divergence between primate and pig, there are some 
physiological barriers that remain to be overcome for successful xenotransplantation. 
Dysregulation of coagulation which is believed to contribute to consumptive 
coagulopathy after xenotransplantation is a major challenge (Cowan et al., 2000). The 
coagulation cascade is tightly controlled by coagulation regulators, which are mainly 
TFPI, protein C system/ thrombomodulin and antithrombin.  
 
In the initiation stage of coagulation, activated FVII binds to TF and initiates a trickle of 
thrombin, which is regulated by the function of TFPI. However, in vitro porcine TFPI 
inefficiently inhibits human TF-dependent FX production and during AHXR, loss of 
porcine TF promotes the development of a procoagulant environment (Kopp et al., 1997).   
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This concept has been challenged by a recent study which showed porcine and human 
TFPI shared about 80% protein and over 80% in the functional Kunitz-1 and Kunitz-2 
domains. The ability to inhibit human FVIIa/TF complex was also similar between both 
TFPIs (Lee et al., 2008). In the propagation stage, the coagulation cascade is mainly 
regulated by thrombomodulin/protein C. Although porcine thrombomodulin shares 69% 
sequence identity with human thrombomodulin and binds to human thrombin, it is a poor 
cofactor to activate protein C and thrombin-activatable fibrinolysis inhibitor, contributing 
to insufficient cleavage of FV and FVIII (Kopp et al., 1998a; Roussel et al., 2008).   
  
In terms of platelet activation,  porcine vWF is known to spontaneously aggregate human 
platelet, in the absence of shear stress via GPIb because of difference in the O-linked 
glycosylation pattern between porcine and human vWF A1 domain (Pareti et al., 1992) 
(Schulte Am Esch et al., 2005). On the other hand, porcine fgl-2 (fibrinogen-like 2), 
which is expressed on activated ECs, converts human prothrombin to thrombin without 
the involvement of the coagulation cascade (Ghanekar et al., 2004). In the rodent model, 
fgl-2(-/-) hearts protected grafts from the injury of AHXR (Mendicino et al., 2005). Ecto-
NTPDases plays a pivotal role to maintain the balance of ADP and adenosine. During 
AHXR, the activity of CD73 is significantly reduced in pig heart and kidney tissue, which 
may have reduced capacity to generate adenosine and thus increased sensitivity to platelet 
aggregation (Cowan and d'Apice, 2008). Transgenic expression of CD39 on the surface of 
mouse ECs was developed to prolong graft survival without overt bleeding tendency in 
the rodent model (Dwyer et al., 2004).  
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Human cytokines produced by the infiltrating mononuclear cells in AHXR trigger the 
interaction between proinflammatory cells. One unpublished data described that human 
IFN-γ do not stimulate PAECs and such incompatibilities might attenuate immune 
response of xenografts (Bach et al., 1996). Nevertheless, mouse renal allografts lacking 
IFN-γ receptors rapidly developed ischemic necrosis because of massive damage to the 
microcirculation of the graft by infiltrating cytotoxic T lymphocytes (Sis et al., 2007). 
These observations support the hypothesis that INF-γ induced major histocompatibility 
complex class I proteins on donor tissue engage inhibitory receptors on recipient 
cytotoxic T lymphocytes and prevent them from injuring the microcirculation by 
perforin–granzyme mechanisms. Therefore, incompatibility of cytokines may indirectly 
promote coagulopathy in xenotransplantation.  
 
1.9 INTERACTIONS BETWEEN INFLAMMATION AND COAGULATION  
Inflammation and coagulation play pivotal roles and are intertwined in the pathogenesis 
of vascular disease. Inflammation results in activation of coagulation; but coagulation 
also considerably affects inflammatory activity. For example, the development of 
systemic coagulation activation, which results from the systemic inflammatory response 
to severe infection or sepsis contributes to multiple organ dysfunction. Conversely, 
coagulation factors such as thrombin, FVII and protein can also substantially modulate 
inflammatory activity. 
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1.9.1 TF expression on inflammatory cells  
The thrombin generation during inflammation is TF-dependent. Blocking TF activity 
completely abrogates coagulation activation in models of experimental endotoxemia or 
bacteremia, whereas anti-FXII monoclonal Ab that inhibits intrinsic pathway has no 
effect on thrombin formation (Levi et al., 1994; Pixley et al., 1993). The sources of TF 
may be different in various diseases and in various inflammatory situations. In 
atherosclerotic plaques, macrophages produce abundant TF at their surface and release it 
into blood upon plaque rupture. The pathophysiology of DIC was demonstrated to be 
mediated by the expression of TF. Many diseases such as cancer, severe trauma, and 
obstetric disorders are associated with DIC, and TF expression has been detected in the 
involved cells (Levi and Ten Cate, 1999).  
 
1.9.2 Downregulation of anticoagulation system during inflammation    
During inflammation, anticoagulation properties of TFPI, thrombomodulin and 
antithrombin can be impaired. The level of antithrombin dramatically reduces because of 
impaired synthesis and rapidly consumption after initiation and ongoing formation of 
thrombin (Levi et al., 2004). Proinflammatory cytokines also cause reduced synthesis of 
heparan sulfate (glycosaminoglycans) on the EC surface, which will also contribute to 
reduced antithrombin function (Kobayashi et al., 1990). Moreover, the protein C system 
is suppressed, mainly owing to downregulation of thrombomodulin at the EC surface, 
mediated by the proinflammatory cytokines TNF-α and IL-1β (Nawroth and Stern, 1986). 
The expression of TFPI was also shown to be inhibited by cytokines in rodent model 
(Shimokawa et al., 2000). 
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1.9.3 Inflammation inhibits fibrinolysis 
On the other hand, the fibrinolytic response is exerted by the release of plasminogen 
activators from storage sites in vascular ECs upon the formation of fibrin. However, PAI-
1 is increased and subsequent plasmin generation is counteracted (van der Poll et al., 
1991). As a result, during inflammation fibrinolysis is inhibited and inadequate fibrin is 
removed, thereby contributing to microvascular thrombosis.  
 
1.9.4 Interactions between coagulation and inflammation   
In addition to TF and thrombin, fibrinogen and fibrin can directly stimulate expression of 
proinflammatory cytokines (such as TNF-α and IL-1ß) on mononuclear cells and induce 
production of chemokines (including IL-8 and mCP-1) by ECs and fibroblasts (Szaba and 
Smiley, 2002). Once thrombin is formed, this will activate additional platelets. Activated 
platelets mediate the adherence of platelets to leucocytes and ECs by the expression of P-
selectin on the surface. Subsequently, the binding of activated platelets to neutrophils and 
mononuclear cells will enhance the expression of TF on monocytes via the pathway of 
NF-κB activity. 
 
The intricate interactions between inflammation and coagulation may affect each other. 
This cross-talk occurs at the levels of thrombin formation, platelet activation, leucocytes 
activation and cytokine interaction, resulting in inflammation to become critical 
conditions such as DIC.   Increased insight into the molecular mechanisms in the close 
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relationship between inflammation and coagulation may contribute to the identification of 
new targets for therapies that can modify excessive activation in this system. 
 
1.10 PLATELETS   
Platelets are the principal effectors of cellular homeostasis in human and other mammals. 
During injury, they adhere to exposed subendothelial matrix (fibrinogen) and aggregate in 
response to prothrombotic signaling.  As a result, the formation of platelet-fibrin clots 
seals vascular disruptions, which is critical for ultimate wound and vessel repair. 
   
In the course of evolution, ancient homeostatic functions were operated by a cell or a 
small number of cell types rather than a specialized cellular repertoire. In many 
invertebrates, a single type of cell performs innate defensive functions and aggregates to 
have primitive wound-sealing functions. By the vertebrate stage, distinct specialized types 
of cells were developed in blood. In humans, platelets are anucleate cells that are derived 
from megakaryocytes in the bone marrow and then released into the circulation, where 
they remain for an average of 10 days. Eventually, they are either consumed in thrombus 
formation or destroyed in the spleen.  
 
In addition to thrombosis, it has become evident that platelets also have relevant functions 
in inflammation by interplay with the immune system, which have been studied in 
vasculitis and atherosclerosis (May et al., 2008). Similar mechanisms may contribute to 
acute and chronic vascular lesions in transplants. Thus, platelets play a pivotal role both 
in thrombosis and inflammation. 
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1.10.1  Platelets and primary haemostasis 
At the site of injury, platelet adhesion occurs to form a monolayer plug of activated 
platelets through the receptor GPIb to newly exposed collagen fibrils within the vessel 
wall and soluble vWF. Further platelet activation results from other physiological stimuli, 
which are generated in the proximity of vascular injury. They include the formation of 
thrombin on the surface of activated platelets and a variety of substances from the 
granules of activated platelets.  The substances include 1) ADP, adrenaline and serotonin 
to activate adherent platelets in an autocrine manner by amplifying integrin adhesiveness, 
2) fibronectin and thrombospondin that reinforce and stabilize the platelet aggregation, 3) 
fibrinogen to serve as a further source at the site of vascular damage for reinforcing 
platelet clot, and 4) thromboxane A2 to allow vascular constriction and further platelet 
activation and aggregation. Activated platelets undergo a shape change and stick to each 
other via bridges formed by the GPIIbIIIa integrin and multivalent adhesive proteins such 
as fibrinogen, fibrin, and vWF. This results in the accumulation of platelets into plugs and 
accelerates thrombus formation (Brass et al., 2005). Finally, platelets provide the 
exposure of procoagulant phospholipids to augment clotting reactions during the 
coagulation cascade (Bevers et al., 1985). 
 
1.10.2  von Willebrand factor (vWF)  
vWF is a multifunctional adhesive glycoprotein stored in platelet α-granules and Weibel-
Palade bodies of ECs. In its mature form, it consists of disulfide-linked, approximately 
275-kDa subunits forming multimers of at least 20,000 kDa. Each subunit is composed of 
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conserved domains: D′ -D3-A1-A2-A3-D4-B1-B2-B3-C1-C2. The A1 domain 
encompassing the disulfide bond at C1272–C1458 (C509–C695 in the mature sequence) 
contains the binding site for GPIbα, heparin, and other binding partners (Andrews et al., 
1997). The vWF A3 domain binds collagen, while C1 contains an Arg-Gly-Asp (RGD) 
sequence that binds the receptor GPIIbIIIa on platelets.  The GPIb-binding site on vWF 
A1 is cryptic under static conditions, but becomes competent to bind receptor when 
exposed to shear force, or activated by non-physiological modulators. The interaction 
between vWF and GPIb is easily dissociated and not irreversible; subsequent activation of 
GPIIbIIIa platelets eventually provides irreversible adhesion by binding to the RGDS 
sequence in the vWF C1 domain. Ultra-large vWF multimers expressed on activated ECs 
are highly prothrombotic and bind platelets with high avidity. Under shear stress, the 
metalloproteinase (a disintegrin and metalloproteinase with a thrombospondin type 1 
motif–13, ADAMTS-13) cleaves within the A2 domain, between Y1605 and M1606, 
decreasing vWF size and downregulating GPIb-dependent platelet adhesion (Andrews 
and Berndt, 2008).  
 
1.10.3  Interactions between platelets and endothelium 
Like leucocytes, unactivated platelets were found to roll on activated endothelium in 
mesenteric venules. By intravital microscopy, the rolling process was first revealed on 
leucocyte movement, which is the initial step of leucocyte extravasation to the site of 
inflammation (Springer, 1994). Similarly, platelets rolling on endothelium dependent on 
shear rate are supported by P-selectin or vWF (Wagner and Frenette, 2008). One member 
of adhesion molecules, P-selectin is stored in granules of platelets (Berman et al., 1986) 
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and in Weibel-Palade bodies of ECs (McEver et al., 1989); then secreted and expressed 
on the cell surface of both platelets and ECs after stimulation.  When shear rate is higher, 
e.g. in small venules or arterioles, the rolling process is supported by P-selectin (Frenette 
et al., 1995). In veins with lower shear rate, the process of adhesion was demonstrated to 
be mediated by vWF released from Weibel-Palade bodies on the endothelium and 
receptor of GPIbα on the platelets. The adhesion of murine platelets was exclusively 
inhibited by human GPIbα antagonist (Andre et al., 2000).  On the other hand, the 
receptor of vWF, GPIbα, has also been shown to be a counter-receptor of P-selectin 
(Romo et al., 1999). This interaction of P-selectin is distinctive from that with P-selectin 
glycoprotein ligand 1 (PSGL-1), requiring neither calcium nor carbohydrate core-2 
branching or alpha 1,3-fucosylation.  This may thus suggest platelets roll on endothelium 
via P-selectin and GPIbα interaction (Polgar et al., 2005). 
  
Whether E-selectin plays a role in the interaction between platelets and ECs is still 
unknown. The same group (Wagner DD) also demonstrated that E-selectin, whose 
expression is induced by cytokines, contributes to resting platelets rolling on endothelium 
and a ligand(s) for E- and P-selectins is constitutively expressed on the surface of platelets 
(Frenette et al., 1998).  The ligand on the platelets to E selectin of ECs remains 
unidentified. Such a ligand is likely to bear specific carbohydrate moieties carried by a 
protein or a glycolipid scaffold. Interestingly, purified glycolipids (gangliosides) from 
human platelets contain sialyl-Lewisx epitopes (Cooling et al., 1995), and similar 
glycolipids isolated from human myeloid cells have been shown to bind E-selectin 
(Stroud et al., 1996a; Stroud et al., 1996b). 
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1.10.4  Proinflammatory effects of activated platelets    
Platelets contain various compartments, such as 3 different granules (α-granules, 
lysosomes, dense core granules), and a complex membranous system that allows them to 
store and rapidly release a variety of factors after stimulation. The molecules and 
functions are summarized in Table 1.10-1.  These proteins act in a concerted and finely-
regulated manner, influencing widely differing biologic functions, such as cell adhesion, 
cell aggregation, chemotaxis, cell survival and proliferation, coagulation, and proteolysis, 
all of which accelerate inflammatory processes and cell recruitment. Activated platelets 
enhance not only lymphocyte and NK cell adhesion and cells infiltration but also Ab 
production by B cells and the cytotoxicity of cytolytic T cells and NK cells (Li, 2008). 
The cross-talk is based on the interaction of P-selectin on platelets and PSGL-1 on 
leucocytes. Leucocytes are recruited into growing thrombi and promote fibrin deposition 
that is inhibited by Abs to P-selectin (Palabrica et al., 1992). Clotting was accelerated in 
P-selectin-knock-in mice that lack the cytoplasmic domain (ΔCT mouse) or the mice with 
high levels of soluble P-selectin in the plasma. These observations indicate that P-selectin 
plays an important role in a procoagulant state of the animals (Hartwell et al., 1998). 
Activated platelets were also demonstrated to induce monocytes and ECs to express TF 
activity. On the other hand, platelets also modulate humoral immunity by stimulating B 
cell proliferation and facilitating Ab production.  Platelet-associated CD40L (CD154) was 
competent to induce the CD40-dependent proliferation of B lymphocytes in response to 
the GPIIb/IIIa when platelets and peripheral blood B lymphocytes from idiopathic 
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thrombocytopenic purpura patients with circulating anti-GPIIb/IIIa Abs were cultured 
together (Solanilla et al., 2005). 
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Location  Category   Molecule  Functions  
α- granule  Adhesion P-selectin Adhesion platelets, ECs & 
leucocytes 
  vWF Facilitates rolling 
 Chemokine  CCL3 Monocyte & T-cell recruitment 
  CCL5 Monocyte, eosinophil & T-cell 
recruitment 
  CCL7 Monocyte, eosinophil & T-cell 
recruitment 
  CXCL4 Neutrophil & T-cell recruitment 
  CXCL7 Neutrophil recruitment 
  CXCL8 Neutrophil recruitment 
  CXCL12 Lymphocyte & progenitor cell 
recruitment 
 Cytokine  IL-1β Activates ECs & lymphocytes 
  TNF-α Activates ECs & increases 
vascular leakage 
  TGF-β Cell proliferation, differentiation, 
apoptosis, fibrosis 
  CD40/CD40L Maturation of antibody  
 Growth factor PDGF Angiogenesis & fibrosis 
Dense granule  Nucleotide  ATP/ADP Stimulate platelets & endothelial 
cells 
 Transmitter  Serotonin  Stimulates platelets & T cells 
Lysosomes Coagulation factors Factor V Coagulation  
  Factor XI Coagulation 
  Protein S Anti-coagulation  
  Plasminogen Fibrinolysis  
  PAI-1 Antifibrinolysis  
Membrane  Ligand receptors  PSGL-1 Ligand for P-selectin 
  PAR 1 Receptor for thrombin 
  ADP receptor  Stimulates platelets 
  GPIa Binds to collagen 
  GPIb Binds to collagen 
  GPIIbIIIa Binds to vWF & fibrinogen 
  GPIV Binds collagen strongly 
Table 1.10-1 Partial list of granular contents and membrane expressed receptors on 
human platelets that are relevant to organ transplantation. (Adapted from Morrell et 
al., AJT 2007.) 
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1.10.5  Platelets synthesize do novo proteins through pre mRNA splicing  
Gene expression is regulated at several checkpoints. A critical step is to remove 
noncoding introns from newly-transcribed pre-mRNAs. This process occurs 
cotranscriptionally in the nucleus by a trans-acting complex termed the spliceosome 
(Maniatis and Reed, 2002). The human spliceosome contains small nuclear 
ribonucleoproteins (snRNPs) and auxiliary proteins that impart the correct architecture 
necessary for proper intron recognition and excision. Splicing ensures that mature, 
translatable mRNAs are available for transportation to cytoplasm. Initially, the study 
indicated that this process was operated within the nucleus. Denis et al. proved that the 
process of splicing of pre-mRNAs could be operated beyond the boundary of the nucleus 
and occur in anucleate cells, such as platelets, which also confer the spliceosome 
component (Denis et al., 2005). In this way, platelets were found to synthesize the de 
novo proteins, such as Bcl3, interleukin-1, PAI-1, and TF after activation (Brogren et al., 
2004; Lindemann et al., 2001; Panes et al., 2007; Schwertz et al., 2006; Weyrich et al., 
1998).    
 
1.10.6  Receptor of glycoprotein IIbIIIa (CD41) 
The platelet integrin (GPIIbIIIa) is the final common pathway of platelet activation, 
which not only binds fibrinogen and vWF to mediate platelet aggregation and adhesion, 
but also as a signaling receptor. Platelet agonists, such as ADP, thrombin and collagen, 
induce “inside-out” signaling which activates the receptor function of GPIIbIIIa for 
soluble fibrinogen. Subsequent platelet aggregation leads to “outside-in” signaling, 
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inducing platelet aggregate stabilization and triggering a variety of functions important to 
platelet physiology.  
 
During the process of outside-in signaling, thromboxane A2 is generated and functions in 
an autocrine loop to stimulate platelets and confer the ability of vasoconstriction. The 
molecules in the α or dense granules are secreted and released to appear  in autocrine 
loops that augment further platelet aggregation and adhesion (Phillips et al., 1991). 
 
1.10.7  Adenosine diphosphate (ADP) receptor 
ADP is an important physiological molecule that plays a vital role in normal haemostasis 
and thrombosis. Despite being a weak agonist and only inducing reversible platelet 
aggregation compared to thrombin or collagen, ADP is an important so-called secondary 
agonist which amplifies most of the platelet responses and contributes to the stabilization 
of thrombus because of its presence in large amounts of the dense granule of platelets and 
injured vascualr sites (Gachet, 2008).  Platelets possess three P2 receptors for adenine 
nucleotides: P2Y1 and P2Y12, which interact with ADP, and P2X1, which interacts with 
ATP. ADP-induced platelet activation is initiated via the platelet P2Y1 receptor, which is 
coupled to Gαq and phospholipase C and mediates calcium mobilization from internal 
stores, shape change and an initial aggregation response. Platelet activation and the 
aggregation response are amplified and sustained by the P2Y12 receptor, which is coupled 
to Gαi, leading to inhibition of adenylate cyclase and activation of phosphoinositide-3-
kinase, Rap1b, Akt and potassium channels (Jackson et al., 2005). P2X1 receptor is an 
ion channel that causes a rapid influx of calcium and platelet shape change in response to 
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ATP and contributes to the platelet activation induced by low concentrations of collagen 
(Burnstock, 2007).  
 
The P2Y1 and P2Y12 receptors are also differently involved in the procoagulant activity 
of platelets (Storey et al., 2000). Whilst both receptors are indirectly associated with the 
role in platelet P-selectin exposure and in the formation of platelet-leucocyte aggregates 
leading to leucocyte tissue factor exposure, the P2Y12 receptor is also directly implicated 
in the exposure of phosphatidylserine at the surface of platelets (Leon et al., 2003). 
Moreover, administration of P2Y12 antagonists limits the ability of platelets to adhere to 
and activate leucocytes and reduces the release of important mediators such as sCD40L 
(Judge et al., 2005).  
 
1.10.8  ECs generate adenosine 
In addition their presence in dense granules of platelets, nucleotides are present in 
intracellular fluid as a consequence of cell lysis, selective permeabilization of the plasma 
membrane and exocytosis of secretory vesicles, such as dense bodies. Ecto-NTPDases are 
a family of ectonucleotidases, which largely expressed by ECs in the vascular 
environment, sequentially converts extracellular purine nucleotides in the blood, such as 
ATP and ADP, to the monophosphate form (AMP).  
ATP ADP AMP Adenosine 
CD39 CD39 CD73
 
CD39 is the main E-NTPDase in the endothelium of the vasculature system. The ecto-
nucleotidase cascade is initiated by CD39, hydrolyzing ATP and ADP to AMP. Then 
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AMP is converted to adenosine via CD73. Both of them closely regulate the local and 
extracellular plasma concentration of adenosine (Goding et al., 1998). Through regulating 
ADP metabolism, ecto-NTPDases become one of the important pathways by which ECs 
influence the behaviour of platelets. ADP is a platelet agonist that triggers aggregation, 
augments the action of other platelet agonists, and mediates adrenaline release to induce 
vasoconstriction, while adenosine has opposing effects and creates an innate protective 
environment. Thus, by actively suppressing platelet-EC interactions and promoting 
downstream generation of adenosine, CD39 acts in conjunction with locally released 
mediators, such as prostacyclin and nitric oxide (NO), to maintain the balance between 
proinflammatory and anti-inflammatory factors.  
 
1.11 ANTI-PLATELET AGENTS  
The regulation of platelet function, and thereby haemostasis and thrombosis, is a 
precarious balance between activation and inhibitory mechanisms that control platelet 
activation upon exposure to damaged tissues, yet enable platelets to remain quiescent in 
the undamaged circulation. Understanding of these mechanisms (agonists, receptors and 
signaling pathways) is essential for the development of more effective anti-platelet 
therapies. Several drugs have been developed to prevent or treat vascular thrombotic 
diseases through different mechanisms (Figure 1.11-1).  
 
1.11.1  Cyclooxygenase inhibitors  
The product of cyclooxygenase, prostacyclin, is a vasodilator prostanoid that inhibits 
platelet activation in response to a variety of agonists. Conversely, thromboxane A2 is a 
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potent vasoconstrictor and activator of platelets. In a murine model of catheter-induced 
carotid injury, vascular proliferation and platelet activation were enhanced in prostacyclin 
receptor (–/–) mice but were inhibited in thromboxane A2 receptor (–/–) mice (Cheng et 
al., 2002).  Low-dose aspirin reduces production of thromboxane A2  from platelets by 97 
to 99% in humans,(Davi and Patrono, 2007) and this reduction has been similar to the 
effect in a mouse model with hypomorphic COX-1 alleles (COX-1”"knockdown"). The 
97% decline in production of platelet thromboxane A2 in these mice decreased platelet 
aggregation and prevented arterial thrombosis induced by photochemical injury (Yu et al., 
2005).  
 
1.11.2  ADP receptor blocker 
The interaction of ADP with its platelet P2Y12 receptor is essential for platelet activation.    
P2Y12–/– mice have a prolonged bleeding time and are protected against arterial 
thrombosis induced by ADP or a PAR-4-activating peptide (Andre et al., 2003). P2Y12 
blockers, such as ticlopidine and clopidogrel, were invented to interfere with this 
interaction. The effects on reducing the risk of major vascular events were similar to that 
achievable with low-dose aspirin (Patrono et al., 2004).  
 
1.11.3  Blocker of CD41 receptor 
Since GPIIb/IIIa plays a pivotal role in the final common pathway leading to platelet 
aggregation, inhibitors or Abs of this integrin have been expected to prevent platelets 
aggregation. Many studies showed GPIIb/IIIa inhibitors to reduce morbidity and 
mortality in patients with acute coronary syndromes (1998). Eptifibatide, a synthetic 
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cyclic heptapeptide, is a selective high-affinity inhibitor of the platelet glycoprotein 
IIb/IIIa receptor, which binds to recognition sites on the activated GPIIb/IIIa receptor, 
thereby inhibiting binding to fibrinogen.   
 
1.11.4  Other anti-platelet agents  
A phosphodiesterase inhibitor is a drug that blocks phosphodiesterase, which would 
prevent the activation of the intracellular second messengers, cyclic AMP (cAMP) and 
cyclic guanosine monophosphate (cGMP). By inhibiting the formation of thrombin, the 
anti-thrombotic agents, such as heparin, also exert ant-platelet effects.  
 
Figure 1.11-1 Targets of anti-platelet drugs.  
Platelets have a variety of cell-surface receptors that mediate their activation (red curve 
line).  Anti-platelet drugs and their targets are indicated in blue dash lines. Thromboxane 
A2 (TXA2), protease-activated receptor 1 (PAR1).  
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1.12    STATIN  
The statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, 
significantly reduce synthesis of cholesterol (Downs et al., 1998; Sacks et al., 1996). 
Clinical trial evidence demonstrates statins reduce the progression of atheroscelerosis and 
may lead to the regression of plaque and reduction in stenosis. This benefit in coronary 
cardiovascular disease was thought to be associated with the lowering of cholesterol. 
However, recent studies indicated the clinical benefit of statin is disproportionate to the 
rather modest improvement seen in luminal diameter. These observations suggest statins 
have other lipid-independent effects, such as immuno-regulatory, anti-inflammatory, and 
anticoagulant actions (LaRosa, 2001; Palinski, 2001). 
 
1.12.1  Pharmacology  
HMG-CoA reductase is the rate-limiting enzyme of the mevalonate pathway, through 
which cells synthesize cholesterol from acetate moieties (Figure 1.12-1). Inhibition of 
HMG-CoA reductase, and the subsequent reduction in cholesterol synthesis, results in 
hepatocytes increasing their surface expression of LDL-receptors, so increasing uptake of 
LDL and reducing plasma LDL and cholesterol. The statins exert their action because of 
their ability to bind to HMG-CoA reductase more potently than HMG-CoA (Istvan ES, 
2001). Apart from the reduction in cholesterol biosynthesis, interference with the 
mevalonate pathway also prevents the synthesis of isoprenoid intermediates, including 
FPP (farnesylpyrophosphate) and GGPP (geranylgeranylpyrophosphate) (Goldstein and 
Brown, 1990).  Geranylgeranyl and farnesyl are lipid attachments important in the post-
translational modification of signaling proteins, including the small GTPases Rho, Rac 
  82 
and Ras and the G-proteins (Casey, 1995). These molecules may alter cell signaling, 
membrnane stability, membrane trafficking and gene transcription.  











(RhoA, Rac1, Cdc42) 
 
Figure 1.12-1 The pathway of cholesterol synthesis 
Inhibition of HMG-CoA reductase by statins has multiple downstream effects, including 
inhibition of cholesterol biosynthesis and of isoprenoid intermediates such as FPP and 
GGPP. Geranylgeranyl and farnesyl are lipid attachments important in the post-
translational modification of signalling proteins, including the small GTPases Rho, Rac 
and Ras and G proteins. PP, pyrophosphate. 
 
1.12.2  Statin function on ECs  
The beneficial effects of statins on vascular endothelium have been reported within 1 
month of starting treatment and in the absence of lipid lowering. The lipid –independent 
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benefit is associated with NO bioavailability. Administration of statins augmented 
stimulated and basal NO dilator functions of the endothelium (O'Driscoll et al., 1997). 
Endothelial NO is a vasodilator, inhibits smooth muscle proliferation, platelet aggregation, 
endothelial adhesion molecule expression and leucocyte–EC interactions. The 
demonstration that statins are able to enhance local NO generation in ECs, by increasing 
the half-life of eNOS (endothelial NO synthase) mRNA, contributed to the acceptance for 
lipid-independent effects of statins (Landmesser et al., 2004). In addition, the evidence 
that statins inhibited  the expression of the potent vasoconstrictor endothelin-1in ECs 
through Rho proteins supported the beneficial effect of statins independent of  lowering 
lipid (Hernandez-Perera et al., 2000). 
 
1.12.3  Thrombotic and fibrinolytic effects  
Statins have various effects on haemostasis and thrombosis, which may be especially 
important at sites of atherosclerotic plaque rupture (Rosenson and Tangney, 1998). The 
effect is attributed to inhibition of platelet activation, and maintenance of a favourable 
balance between prothrombotic and fibrinolytic mechanisms.  Lipophilic statins 
(fluvastatin, simvastatin) suppress TF antigen and activity with the diminution of TF 
mRNA by cultured human macrophages through inhibition of a geranylgeranylated 
protein (Colli et al., 1997). The evidence was also confirmed in an animal study that 
showed that statins alter plaque biology by reducing proliferation and expression of MMP 
and TF of macrophages (Aikawa et al., 2001). Similarly, simvastatin prevents TF 
induction of human aortic ECs and vascular smooth muscle cells (VSMCs) by thrombin, 
at least in part through inhibition of Rho-kinase-dependent Akt dephosphorylation (Eto et 
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al., 2002). The inhibition of TF by statins has also been demonstrated in an animal study 
(Baetta et al., 2002). Another anti-thrombotic effect is that statins encourage fibrinolysis. 
Lovastatin, fluvastatin, atorvastatin and simvastatin have been shown to increase the 
profibrinolytic factor, tissue plasminogen activator (tPA), while inhibiting synthesis of the 
antifibrinolytic PAI-1 by ECs, macrophages and VSMCs (Bourcier and Libby, 2000; 
Lopez et al., 2000).  
 
1.12.4  Inhibition of platelet aggregation  
An important additional anti-thrombotic action is inhibition of platelet activation and 
function. Statins may reduce platelet aggregation by changing the cholesterol content of 
platelet membranes, which alters membrane fluidity by modulating cytosolic Ca2+ in 
platelets by affecting Ca2+ transport pathways (Le Quan Sang et al., 1995). In addition, a 
study has reported that lovastatin increases ecto-NAPDases activity and membrane 
expression in ECs, thus enhancing the inhibition of platelet aggregation at the EC surface 
through the action of the ecto-NAPDases product adenosine. This action appears to be 
independent of changes in membrane cholesterol (Hale et al., 1998; Laufs et al., 2000).  
 
1.12.5  Immunoregulatory effects  
Statins also exert immunoregulatory effects through lipid-lowering-independent 
mechanism. The function of macrophages and monocytes (Pahan et al., 1997; Romano et 
al., 2000), the activation and proliferation of  B lymphocytes (Rudich et al., 1998) and 
cell cytotoxicity of T lymphocyte may be mitigated through inhibition of cytokine 
production and induction of  NO synthase as shown in vitro and in vivo demonstrations 
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(Mason, 2003).  Furthermore, pravastatin, lovastatin and atorvastatin have been shown to 
inhibit IFNγ-induced expression of MHC class II in macrophages, ECs and VSMCs. This 
effect provides a scientific rationale for using statins as immunosuppressants in organ 
transplantation (Kwak et al., 2000). 
 
In a study based on cardiac transplantation, pravastatin had beneficial effects on 
cholesterol levels, the incidence of rejection causing hemodynamic compromise, one-year 
survival, and the incidence of coronary vasculopathy (Kobashigawa et al., 1995). In a 
pilot study, statin also reduced episodes of biopsy proven acute rejection in kidney 
transplant recipients treated with cyclosporine-based immunosuppression (Katznelson et 
al., 1996). 
 
Although these effects require larger scale studies, the pleiotropic functions of statins 
offer the opportunities to link between different areas of medicine. It may turn out to be of 
great interest to explore the role of statins in xenotransplantation, where multiple 
challenges have to be dealt with simultaneously.  
 
1.13 SUMMARY  
Complement activation and coagulation has been recognized as pivotal issues for 
successful xenotransplantation. The generation of the GT-KO pigs was a huge step 
forward, eliminating the target of a whole class of pre-existing complement-fixing 
antibodies and the source of a major contributor to the induced humoral response. 
However, in this chapter I have attempted to 
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show that the remaining challenges from non-humoral immune response such as 
molecular incompatibilities and unregulated coagulation are by no means insignificant , 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 ENDOTHELIAL CELLS   
 
2.1.1 Harvest and cultures of porcine aortic endothelial cells (PAECs) 
Thoracic aortas from wild-type (WT) or transgenic pigs were harvested immediate after 
euthanasia and stored in UW solution or RPMI-1640 supplement with 20% heat-
inactivated (HI) fetal calf serum (FCS, Sigma, St. Louis, MO ), penicillin (100 U/ml, 
Sigma) and streptomycin (25µg/ml, Sigma) at 4ºC.  
 
PAECs were obtained from freshly harvested porcine aortas by treatment with 0.05% 
collagenase B (Roche Applied Science, Indianapolis, IN).  The cells were collected and 
washed with washing medium (RPMI-1640 containing 10% HI fetal bovine serum (FBS, 
Invitrogen, Carlsbad, CA)) to inactivate the collagenase, and were resuspended in PAEC 
culture medium (medium 199, Invitrogen) containing 10% HI FCS and antibiotic-
antimycotic (Invitrogen) and endothelial growth factor (30μg/mL, BD Biosciences, San 
Jose, CA) and plated into collagen I-coated 6-well, 25 cm2 or 75 cm2 tissue culture flask 
(BD) at 37°C in 5% CO2 (Appendix 1,2,3,4). Trypsin-EDTA (0.05% trypsin-0.02% 
EDTA, Invitrogen) was used to passage cells and all cells in the experiments were within 
passage 6.  
 
2.1.2 Human ECs and breast cancer cell line 
Human aortic ECs (HAECs) (as an allograft control compared to PAECs), purchased 
from Cambrex (Walkersville, MD) and a human breast cancer cell line (ZR-75-1; as a 
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positive allograft control for the expression of human TF) were cultured in EC basal 
medium (EBM-2, Lonza, Walkersville, MD) under the same conditions as PAECs 
 
2.1.3  Phenotype of PAECs    
The phenotype of PAECs was determined by fluorescence-activated cell sorter analysis 
using anti-CD31 Ab. PAECs (purity >90%) were used in the following experiments. The 
phenotypes of PAECs from WT, GT-KO or MCP (CD46, (+/+)) pigs were confirmed by 
flowcytometry (Figure 2.1-1).   Surface expression of Gal and CD46 was measured by 
direct immunofluorescence using FITC-conjugated isolectin B4 from Bandeiraea 
simplicifolia (BS-IB4, Sigma), FITC-conjugated lectin from Ulex europaeus (UEA-I, 
Sigma), FITC-conjugated mouse anti-human CD46 Ab (Serotec, Raleigh, NC), and 
FITC-conjugated mouse IgG1 isotype control (Serotec). Cells were incubated for 30 min 
at 4 °C. Isotype-matched Ab or staining buffer alone (for BS-IB4, UEA-1) were used as 
negative controls.  

















Figure 2.1-1 Surface expression of Gal and CD46 on PAECs. 
PAECs from WT (upper panel), GT-KO (middle panel) and MCP (+/+) (lower panel) 
pigs were stained for BSI-B4, CD46 and CD31. Dashed lines – isotype control.  
 
2.2  PREPARATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS 
(PBMCS) 
 Peripheral human blood was drawn from healthy volunteers by venopuncture using 
pyrogen free syringes and needles combined with heparin for anticoagulant. Alternatively, 
cells were obtained from buffy coats. Blood was diluted in 1:1 PBS whilst buffy coats 
were diluted in 1:3 Peripheral blood mononuclear cells (PBMCs) from normal human 
blood were obtained using a standard Ficoll-Paque density gradient. After spinning 
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2000rpm for 20 minutes at room temperature, the middle layer of PBMCs were 
transferred to a new 50 ml tube for washing twice. The PBMCs were resuspended in 1ml 
of magnetic activated cell separation (MACS, Appendix 5) buffer; then incubated with 50 
µl mouse anti-human CD14 (Miltenyl Biotec, Auburn, CA) for 30 minutes on a roller. 
The monocytes were positively selected from PBMCs by using a magnetic cell separator 
(Miltenyl Biotec). The monocytes were counted on a hemocytometer.   
 
2.3 PERPARATION OF PLATELETS 
Venous blood was collected from healthy volunteers not taking anti-platelet drugs into 
tubes with anticoagulants of ethylenediaminetetraacetic acid (EDTA, 5 mM) or acid-
citrate-dextrose (ACD). After centrifugation (10 minutes at 150g), the top two-thirds of 
platelet-rich plasma (PRP) was removed and centrifuged (8 minutes at 1400g). The pellet 
was washed with buffer (137 mM NaCl, 5.3 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 4.1 
mM NaHCO3, and 5.5 mM glucose [pH 6.5]) containing  prostaglandin E1 (PGE1, Sigma ) 
(120 nM). Platelets were centrifuged (150g for 5 minutes) to remove residual leucocytes 
(Panes et al., 2007). Cell counts were performed by contrast microscopy. Platelets were 
kept at 4°C during all the isolation steps after blood draw to avoid activation. The 
phenotypes and purity of platelets were evaluated by flow cytometry with anti-CD45 and 
anti-CD41Abs (BD Biosciences, Palo Alto, CA) to exclude leucocyte contamination.  
 



















Figure 2.3-1 Phenotype and purity of isolated platelets. 
Platelets were double stained with anti-CD42a and anti-CD45 Abs. The phenotype of 
platelets and the percentage of leucocytes (CD45 positive) were determined by 
flowcytometry.  
 
2.4 PREPARATION OF SERUM AND PLASMA  
 Human or baboon plasma and serum were prepared after whole blood without/with 
anticoagulant agents were centrifuged at 1800 rpm for 5 minutes. Serum was heated at 
56ºC for 45 minutes to inactivate complement activity. Primate plasma and serum were 
stored at -80ºC until use.   
 
2.5 LACTATE DEHYDROGENASE (LDH) ASSAY  
 LDH (lactate dehydrogenase) assay was performed to evaluate complement-dependent 
cytotoxicity (CDC). 1×104 of PAECs were cultured in a 96-well, flat-bottom plate 24 
hours prior to this assay. The cells were washed twice with PBS immediately before a 
series of concentrations of human serum was added. 100 µl of 0.9% Triton X-100 
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(Promega, San Luis Obispo, CA) was used as positive control.  After 4 hours incubation, 
a Cytotox 96 kit (Promega) was used to quantify the activity of cytoplasmic LDH in 50 µl 
of cell lysate. Optical density values were measured on a microplate recorded at 492nm 
and the data analysis was carried out using Microsoft Excel. 
 
Complement-mediated cytotoxicity = OD492 (total)- OD492 (background )/ OD492 (Triton)- 
OD492  (background ) × 100% 
 
2.6 CH50 ASSAY  
The CH50 assay (Dia Medix, Miami, FL) was used for determination of classical 
pathway complement activity in the fluid phase. The sensitized sheep erythrocytes were 
equilibrated at room temperature for one hour and resuspended with a vortex or by 
shaking vigorously. 5μl serum samples together with reference sera were added into the 
tubes containing the sensitized sheep erythrocytes. After one hour incubation at room 
temperature, the contents of the tubes were mixed by inverting them 3 -4 times.  After 
centrifugation for 10 min at 1750 g, hemolysis was determined in the supernatant by 
measuring the absorbance of released hemoglobin at 412 nm, compared to the references.  
 
2.7   ANTIBODY BINDING ASSAY  
Binding of anti-porcine or anti-nonGal Abs to PAECs was measured by incubating 105 
cells with 20% HI human serum or FACS buffer (control) for 30 minutes at 4˚ C.  After 
incubation, the cells were washed twice in 2mL fluorescence activated cell sorting (FACS) 
buffer (Appendix 6) and centrifuged at 800g for 5 minutes. The supernatant was 
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discarded. To prevent non-specific binding, 10μL of 10% goat serum was added.  
Detection of IgM or IgG binding was performed by further incubating the serum with 
FITC-conjugated goat anti-human IgM (μ chain-specific) and IgG (γ chain-specific) 
(Invitrogen) for 30 minutes in the dark at 4˚C.  The samples were washed twice, and  the 
cells resuspended with FACS buffer.  Data acquisition was performed with BD™ LSR II 
flow cytometer (BD).  Dead cells were excluded from the analysis by forward-scatter and 
propidium iodide (PI)(BD) staining. Measurement of mean fluorescence intensity (MFI) 
was performed on viable cells.  Binding of IgM and IgG were assessed using relative MFI 
with the absence of serum (secondary Ab only) being scored as 1.  The binding of anti-
nonGal Abs was determined by incubating serum with GT-KO PAECs.   
 
2.8 RECALCIFICATION CLOTTING ASSAY 
 
2.8.1 Clotting assay in normal plasma 
Functional TF activity of cells was determined by the recalcified clotting assay after 8-
hour incubation with various stimuli. PAECs, monocytes, PBMCs or platelets were 
suspended in 50 µl Tris-buffered saline (TBS, Appendix 7)  and mixed with 100 µl of 
normal human plasma (Haematologic Technologies, Essen Junction, VT) in glass tubes 
(Corning, Corning, NY). 100 µl of 25 mM CaCl2 in TBS were added and the tube 
incubated at 37°C in a water bath; the time for a fibrin clot to form was measured, during 
which time the tubes were continuously agitated by tilting. In the clotting assay with 
platelets, another 100µl phospholipid (Diagnostic Reagents) was added. The time for a 
fibrin clot to form was determined in triplicate for statistical analysis. There is one 
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drawback by using clotting assay to detect TF activity. First, even unactivated cells which 
do not express TF shorten clotting time compared to blank control (no cell). This 
shortening of clotting time between unactivated cells and blank control could result from 
the effects of other coagulation factors such as fgl2.  
 
2.8.2 Clotting assay using FVII-deficient plasma 
Since TF requires the involvement of FVII to initial the coagulation cascade, the 
recalcified clotting assay was repeated in FVII-deficient plasma to confirm that the 
shortening of clotting time was associated with the activity of TF. The shortening of 
clotting time in normal plasma will be normalized in FVII-deficient plasma if it is 
initialized by the presence of TF activity from the cells. 
 
2.8.3 Clotting assay in FVII -deficient plasma with/without FVII 
 
2.8.3.1 Dosage of FVII in the recalcified clotting assay  
In these assays, TF-dependent thrombin generation required the participation of factor VII 
(FVII, Haematologic Technologies). The clotting time was shortened when FVII was 
added to this system. The amount of FVII was determined by adding a series of 
concentrations of FVII in the clotting assay with TNFα-activated PAECs. Therefore, 0.05 
U/10ul of FVII was used in the further experiments (Figure 2.8-1).  





















Figure 2.8-1 The dosage of FVII was determined in FVII-deficient plasma recalcified 
clotting assay with the addition of FVII. 
The recalcified clotting assays were performed in FVII-deficient plasma by using 1x 105 
PAECs, which had been activ ated  b y TNFα for 8  hours. The clotting  times were 
measured when a series of diluted concentrations of FVII were added. 
 
2.8.3.2 Standard curves of TF activity  
The procedure was repeated with the addition of FVII (in a separate assay) and the 
activity of TF was determined by the ratio of the clotting times measured with/without 
FVII. The clotting times were determined in triplicate and results, were quantified from a 
standard curve prepared by a series of dilutions of soluble recombinant human TF (R&D, 
Minneapolis, MN) and expressed as a procoagulant activity equivalent to ng human TF 
per 1x 105 PAEC , 1x 105  PBMCs or 2x 106 platelets ( Figure 2.8-2).   





































































Figure 2.8-2 Standard curves of TF activity in FVII-deficient plasma clotting assay. 
PAECs (A), platelets (B) and PBMCs (C).  
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2.9 FLOWCYTOMETRY   
Flow microfluorometry of cells was performed with an argon laser emitting 488 nm and a 
quartz flow cell. For non-suspension cells (ECs), the cells were harvested by trypsin-
EDTA, and then maintained at 4ºC for all subsequent handling. The cells were washed 
twice, then counted and assessed for viability. The cells were pelleted again by 
centrifugation for 5 minutes at 1800 rpm at 4ºC and resuspended in cold FACS buffer 
containing fluorescently-conjugated primary Abs or non-conjugated primary Abs. If 
unlabeled primary Abs were used, the cells were stained again with fluorescently-
conjugated secondary Abs after 30 minute incubation with primary Abs and washing 
twice. The primary and secondary Abs were listed in Table 2.9-1,2. 
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Antigens Clones (isotype)  Sources  
CD31 PE TLD-3A12 (mouse IgG1κ) BD Pharmingen 
CD42a FITC ALMA,16 (mouse IgG1) BD Pharmingen 
CD45RA  PE-Cy™5 5H9 BD Pharmingen 
CD46 FITC MEM-258 (mouse IgG1) Serotec  
CD62p FITC AC1.2 (mouse IgG1) BD pharmingen 
CD62P/E (human)  1.2B6 (mouse IgG1) Serotec  
CD62P (human) AK4 (mouse IgG1κ) eBioscence  
CD62P (pig) 12C5 (mouse IgG) Gift from Professor Haskard 
CD106  10.2C7 (mouse IgG)  Gift from Professor Haskard 
(Imperial College) 
Gal (BS-IB4) FITC   Sigma  
Gal (UEA-1) FITC  Sigma 
IgG (γ chain-
specific) 
 Invitrogen  
IgM (μ chain 
specific)  
 Invitrogen  
Mouse IgG1 isotype  X40 BD Pharmingen  
Mouse IgG1 FITC  clone W3/25 Serotec 
Mouse IgG1 PE  Serotec  
Mouse IgG2b X40 BD Pharmingen 
Sheep IgG   Affinity Biologicals 
TF Goat polyclonal IgG Affinity Biologicals  
TFPI Rabbit polyclonal IgG  American Diagnostica   
vWF  F8/86 (mouse IgG1) Dako  
 
Table 2.9-1 Primary antibodies for flowcytometery.  
 
Determinants  Conjugates   Sources  
Anti-mouse IgG (goat) FITC Sigma  
Anti-sheep IgG (donkey) FITC  Sigma  
 
Table 2.9-2 Secondary conjugated antibodies for flowcytometery. 
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2.10 QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN 
REACTION (RT-PCR)  
 
2.10.1  Preparation of RNA from cells and tissues   
Total RNA was extracted by using the 500 µl Trizol reagent (Invitrogen) from the cells (2 
x 105 PAECs, 2 x 106 PBMC and 2 x 107 platelets) and tissue (native or transplanted heart, 
kidney and liver), which were grind to particles on dry ice as small as possible. 100 µl of 
chloroform (Sigma) was added to the suspension, which was votexed for 15 sec and 
incubated on the ice for 10 minutes prior to centrifugation at 14,000g for 10 minutes. The 
upper layer containing RNA was mixed with equal volume of isopropanol (Sigma) at 4ºC 
for 10 minutes. The RNA was precipitated by centrifugation at 14,000 g for 10 minutes. 
The RNA pellet was washed once with 75% ethanol and suspended in 1µl gel, showing 3 
RNA bands (no evidence of laddering indicative of RNA degradation).  RNA content was 
measured using 260/280 UV spectrophotometer.  
 
2.10.2  RT-PCR  
RT-PCR was performed by a two step technique. Complementary DNA (cDNA) was 
prepared from RNA.  Three micrograms (3μg) of total RNA in 10µl from each sample 
and 1µl oligo dT (10µg/µl) (Invitrogen) were heated to 68ºC for 4 minutes and immediate 
cooled to 4ºC for 15 minutes. The reaction matrix containing 4µl 5x first strand buffer 
( 250mM Tris-HCl,  375mM KCl, 15mM MgCl2) (Invitrogen), 2µl of 100mM 
dithiothreitol (DTT) (Invitrogen), 2µl of RNAase free water, 1µl of 10mM dNTPs 
(Invitrogen) and 1µl of  Superscript III (Invitrogen) was added to RNA to generate first-
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strand cDNA. The sample was incubated for 1 hour at 42ºC, and heated to 72ºC for 15 
minutes to stop the reaction. The synthesized cDNA was stored at -20ºC. 
 
2.10.3  Quantitative PCR   
PCR mixture was prepared using 8 µl cDNA (0.15µg/µl), 10µl SYBR Green PCR Master 
Mix (Applied Biosystems) and 1 µl of sense and anti-sense primers. Primers for porcine 
and baboon TF were purchased from Invitrogen and are listed in Table 2.10-1. The 
primers were design to span at least one intron of the genomic sequence to avoid genomic 
DNA contamination. The sequences of the above primers were analyzed in triplicate. 
Thermal cycling conditions were 10 minutes at 95°C to activate the Amplitaq Gold DNA 
polymerase, followed by 40 cycles of 95°C for 15sec and 60°C for 1minute on an ABI 
PRISM 7000 Sequence Detection System (Applied Biosystems). Using the 
manufacturer's software, real-time PCR data were plotted as the ΔRn fluorescence signal 
versus the cycle number. The threshold cycle was defined as the cycle number at which 
the ΔRn crosses this threshold. The expression of each gene was normalized to actin 
mRNA content and calculated relative to control using the comparative CT method.   
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Primers  Sequences  
Baboon TF  Sense 5’-TGCTTTTACACAGCAGACACAGAGT-3’ 




 Anti-sense 5’ TACTATCCAATCCTAGAAAGAACATG-3’ 
Porcine TF  Sense 5’- TTTACCAACTCGCCCCCCTTC -3’ 
 Anti-sense 5’- AATGTGCCGTTCACCCTGACTAAG -3’  
Po rcine  β 
actin 
Sense 5’- CTCGATCATGAAGTGCGACTG -3’ 
 Anti-sense 5’-GTGATCTCCTTCTGCATCCTGTC-3’ 
 
Table 2.10-1 RT-PCR primers of TF and β actin.  All primers are known to span intron. 
 
2.11 IMMUNOFLUORESCENCE STAINING  
Tissues were harvested, immersed in OCT compound (Miles, Elkhart, Indiana), snap-
frozen in liquid nitrogen and stored in -80ºC. Sections were cut on a Cryostat and dried 
for one hour at room temperature. 4μm-frozen sections were prepared on gelatin-coated 
slides at the Department of Pathology in the Thomas E. Starzl Transplantation Institute.  
The samples were kept at room temperature for 30 minutes and fixed in cold acetone 
(Sigma) for 10 minutes. After washing with 0.5% PBS, slides were transferred to 5% goat 
serum (Sigma) for 20 minutes at room temperature to prevent nonspecific Ab binding.  
Then the slides were stained with primary Abs for 60 minutes at room temperature or 
overnight at 4ºC in the dark; then after washing×3, appropriate secondary Abs were 
stained for another 60 minutes at room temperature. DAPI (Vector Laboratories, 
Burlingame, CA) was used for nuclear DNA staining. Finally, the slides were fixed with 
4% paraformaldehyde and prepared by coverslips with gelvatal. The slides were 
examined in a fluorescent microscope (Olympus, CenterValley, PA). The primary and 
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secondary Abs used in immunofluorecent staining are summaried in Table 2.11-1.
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Determinants Clones (Isotype) Sources 
CD31(pig)  mouse IgG  Atigenix American  
CD41 (human) rabbit polyclonal IgG Abcam 
CD45 (human) NPH BD Pharmingen  
CD106 (human) 10.2C7( mouse IgG) Gift from Professor Haskard 
Fibrin (human) Sheep polyclonal Affinity Biologicals  
TF (human) Sheep polyclonal Affinity Biologicals  
TF (pig ) rabbit polyclonal IgG Gift from Dr Vladimir Bogdanov 
Secondary   Conjugation    
Donkey anti-sheep IgG   Cy2 Jackson ImmunoResearch   
Goat  anti-mouse IgG   Cy 3  Jackson ImmunoResearch 
Donkey anti-rabbit IgG   Cy 5 Jackson ImmunoResearch  
 
Table 2.11-1 Primary and secondary antibodies for immunofluorescence staining  
 
2.12 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
The histological and immunohistochemistry examinations of all tissues were performed 
by Dr Bertha Garcia in the Department of Pathology, University of Western Ontario, 
London, Canada. For conventional histology, tissues were fixed in 10% formalin and 
embedded in paraffin. Four-micron (4μm) sections were stained with hematoxylin and 
eosin (H&E) and with martius-scarlet-blue (MSB) for light microscopy.  
Immunohistochemistry staining for IgM, IgG, C3, C4d, and fibrin was performed on 
paraffin sections.  
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2.13 IN VITRO CULTURE SYSTEM 
 
2.13.1  Optimization of culture system 
PAECs or HAECs adherent to a culture flask were pre-incubated for 8 hours with fresh or 
HI human serum (5%), human platelets (5X107/ml), monocytes (5×105/ml), or 
combinations of all three. Five percent (5%) human plasma was selected because this 
concentration resulted in near-saturation of IgG and IgM binding to PAECs by 
flowcytometry, and caused <10% CDC (Figure 2.13-1). Human serum, human platelets 
and monocytes were isolated from blood type A volunteer donors to minimize the effect 
of ABO-incompatibility. After coculture, human monocytes or platelets were collected 
from supernatants, and PAECs were harvested by prewarmed 0.5% trypsin at 37°C for 
flow cytometry and recalcified clotting assay analysis, respectively. 
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Figure 2.13-1 Complement dependent cytotoxicity and antibody binding determine 
optimal concentration of human plasma in the culture system. 
A. The PAECs were incubated with a series of concentrations of fresh or heat-inactivated 
(HI) human plasma (HP) for 4 hours. The CDC of human serum was determined by 
LDH lytic assay.  
B. The PAECs were incubated with a series of concentrations of HI human plasma for 30 




  107 
2.13.2  Transwell culture system  
To dissect the molecular interactions between adhesive PAECs and platelets or 
monocytes, a transwell system was used to separate the two components and determine 
the role of cell-to-cell contact. Adhesive PAECs were cultured in the lower chamber; 
platelets and monocytes/PBMCs were incubated in the upper chamber. The conditions of 
the culture system were the same as in the non-transwell culture system.  
 
2.13.3  Neutralizing antibody experiments    
In some experiments, the cells involved in the culture system were pe-incubated with a 
series of  diluted concentrations of neutralizing Abs for 30 minutes at 4ºC in the same 
medium as used in the culture system. The neutralizing Abs are listed in the Table 2.13-1. 
Then the cells were incubated as previous described without washing.  
 
Determinants Clones (Isotype) Sources 
CD106 (human) 10.2C7 ( mouse IgG) Gift from Professor Haskard 
CD162 (human) PL1 (mouse IgG1κ) MBL International 
CD41 (human) PM6/288 (mouse IgG1) Serotec 
CD42b (human) Ak2 (mouse IgG1) Serotec 
CD62P (human) AK4 (mouse IgG1κ) eBioscence 
CD62P (pig) 12C5 ( mouse IgG) Gift from Professor Haskard 
CD62P/E (human) 1.2B6 (mouse IgG1) Serotec 
Clk-1 (human) Goat polyclonal IgG Santa Cruz  
IgG Fab (human) Goat IgG Sigma 
PAR-1 (human) Goat polyclonal IgG R&D system 
SLA I 1E3 (mouse IgG1) BD 
SLA II (SLA-DR) 1053h2-18-1(mouse 
IgG2a) 
BD 
TF (human) Sheep polyclonal IgG Affinity Biologicals 
vWF (human) 1.B 690 (mouse IgG1)  Santa Cruz  
 
Table 2.13-1 Neutralizing antibodies.   
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2.14 IN VITRO PLATELET AND PBMC AGGREGATION MODEL  
Platelets play a key role in mediating inflammatory and thrombotic responses during 
health and disease. Once activated, circulating platelets bind to leucocytes, predominantly 
monocytes, forming platelet-leucocyte aggregates. Importantly, we observed that platelet-
leucocyte aggregates dramatically increased during development of consumptive 
coagulopathy in pig-to-primate organ transplantation (Chapter 7).  
 
Therefore, an in vitro model was set up to clarify the interaction between platelets and 
PBMCs by the aggregates. Platelets and PBMCs were isolated from the same individual 
primates. 5×105 PBMCs and 5×106 platelets (1:10 ratio) were co-cultured with medium 
(control), HAECs (allograft control) and PAECs in 6 well plates with 2ml culture medium. 
The cells were stained by CD45RA as a PBMC marker and CD42a as a platelet marker. 
The percentage of CD42a-positive cells in CD45RA cells were designated as platelet and 
PBMC aggregates. 
 
2.15 ANIMAL MODELS  
Baboons (Papio species, Division of Animal Resources, Oklahoma University Health 
Sciences Centre, Oklahoma City, OK, and the Southwest Foundation for Biomedical 
Research, San Antonio, TX) weighing 6-10kg and of known ABO blood type, were 
recipients. Pigs of blood group O (nonA), weighing 10-20kg (Revivicor, Blacksburg, VA), 
served as sources of xenograft organs, and were generated by nuclear transfer/embryo 
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transfer from modified fibroblasts from Large White/Landrace/Duroc cross-breed pigs. 
All pigs were negative for expression of cytomegalovirus (CMV). 
 
Pigs from 4 sources, namely (i) wild-type (WT) or (ii) GT-KO pigs, or (iii) pigs 
transgenic for the complement-regulatory protein, CD46, or (iv) TFPI.  The WT, GT-KO, 
and TFPI transgenic pigs were of Large White/Landrace/Duroc cross-breed, but were not 
from identical clones; however, the only major difference was in the absence of Gal 
antigens in the GT-KO pigs (Phelps et al., 2003) or the expression of TFPI.  The 
differences of DNA sequences between wild type of GT-KO pigs were presented in 
Figure 2.15-1 Sequencing analysis of the 1,3GT gene from wild-type pig cells and DKO 
porcine fetal fibroblasts.. The CD46 transgenic pigs were derived from a different herd of 
Large White pigs (Loveland et al., 1993). Constructs of TFPI encoding three human 
Kunitz domains of TFPI-CD4-P-selectin, and in vitro characterization after expression on 
endothelial cells have been described previously (Chen et al., 1999a; Chen et al., 1999b; 
Chen et al., 2004b; Riesbeck et al., 1997). A human CD31 promoter was generated and 
cloned into the vector for microinjection .  
 
The pig-to-baboon organ transplantations included kidney, liver and aortic patch grafts. 
The aortic and kidney transplantation were organized by Dr Cooper and Dr Ezzeelarab; 
the liver was organized by Dr Cooper and Dr Ekser. 
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Figure 2.15-1 Sequencing analysis of the 1,3GT gene from wild-type pig cells and 
DKO porcine fetal fibroblasts.  
Small letters and capital letters denote intron and exon sequences, respectively. 
Underlined capital letters indicate the nucleotide where the point mutation occurred. 
Amino acids deduced from the correspondent mutated and wild-type DNA sequences are 
underlined (Adapted from Phelp CJ, Science, 299:411, 2003.) 
  
2.15.1  Preoperative preparation of baboons 
In the pig-to-primate xenotransplantation model, the baboons were quarantined for at 
least one month to exclude infective diseases. Three weeks before operation, the baboons 
were shaved to remove hair on the truck and upper arms and were put in jackets. After 
one-week training, a tether was fixed to the jacket and connected to the cage for another a 
week training. Approximately 7 days pretransplantation, intravascular catheters were 
inserted into the right internal and external jugular veins and carotid artery under general 
anesthesia, allowing drug and fluid administration and blood withdrawal. Antibiotics 
(cefazolin) and analgesia were administered twice a day for 3 days and an anti-ulcer drug 
(histamine2 –blocker, famotidine 0.25 mg/kg) was given twice a day. 
  111 
 
2.15.2  Donor organ harvest  
Under full inhalational anesthesia, the surgery was begun with a long midline laparotomy, 
usually performed by Dr Hara and Dr Echeverri. After heparinization (300 units/kg, IV), 
1 liter of cold UW solution was perfused via the abdominal aorta, allowing the effluent to 
drain from the hepatic veins after division of the inferior vena cava. The organs, such as 
liver and kidneys were covered with cold saline and ice slush to cool them externally 
while the perfusate was running. The donor organs such as kidney, liver were procured by 
dividing the adjacent vessels and stored in ice-packed UW solution until transplanted.  
The donors were euthanized by exsanguination under anesthesia. 
  
2.15.3  Aortic patch transplantation  
A long midline laporotomy was performed as a sterile procedure and the abdominal aorta 
was isolated. The aorta was opened longitudinally between the origin of the inferior 
mesenteric artery and the bifurcation. An oval-shape aorta patch, which was harvested 
from internal carotid or iliac arteries of  a GT-KO pig were sutured under the side clamp 
of aorta (Figure 2.15-2) When all bleeding was meticulously stopped, the abdominal 
incision was closed layer by layer with interrupted sutures to minimize the risk of 
dehiscence. This model was used to test the efficacy of different combinations of 
immunosuppressants compared with no immunosuppressant. At the same time, the 
baboons in the control group without immunosuppression were sensitized by grafts from 
GT-KO pigs and conferred therefore high titres of anti-nonGal Abs. 
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Figure 2.15-2 Aortic patch transplantation.  
Aortic patch from GT-KO pig (Arrow) was implanted into lower abdominal aorta of a 
baboon. 
 
2.15.4  Kidney transplantation  
Through a midline laporatomy, both kidneys were isolated and removed by ligation and 
division of renal arteries, veins and ureters. The porcine donor kidney was implanted by 
renal artery-aortic, renal vein-caval anastomoses and ureterocystostomy. Since both 
native kidneys were removed, all urine was excretion was from the implanted xenograft, 
which was one of the parameters of renal function.  This model was performed to test the 
benefit of organs from genetically-modified pigs, such as GT-KO, MCP (+/+) and GT-
KO with MCP (+/+). 
 
2.15.5  Liver transplantation 
Through a midline laparotomy, the native liver was removed by division of the common 
bile duct, hepatic artery, portal vein and inferior vena cava. The donor liver was 
  113 
implanted by cavo-caval anastomoses for outflow reconstruction, subsequently portal-
portal and hepatic artery to celiac trunk anastomosis and choledocho-choledochostomy 
for biliary reconstruction. The model was performed to examine the possibility of a 
xenoliver transplantation becoming a bridging procedure to allotransplantation for 
patients with acute hepatic failure, and to investigate the benefit of donor organs from 
GT-KO and GT-KO/ MCP (+/+) pigs compared to WT pigs. 
 
2.15.6 The definition of consumptive coagulopathy  
Although consumptive coagulopathy has been recognized for a long time in 
xenotransplantation, the distinct definition and clinical manifestations remain unclear. 
Several coagulation profiles such as fibrinogen, thrombin-antithombin, D-dimstill rer and 
PT/INR, were used to detect consumptive coagulopathy ( Cozzi et al., 2004; Chen et al., 
2005). 
  
During AHXR, many recipients develop consumptive coagulopathy, which presents with 
massive consumption and exhaustion of coagulation proteins and activation and 
aggregation of platelets. In this study, consumptive coagulopathy was defined when the 
following signs occurred: 1. unexplained thrombocytopenia and anemia; 2. decreased 
serum level of fibrinogen; 3. baboons being unwell clinically and requiring euthanasia; 4. 
overt bleeding. 
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2.15.7 Animal groups 
Organ transplantation was divided into 4 groups. A baboon-to-baboon liver 
allotransplantation was used as an allograft control, and designated as Group I (liver, n=1). 
A HAR model was developed by using WT pig-to-baboon xenograft without any 
immunosuppressant as Group II; (liver, n=1 and kidney, n=1). Non-HAR models were 
performed by transplanting organs from WT, GT-KO or GT-KO/MCP (+/+) pigs into 
baboons with or without immunosuppressants to avert HAR and were designated as 
Group III (kidney, n=8) and Group VI (liver, n=4). The types of grafts and 
immunosuppression are described in Table 7.2-1.  Four baboons that underwent liver 
allotransplantation (2) and xenotransplantation (2) were excluded because their survivals 
were less than 24 hours due to severe hypotension or hypoxic injury during the operation. 
Immunosuppressive protocol 
 
The recipient baboons received either no immunosuppressive therapy (n=4), MMF-based 
immunosuppressant for kidney grafts (n=5), or tacrolimus-based immunosuppressant for 
liver transplantation (n=5). Thymoglobulin, low-dose anti-CD154mAb (with a human 
anti-human CD154mAb (ABI193) generously provided by NovartisPharma, Basel, 
Switzerland) and mycophenolate mofetil   (MMF) were routinely used in kidney 
transplantation groups with immunosuppressants. CVF was used in one WT baboon 
(B3907) but not in other baboons when the grafts were from pigs that were transgenic 
MCP. In liver transplantation, thymoglobulin, tacrolimus and MMF were given. 
Methylprednisolone was administered in both groups, then tapered. The details of dosage 
and timing of immunosuppressants are summarized in Table 2.15-1,2. 
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________________________________________________________________________
Induction Therapy          Dose                    Duration 
Thymoglobulin          1-10mg/kg           day -3 and -1    
Cobra venom factor          100 units/day          days -1 to 3                                     
Maintenance Therapy     Dose                      Duration   
Anti-human CD154mAb    25mg/kg               days -1, 0, 4, 7, 10, 14, and then  
                                          20-25mg/kg            every 5 days (to maintain a blood                       
                                                                         trough level >400μg/mL)                                                          
Mycophenolate mofetil  25-110mg/kg/day      from day –2 (to maintain a constant 
                                                                                blood level of 3-5μg/mL)   
Methylprednisolone           4 - 0.5mg/kg           from day 0 (tapering) 
Supportive therapy          Dose                      Duration   
Prostacyclin                       20ng/kg/min            days 0-7  
Dopamine                          2-3µg/kg/min           day 0  
Ganciclovir                       5mg/kg/day               from day -5  
Famotidine                        0.25mg/kg/x2/day     from day -5  
Heparin                             5-50U/kg/h                from day 0 (to maintain PTT at  
                100-150 sec from day 3) 
________________________________________________________________________ 
Table 2.15-1 Immunosuppressive and supporting therapy in kidney 
xenotransplantation.  
*All therapy was given intravenously, PTT = activated partial thromboplastin time 
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Induction therapy  Dosage  Duration  
Thymoglobulin  1-10 mg/kg IV 1-10 mg/kg IV 
Maintenance  therapy  Dosage  Duration  
Tacrolimus  0.05-0.2 mg/kg twice a day 
IM 
Starting from -2 
MMF 110 mg/kg continuous IV  Starting from -4 
Steroid  10 mg/kg/day  Starting from 0 and taper 
 
Table 2.15-2  Immunosuppressive protocol for liver xenotransplantation.  
IV: intravenous, IM: intramuscular 
 
2.15.8 Postoperative medication and supportive care 
All animals received prophylactic intravenous (iv) antibiotics for the first 3 post-
transplant days and some animals received daily ganciclovir for prophylaxis of CMV 
infection. Because consumptive coagulopathy can develop in baboons with pig organ 
grafts and in view of the published association of some anti-CD154mAbs with 
thromboembolic complications, heparin was begun on day 0 (day of Transplantation) and 
gradually increased in an effort to maintain the activated partial thromboplastin time at 
approximately 150sec from day 3.  However, this goal was not always achieved.  Washed 
baboon red blood cells were administered when necessary to maintain the hematocrit 
>20%.   
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2.15.9 Monitoring of recipient baboons 
Blood cell counts, chemistry, and coagulation parameters were measured initially daily 
and subsequently at several time-points each week or weekly by standard methods.  The 
serum trough level (immediately before the next dose) of the anti-CD154mAb was 
monitored by ELISA (maintained at >400μg/mL in baboons). Blood cultures were 
performed when indicated by clinical features suggesting infection.  
  
2.15.10  Euthanasia of animals 
For the welfare of the animals, they were euthanized with sodium pentothal in the 
necropsy room. Blood were tissue samples were harvested during euthanasia.  In the 
studies related to this thesis, the baboons were euthanized when they developed 
untreatable consumptive coagulopathy or the grafts failed.     
 
2.16 HEMATOLOGICAL AND BIOCHEMICAL PARAMETERS  
Whole blood was collected in 3.2% trisodium citrate anticoagulant solution. All 
hematologic and biochemistry tests were performed at the Central Laboratory or 
Transfusion Medicine Diagnostics Coagulation Reference Laboratory of University of 
Pittsburgh Medical Centre.  Both automated and manual assays were utilized in this study. 
Automated assays were performed using a Behring Coagulation System (BCS; Dade 
Behring, Newark, DE) and an ACL 3000 (Instrument Laboratories, Miami, FL).  
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2.17 STATISTICAL ANALYSIS  
Statistical analysis was performed using Student’s t test in SPSS, 11th version (Chicago, 
IL) software. For any in vitro work shown in graphical presentation, the data were 
presented with mean ± SE (standard error) based on 3 independent experiments. P<0.05 
was considered significant. The mean and standard error were calculated using Microsoft 
Excel functions (Microsoft Corporation, Redmond, WT).   
 
2.18 ETHICAL APPROVAL 
All animal care was in accordance with the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and 
Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and 
published by the National Institutes of Health (NIH publication No. 86-23, revised 1985).  
Protocols were approved by the Institutional Animal Care and Use Committee in the 
University of Pittsburgh.   
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CHAPTER 3  
TF EXPRESSION ON PAECS, PLATELETS 
AND MONOCYTES IN VITRO  
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3.1 INTRODUCTION  
The Ab-mediated immunologic barrier between primates and pigs hinders the success of 
xenotransplantation. Several strategies have been developed to overcome HAR and 
prolong graft survival (Cooper et al., 2007). Nonetheless, AHXR ensues and leads to 
intravascular thrombosis.  
 
For example, transplanting hearts from GT-KO pigs (Phelps et al., 2003) into baboons 
prolonged median survival to 78 days, but eventually all grafts succumbed to ischemic 
necrosis from thrombotic microangiopathy (TM) (Kuwaki et al., 2005). Nevertheless, the 
pathology in these grafts was different from typical AHXR and revealed microvascular 
thrombosis in arterioles, capillaries, and venules, with only rare interstitial mononuclear 
cells. Whether these changes resulted from low-grade humoral rejection or non-
immunologic factors, such as coagulation dysregulation, remains uncertain. 
 
TF binds FVII/VIIa, and the complex TF-FVIIa activates FX and FIX to initiate 
coagulation (Mackman, 2004; Morrissey, 2001). ECs and monocytes constitute the main 
origins of TF, as shown in inflammation and sepsis models (Keller et al., 2003; Warr et 
al., 1990). Microparticles shed from EC, or monocytes, are the main source of circulating 
TF, and transfer TF to platelets (Giesen et al., 1999; Monroe and Key, 2007). Recently, 
platelets have been shown to be capable of synthesizing and expressing functional TF 
(Schwertz et al., 2006). 
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The importance of TF as the initiator of thrombosis after xenotransplantation has not been 
formally studied. In vivo studies demonstrated that expression of TF was up-regulated in 
necrotic xenografts (Ierino et al., 1998; Nagayasu et al., 2000; Shimizu et al., 2005). The 
expression of TF on PAECs was up-regulated by activated platelets or complement by 
XNA (Gollackner et al., 2004; Xu et al., 2001). These studies suggested TF as an initiator 
of xenograft thrombosis.  
 
However, the origins of TF and the interaction between PAECs, human monocytes and 
platelets are not fully understood.  In this study, we developed an in vitro model to 
attempt to elucidate the interactions between PAECs and human monocytes and platelets 
in terms of expression of TF, and we attempted to demonstrate that TM is initiated by TF.   
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3.2 RESULTS  
 
3.2.1 The characteristics of anti-human TF antibody  
Upregulation of cell surface TF expression was detected on PAECs after activation by 
TNF-α (10 ng/ml, Sigma) by FACS analysis using the sheep anti-human TF Ab (Figure 
3.2-1A). These cells promoted shorter clotting times of recalcified normal plasma 
compared to control unactivated PAECs (Figure 3.2-1B), however the Ab failed to inhibit 
this difference, indicating that although it detected TF expression on the surface but it did 
not functionally inhibit porcine TF-initiated coagulation. The shortening of clotting 
involved with activated PAECs resulted from the effect of TF since it was normalized 
when performed in FVII-deficient plasma (Figure 3.2-1C).  In contrast, it was able to 
inhibit the activity of human TF on a TF-positive control human breast cancer cell line 
(Figure 3.2-1B). Therefore, this Ab was used to differentiate the origin of TF, either from 
human or pig. 
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Figure 3.2-1 The characteristics of sheep anti-human TF antibody 
A. PAECs activated by TNF-α (10ng/ml) for 8 hours induced porcine TF activity 
measured by flow cytometry using the sheep anti-human TF Ab (open) or an isotype 
control (black).  
B. Clotting times of recalcified normal human plasma.  Left panel: results without 
exposure to cells (control, blank) or after exposure to a human TF-positive breast 
cancer cells. Right panel: results following no activation (control) or TNFα activation 
of PAECs. (Open bars - no additional sheep anti-human TF Ab.  Closed bars - sheep 
anti-human TF Ab incubated with cells for 30 minutes prior to the clotting assay.)  
C. Clotting time of recalicified FVII-deficient plasma involved with activated PAECs 
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3.2.2 Procoagulant activity of PAECs 
After incubation with human plasma, human platelets, human monocytes, or 
combinations of all three, expression of TF and VCAM-1 (CD106; as an activation 
control) on PAECs was analyzed by flowcytometry. Untreated PAECs were TF-negative 
and VCAM-1-positive. Prior incubation with human plasma induced TF and VCAM-1 
expression (Figure 3.2-2A). When platelets or monocytes were included in the incubation 
step with human plasma, they had no additional impact on TF or VCAM-1 expression 
(Figure 3.2-2A).  Incubation of PAECs with platelets or monocytes alone in the absence 
of human plasma did not induce TF or VCAM-1 expression (Figure 3.2-2A).  However, 
HI human plasma resulted in no induction of TF or VCAM-1. The observed induction of 
TF antigen on the surface of PAECs was confirmed by increased TF activity as evidenced 
by a shortening of clotting times in a normal plasma recalcified assay (Figure 3.2-2B). 
The shortening of the clotting time was shown to be TF-dependent since the PAECs did 
not shorten the clotting time of FVII-deficient plasma (Figure 3.2-2C). The failure of the 
anti-human TF Ab to inhibit the clotting activity demonstrates this activity is porcine TF 
and not human TF derived from the human plasma (Figure 3.2-2B). 
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Figure 3.2-2 PAECs express TF activity dependent on the presence of complement. 
PAECs were co-incubated with various stimuli for 8 hours, and studied by flow 
cytometery and the recalcified clotting assay performed using both normal and FVII-
deficient plasma. Addition of sheep anti-human TF Ab was performed separately to 
determine the origin of TF.  
A.  TF and CD106 expression (open) on PAECs (black: isotype control) by flow 
cytometry.  
B.  Recalcified clotting assay using normal plasma with (black) or  
     without (open) pre-treated with sheep anti-human TF Ab after PAECs  
     were pre-incubated in the presence (left) or absence (right) of fresh human plasma. 
C.  Recalcified clotting assay using FVII-deficient plasma after PAECs were    
     pre-incubated in the presence (left) or absence (right) of fresh human plasma. (ns = no     
    significant difference, HP = human plasma, HI-HP = HI human plasma, Mon =   
    monocytes, PLT = platelets). 
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3.2.3 Procoagulant activity of human monocytes and platelets in the presence of 
human plasma  
To determine the procoagulant effect on monocytes or platelets of 8-hour co-incubation 
with PAECs and human plasma, these cells were isolated and analyzed by flow cytometry. 
Low levels of TF expression were detected on monocytes after coincubation with HAECs 
and human plasma but not on platelets.  However, TF expression was significantly 
induced on both monocytes and platelets after coincubation with PAECs in the presence 
of human plasma (Figure 3.2-3A).  In clotting assays with recalcified normal plasma, 
clotting times induced by these cells were shortened compared to those induced by 
untreated monocytes or platelet controls (Figure 3.2-3B), but only in normal, not FVII-
deficient plasma clotting assays (Figure 3.2-3B), demonstrating that this shortening was 
TF-dependent.  The anti-human TF Ab inhibited shortening of the clotting time, 
consistent with the findings flowcytometry, indicating human TF was expressed on 
monocytes and platelets.  Incubation with PAECs in the presence of human plasma 
therefore induced pro-coagulant human TF expression on both monocytes and platelets.  






Figure 3.2-3 Human monocytes and platelets express human TF in the presence of 
human plasma. 
Human monocytes and platelets were harvested from supernatants after co-incubation 
with HAECs or PAECs in the presence of 5% human plasma for 8 hours. 
A.  TF expression (open) on monocytes and platelets (black: isotype control) by flow 
cytometry.  
B. Clotting times of recalcified normal (left) and FVII-deficient (FVII(-)) (right) clotting 
assays in the presence of resting (control) or pre-incubated  (with HAECs+HP or 
PAECs+HP) human monocytes or platelets. Clotting assays were also performed 
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following prior incubation of the monocytes or platelets with sheep anti-human TF Ab 
(black) 
 
3.2.4 Procoagulant activity of human monocytes and platelets in the absence of 
human plasma 
To determine the contribution of human plasma to the induction of TF, these experiments 
were repeated without human plasma in the incubation step, so that monocytes and 
platelets were incubated with PAECs alone.  Under these conditions, TF was still induced 
on both monocytes and platelets (Figure 3.2-4A). In clotting assays, the results using 
monocytes were identical to those in the presence of human plasma, indicating that 
procoagulant human TF was induced on monocytes by incubation with PAECs (Figure 
3.2-4B).  Nevertheless, the changes in clotting times induced by activated platelets were 
different. Although the results from FVII-deficient plasma confirmed that shortened 
clotting times were TF-dependent, TF activity was not inhibited by anti-human TF Ab, 
indicating that procoagulant porcine TF was associated with platelets following 
incubation with PAECs. 






Figure 3.2-4 Human monocytes express human TF activity but platelets confer 
porcine TF activity in the absence of human plasma. 
Monocytes and platelets were co-incubated with PAECs in the absence of 5% human 
plasma.   
A. TF expression on monocytes and platelets (open) (black: isotype control) by flow 
cytometry. 
B. clotting times of recalcified normal (left) and factor VII-deficient (FVII(-)) (right) 
plasma clotting assays involved with resting (control) or pre-incubated (with HAECs 
or PAECs) human monocytes or platelets. Coagulation assays were also performed 
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separately following prior incubation of activated the monocytes or platelets with the 
sheep anti-human TF Ab (black). (ns = no significant difference). 
 
3.2.5 Human platelets induce PAECs apoptosis and shedding of TF-positive platelet-
PAEC aggregates  
To further investigate these results, we examined the interaction between human platelets 
and PAECs. After incubation with human platelets for 8 hours, the PAECs underwent 
significant apoptosis, as assessed by flow cytometry using annexin V and PI, which was 
partially inhibited in the presence of human plasma.  In contrast, incubation with human 
monocytes provoked only a minimal increase in apoptosis of the PAECs (Figure 3.2-5A). 
Moreover, platelets were isolated after incubation with PAECs in the absence of human 
plasma, and stained with CD106 (red) and TF (green), and examined using 
immunocytochemical techniques (Figure 3.2-5B). Compared to control platelets, platelets 
incubated with PAECs became TF-positive, CD106-negative (arrow), indicating that the 
encounter with PAECs had activated them.  However, this analysis clearly revealed the 
presence of larger, irregular particles that were double-positive for both markers 
(arrowheads).  These were assumed to be fragments of apoptotic PAECs that expressed 
porcine TF and attached with platelets.  The presence of significant quantities of these 
PAEC-platelet aggregates in the purified platelets accounted for the clotting time results 
(shown in Figure 3.2-4B), suggesting the presence of porcine TF. 












Figure 3.2-5 Human platelets induce PAECs apoptosis. 
A. PAECs were isolated after co-incubation with various stimuli for 8 hours.  Apoptosis 
was measured by flow cytometry. The percentage of cells is indicated. 
B. Immunocytochemical analysis of platelets following co-incubation with or without 
PAECs for 8 hours. Cells were stained with the sheep anti-human-TF Ab (FITC, green) 
and anti-porcine CD106 Ab (TRITC, red), then examined by fluorescence microscopy. 
TF-positive and CD106-negative cells are indicated by arrows and assumed to be 
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activated platelets. The larger, irregular particles double-positive for both markers are 
indicated by arrowheads; these were assumed to be fragments of apoptotic PAEC, which 
expressed porcine TF and attaced to activated platelets (platelet-PAEC aggregates). 
 
3.2.6 Procoagulant activity of PAECs, baboon platelets and PBMCs  
Since baboons are a commonly-used primate surrogate for humans in pig-to-primate 
xenotransplantation models, all experiments were repeated by incubating PAECs with 
baboon platelets and PBMCs in the presence or absence of baboon serum. Monocytes 
were replaced by PBMCs because the Abs for selecting baboon monocytes were not 
available. The results of clotting assay were identical to those found in experiments with 
human components. PAECs were activated to express TF only in the presence of 
complement, and PAECs activated baboon platelets and PBMCs to express TF activity 
independent of the presence of baboon serum (Figure 3.2-6). 









































Figure 3.2-6  Baboon serum activates PAECs and PAECs activate baboon platelets 
and PBMCs to TF activity.   
A. PAECs were incubated with medium (control), fresh or HI baboon serum (BS) for 8 
hours. TF activity of PAECs was determined by clotting assay in normal plasma.  
B. Baboon platelets and PBMCs were incubated with medium (control) or PAECs 
with/without BS for 8 hours. TF activity of PBMCs (white) or platelets (grey) was 
determined by clotting assay in normal plasma. (*,#: p<0.05, compared to control 
group resepectively)   
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3.3 DISCUSSION  
The expression of TF has been increasingly recognized during HAR or AHXR 
(Gollackner et al., 2004; Ierino et al., 1998; Nagayasu et al., 2000) and linked to the 
activation of PAECs. The factors resulting in procoagulation have been hypothesized to 
play an important role in early xenograft failure.  Most previous studies have focused on 
EC activation by XNA or/and subsequent complement activation as the trigger to 
coagulopathy and graft failure after xenotransplantation. However, two other factors are 
important to consider.  
 
First, molecular incompatibilities of the coagulation-anticoagulation system of pig and 
primate may also contribute to the development of coagulation disorder. For example, 
porcine vWF aggravates the thrombotic process (Schulte Am Esch et al., 2005), and, 
conversely, TFPI and thrombomodulin fail to down-regulate the propagation of 
thrombosis (Kopp et al., 1998a; Kopp et al., 1998b; Siegel et al., 1997).  Second, 
thrombosis can be initiated not only by TF activity on ECs but also by blood-borne TF, 
expressed by monocytes, platelets or circulating microparticles, all of which may have 
prothrombotic activity and substantially contribute to the formation of thrombosis 
(Bogdanov et al., 2003; Falati et al., 2002).  
 
My study has attempted to address the relevance of this blood-borne TF as a potential 
mechanism that may contribute to the coagulopathy seen in AHXR. The present study 
confirmed that PAECs express TF after incubation with human plasma, and that this 
effect is lost after with HI human plasma, suggesting that it is a complement-dependent 
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process, compatible with the previous findings of other groups (Gollackner et al., 2004).  
We have assumed this is due to the presence of XNA, so it could be labeled as a 
procoagulant effect that is humoral immune response-dependent. 
 
These results also clearly show that resting platelets and monocytes are unable to up-
regulate TF expression of PAECs, consistent with other studies that have shown that only 
activated platelets can activate PAECs to express TF (Bustos et al., 2001; Xu et al., 2001).  
In an allogeneic setting, one study has shown that activated, but not resting monocytes 
were able to activate human ECs in allogeneic experiments. Although others reported 
resting monocytes could also upregulate TF expression on human ECs (Fan et al., 1993).  
 
In systemic inflammatory processes monocytes and platelets are activated to express TF.  
For example, it has been previously reported that monocytes can be activated by 
allogeneic or xenogeneic EC (Kopp et al., 1998b). These results also revealed that 
monocytes were weakly activated by HAECs but much stronger by PAECs. However, 
there are no reports of platelets expressing TF in AHXR. In this study, resting PAECs 
activated monocytes and platelets to express TF, without the requirement of human 
plasma. This is clearly independent of the action of XNA, so could be labeled as being 
humoral immune response-independent.  The situation appears complex for platelets, but 
mainly because, in the absence of human plasma, PAECs undergo significant apoptosis, 
and contribute to the formation of platelet-PAEC aggregates. These porcine TF-positive 
aggregates then resulted in the enhanced clotting seen in re-calcified clotting assay.  
Nevertheless, the staining experiments showed that platelets are activated in these 
  137 
circumstances to express human TF, so we can state with some confidence that PAECs 
induce TF expression on platelets independently of XNA, and therefore independently of 
a humoral immune response.   
 
These results suggest that recipient monocytes and platelets may play an important role in 
thrombotic complications during porcine organ xenotransplantation, and that overcoming 
this complication will not be achieved solely by further manipulation of the humoral 
immune response against the xenograft.  
 
An important question is whether the apoptosis on PAECs after incubation with human 
platelets and resulting shedding of TF-positive aggregates that we observed is relevant to 
thrombotic complication. Although AHXR is mainly associated with ECs activation and 
fibrin deposition along the wall of blood vessels, rather than apoptosis in the endothelium 
(Holzknecht et al., 2002), in an animal study by transplanting human DAF transgenic 
kidney xenografts into baboons, numerous TUNEL-positive cells were detected with the 
destruction of the glomerular structure in the grafts, concomitant with the development of 
TM (Shimizu et al., 2005). The present study showed both human platelets and 
monocytes, but not human plasma alone, can induce apoptosis of PAECs (by detection of 
annexin V expression). Notwithstanding, how platelets induced PAECs apoptotsis 
remained further investigating in xenotransplantation, platelets has been shown to induce 
ECs apoptosis in sepsis model(Kuckleburg et al., 2008). The disruption of integrity of the 
ECs and exposure of phosphatidylserine provoke the ECs to become prothrombotic 
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(Bombeli et al., 1997), so that any degree of apoptosis of luminal ECs in vivo might have 
some implications to thrombosis.  
 
Unlike humans with A, B and/or H antigens, only A and H antigen express on the 
epithelial cell in the genetically-defined porcine blood group system. Importantly, they 
are not present on vascular ECs (Oriol et al., 1993). Furthermore, only blood types A and 
O (most are blood type O) exist in pigs. In these experiments, the ABO antigen of the pig 
was not determined, but was presumably A or O (Busch et al., 2006). Therefore, blood 
type A human plasma, platelets and monocytes were used as the recipient blood 
microenvironment to minimize the side effects of ABO-incompatiblity transplantation.  
 
In summary, although there were some limitations of the current model such as no shear 
force in incubation or no in vivo experiments, which can be carried out in the absence of 
plasma , a novel in vitro model system was defined to examine independently the 
contribution and interaction to thrombosis/TM made by PAECs, human platelets and 
monocytes. I have demonstrated that each may contribute to the expression of 
procoagulant TF after pig-to-primate xenotransplantation. The model is expected to be 
useful to investigate the mechanism of TM after xenotransplantation and to provide 
insights into the type of graft manipulation that could modify the process.  
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CHAPTER 4 
ANTI-NONGAL IgG ANTIBODIES 
ACTIVATE PAECS TO EXPRESS TF 
INDEPENDENT OF COMPLEMENT 
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4.1 INTRODUCTION 
The expression and activity of TF plays a significant role during AHXR. In vivo 
expression of TF was upregulated in necrotic xenografts (Nagayasu et al., 2000; Shimizu 
et al., 2005). In vitro, TF on PAECs was activated by the binding of anti-pig Abs and 
complement activation (Gollackner et al., 2004). The study in chapter 3 indicated that TF 
activity on PAECs was increased only in the presence of complement, but not by Abs, 
monocytes, or platelets alone (Lin et al., 2008).  
 
The generation of GT-KO pigs has increased interest in investigating the role of anti-
nonGal Abs in coagulation in pig-to-primate xenotransplantation models. Despite the 
effect of anti-Gal Abs have been successfully eliminated by neutralizing or depleting Gal 
Abs, most graft were still rejected by AHXR within a few weeks. It has been speculated 
that these grafts were rejected because of the presence and induction of anti-nonGal Abs. 
Recently, anti-nonGal Abs were indeed elevated in DAF (+/+) pig-to-primate heart or 
kidney xenotransplantation models (Chen et al., 2006; Lam et al., 2004).  
 
TFPI is the crucial regulator of coagulation pathway, which is initiated by TF. In vitro, 
expression of hTFPI-CD4 on immortalized PAECs effectively prevented pTF-dependent 
clotting induced by TNF-α(Chen et al., 1999b). In this study, we investigated the role of 
nonGal Abs in coagulation during xenotransplantation and also tested whether TFPI 
transgenic PAECs were resistant to activation of anti-nonGal Abs. 
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4.2 RESULTS  
 
4.2.1 Naïve baboon serum activates PAECs to express TF dependent on complement 
PAECs were incubated with fresh or HI naïve BS  for 8 hours, WT PAECs were induced 
to express TF activity in the recalcified clotting assay only by fresh but not by HI naïve 
baboon serum (Figure 4.2-1A). This confirmed previous study that activation of PAECs is 
dependent on the presence of complement in chapter 3. To determine whether PAECs 
transgenic for hCRP are resistant to the activation of primate serum by regulating 
complement activity, MCP (+/+) PAECs were incubated with fresh naïve BS. Naïve BS 
failed to activate MCP (+/+) PAECs to express TF activity by recalicified clotting assay 
(Figure 4.2-1A). Functional TF activity was mirrored by the expression of RNA, which 
was measured by quantitative PCR after PAECs were pre-incubated with serum for 4 
hours (Figure 4.2-1B).  






































Figure 4.2-1 Naive baboon serum activated PAECs to express TF that is dependent 
on complement. 
A. WT or MCP (+/+) PAECs were incubated with medium (control) and a series of 
concentrations of fresh or HI naïve baboon serum (NBS) for 8 hours. The TF 
activity on the surface of PAECs was determined by the recalcified clotting assay. 
B.  The experiements were repeated with incubation for HI-NBS for 4 hours. The TF 
expression of PAECs was determined by quantitative PCR (*p<0.05 vs control). 
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4.2.2 Sensitized baboon serum activates PAECs to express TF independent of 
complement  
 To determine the effect of anti-nonGal Abs on PAECs, sensitized baboon serum was 
collected from baboons that received aortic patch transplant from GT-KO pigs without 
immunosuppressants 4 weeks previously. Anti-nonGal Abs were determined by 
measuring the IgG and IgM binding of serum to GT-KO PAECs by flowcytometry. 
Sensitized baboon serum conferred 5 times higher titres of anti-nonGal Abs compared to 
naïve baboon serum (Figure 4.2-2A). The experiments were repeated by incubating 
PAECs with fresh and HI sensitized baboon serum. WT PAECs were activated to express 
TF activity by recalcified clotting assay not only by fresh sensitized but also by HI 
sensitized baboon serum (Figure 4.2-2B). Moreover, the MCP (+/+) PAECs were not 
resistant to the activation of fresh and HI sensitized baboon serum (Figure 4.2-2B). This 
indicated that sensitized baboon serum with high titres of anti-nonGal Abs was able to 
activate PAECs independent of the involvement of complement. This effect resulted from 
the presence of anti-nonGal Abs since HI sensitized but not naïve baboon serum activated 
GT-KO PAECs to express TF (Figure 4.2-2C). The TF functional activity by the 
recalcified clotting assay was compatible with the finding of RNA expression by 
quantitative PCR (Figure 4.2-2D).  
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Figure 4.2-2 Sensitized baboon serum activates PAECs to express TF activity 
independent of complement. 
A. The IgG and IgM bindings of naïve (N=15) or sensitized baboon serum (N=3) to 
PAECs were determined by flowcytometry. The binding to GT-KO PAECs 
determines the binding of  anti-nonGal Abs.  
B. WT or MCP (+/+) PAECs were incubated with medium (control) and a series of 
concentrations of fresh or HI sensitized baboon serum (SBS) for 8 hours. The TF 
activity on the surface of PAECs was determined by the recalcified clotting assay ( #: 
p<0.01 compared to control). 
C. GT-KO PAECs were incubated with medium (control) and HI naïve (NBS) or 
sensitized (SBS) baboon serum.  
D. WT, MCP (+/+), GT-KO PAECs were medium (control) and 10% of fresh or HI-SBS 
for 4 hours. The TF expression of PAECs was determined by quantitative PCR 
(*p<0.05 vs control).  
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4.2.3 Sensitized baboon serum activates PAECs to express TF via IgG  
To determine which anti-nonGal Abs activates PAECs to express TF activity, 
dithiothreitol (DTT) was used to destruct the disulfide bonds of IgM and eliminate the 
activity of IgM.  The IgG binding of sensitized baboon serum to PAECs remained the 
same, but IgM binding disappeared after HI sensitized baboon serum was pre-treated with 
DTT for 30 minutes (Figure 4.2-3A). The HI sensitized BS, which was pre-treated with 
DTT activated WT PAECs to express the same level of TF activity, compared to non-
treated serum (Figure 4.2-3B). This implied that the ability of anti-nonGal Abs to activate 
PAECs was unrelated to IgM and presumably related to IgG.  To investigate further, HI 
sensitized baboon serum was pre-treated anti-human IgG Fab Ab for 30 minutes at 4 ºC 
before incubation with PAECs.  The anti-human IgG Fab Ab blocked the effect of HI 
sensitized baboon serum to induce WT PAECs to express TF activity (Figure 4.2-3C).  
This indicated that HI-sensitized baboon serum activated PAECs to express TF through 
IgG, but not IgM, Abs. 
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Figure 4.2-3 Anti-nonGal antibodies activate PAEC to express TF activity via IgG. 
A. IgG and IgM bindings of sensitized baboon serum (SBS) after pre-treated with 
dithiothreitol (DTT, 200µl/ml) to PAECs was determined by flowcytometry.  Shadow: 
isotype, solid line: SBS, broken line: SBS treated with DTT. 
B. WT PAECs were incubated with medium (control) or HI SBS. The TF activity on the 
surface of PAECs was determined by the recalcified clotting assay. Black bar: HI SBS 
treated with DTT for 30 minutes. 
C. The same experiments were repeated with HI SBS, which had been treated with IgG 
Fab Ab for 30 minutes at 4 ºC (*p<0.05, #p<0.01 vs untreated). 
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4.2.4 Human anti-nonGal natural antibodies activates PAECs to express TF  
To determine the role of non-Gal Abs in human, human serum were collected from 15 
volunteers. HI human sera were used to activate WT PAECs to express TF and anti-
nonGal IgG Abs were also detected by flowcytometry. 13% (2/15) of sera had 5-fold high 
as titres of anti-nonGal Abs than other subjects. Consistently, the TF activity of PAECs 
induced by HI human serum was correlated with the titre of anti-nonGal Abs in human 
serum (Figure 4.2-4) HI human serum with high titre anti-nonGal Abs also activated 
MCP (+/+) PAEC to express TF activity (Figure 4.2-4B).  
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Figure 4.2-4 Human serum with high anti-nonGal antibodies activated PAECs to 
express TF independent of complement. 
A. The relationship between the titre of anti-nonGal IgG in human sera (n=15) and TF 
activity of PAECs, induced by HI human sera. The IgG binding of human sera to GT-
KO PAECs was measured as anti-nonGal Abs. The same serum was used to activate 
PAECs and TF activity of PAECs, was determined by the recalcified clotting assay.  
B. MCP (+/+) PAECs were incubated with 10% fresh or HI human sera with high titre of 
anti-nonGal Abs (n=2).  TF activity of PAECs was determined by the recalcified 
clotting assay (#: P<0.01).  
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4.2.5 TFPI (+/+) PAECs inhibit the procoagulant effect of PAECs induced by 
baboon serum  
The experiments were repeated by using TFPI (+/+) PAECs to clarify the effect of TFPI 
transgenic pigs. The TF activity was significantly attenuated in TFPI (+/+) PAECs, 
induced by fresh naïve baboon serum, fresh or HI sensitized baboon serum (Figure 
4.2-5A). The inhibitory effect of TFPI (+/+) PAECs disappeared when anti-TFPI Ab was 
present (Figure 4.2-5A). However, RNA expression of TF on TFPI (+/+) PAECs still 
remained the same as those on WT PAECs after incubation with baboon serum (Figure 
4.2-5B).  
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Figure 4.2-5 TFPI (+/+) PAECs inhibits TF activity on PAECs induced by naïve and 
sensitized baboon serum.   
A. TFPI (+/+) PAECs were incubated with medium (control) and 10% of naïve or 
sensitized BS for 8 hours. TF activity was determined by the recalcified clotting assay. 
(White bar: WT PAECs, grey bar: TPFI (+/+) PAECs, filled white bar: TPFI (+/+) 
PAECs were pretreated with anti-TFPI Ab (50µg/ml) for 30 minutes before the 
clotting assay) ( #: p<0.01, untreated vs treated with anti-TFPI Ab). 
B. TF expression was determined by quantitative PCR (*p<0.05, #p<0.01 vs control). 
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4.3 DISCUSSION      
The expression of TF has been increasingly recognized during AHXR and linked to the 
activation of PAECs. Most previous studies have stressed that activation on EC as the 
trigger to thrombotic graft failure is dependent on the involvement of complement in 
response to XNA (Bach et al., 1994; Yang and Sykes, 2007). Abs alone failed to activate 
PAECs without the involvement of complement (Lin et al., 2008). Therefore, pigs 
expressing hCRP such as CD46 or CD55 are expected to protect ECs activation by 
regulating the complement activation. Our results showed that MCP (+/+) PAECs are 
resistant to the activation of naïve baboon serum even in the presence of complement. 
Previous report demonstrated that PAECs from GT-KO pigs additionally transgenic for 
CD46 were more resistant to primate complement-dependent cytotoxicity than those from 
GT-KO pigs (Hara et al., 2008).  
 
The generation of GT-KO pigs removed the main XNA and initially was expected to 
attenuate the humoral immune response. However, anti-nonGal Abs emerges as an 
additional hurdle for successful xenotransplantation.  For instance, anti-nonGal Abs were 
indeed elevated in DAF transgenic pig-to-primate heart or kidney xenotransplantation 
models (Chen et al., 2005; Chen et al., 2006). Moreover, recent study showed that after 
transplanting kidneys from GT-KO pigs to baboons, most of the baboons died from 
severe AHXR. Circulating induced Abs to nonGal antigens were markedly elevated at 
rejection, which mediated strong complement-dependent cytotoxicity against GT-KO 
porcine target cells (Chen et al., 2005). 
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In this study, we found that HI sensitized baboon serum with high titre of anti-nonGal 
Abs activated PAECs to express TF activity. In addition, PAECs that expressed MCP, 
which were resistant to the activation by naïve baboon serum with low titre of anti-
nonGal Abs, was activated to express TF as well. We therefore concluded that anti-
nonGal Abs activated a procoagulant phenotype on PAECs independent of the presence 
of complement. This activation was mainly derived from the effect of IgG Abs since it 
remained unchanged when IgM Abs were eliminated by the addition of DTT. These 
results confirmed the previous report that the elicited Abs, potentially to nonGal epitopes, 
induced PAECs activation and TF expression (Gollackner et al., 2004). Similarly, Saethre 
el al. reported human serum up-regulated E selectin expression on Gal depleted PAECs, 
which was largely complement-independent (Saethre et al., 2007).  Importantly, anti-
nonGal Abs do not only exist in sensitized baboons after transplantation; natural anti-
nonGal Abs in over 10% of the population also had the same effect as elicited Abs if the 
titres were high enough. This implies that the organs from GT-KO pigs that express 
hCRP are not sufficient to overcome coagulopathy completely in pig-to-primate 
xenotransplantation model. This observation is mirrored in in vivo animal studies. Organ 
transplantation into nonhuman primates  from GT-KO pigs that express a hCRP has been 
reported. Although the graft remained functioning, most recipients developed a 
consumptive coagulopathy, presumably associated with the procoagulant change on 
PAECs (Kelishadi et al., 2008).   
 
In this study, we also demonstrated that primate serum up-regulated expression of mRNA 
of TF in PAECs by quantitative RT PCR. This can account, at least in part, for the 
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increased TF activity of PAECs after activation by primate serum seen by the functional 
recalcified clotting assay (Bach, 2006). Another explanation may be through the 
decryption of TF on the cell membrane. Procoagulant activity of TF is suppressed in the 
form of encryption in the cell surface. This function takes effect through decryption after 
stimulation and was evidenced to be associated with the function of TF on the surface of 
many cells (Rehemtulla et al., 1991; Bach, 2006; Pendurthi et al., 2007). Whether primate 
serum activates PAECs to express TF activity by decryption requires further investigation.  
 
Since anti-nonGal Abs play an important role in ECs activation, interest has been directed 
to identify the anti-nonGal Abs. However, it is a formidable task to identify significant 
nonGal antigens, and then proceed to genetically modify pigs by deleting the gene for the 
antigen. A more reasonable approach is to generate GT-KO pigs that express anti-
coagulant genes, such as TFPI, to prevent the development of a procoagulant phenotype 
when PAECs are activated, regardless of the presence of nonGal antigens. In a rodent 
model, Chen et al. reported that hearts from transgenic mice expressing membrane-
tethered fusion proteins based on TFPI were transplanted into rats. In contrast to control 
non-transgenic mouse hearts, which were all rejected within 3 days, 100% of the organs 
from transgenic mice were completely resistant to humoral rejection and survived for 
more than 100 days when T-cell-mediated rejection was inhibited (Chen et al., 2004b). 
These data showed TFPI (+/+) PAECs can functionally inhibit TF activity on PAECs, 
activated by fresh naïve and HI sensitized baboon serum even though mRNA of TF is 
increased after stimulation. These promising results suggest transgenic anticoaglulant 
genes, such as TFPI, will be beneficial to overcome thrombotic problems occurring in 
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AHXR. Actually, our group is waiting for the breeding of GT-KO pigs that express TFPI 
and MCP.  
 
Anti-nonGal IgG activated PAECs to express TF activity through complement-
independent pathway. This implies that GT-KO pigs expressing hCRP alone may be 
insufficient to prevent the development of procoagulant changes in PAECs.  The effect 
can be inhibited by PAECs expressing TFPI. These results offer further approaches to 
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CHAPTER 5  
MOLECUALR INTERACTION BETWEEN 
PRIMATE PLATELETS AND PORCINE 
ENDOTHELIAL CELLS 
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5.1 INTRODUCTION  
The activation and sequestration of platelets, leading to vascular thrombosis, is associated 
with HAR and AHXR. Once activated during xenograft rejection, platelets trigger the 
coagulation cascade in several ways. Activated platelets release endogenous coagulation 
factors to facilitate the coagulation cascade. The release of ADP and the receptor of 
GPIIbIIIa exert a positive feedback pathway to boost the activation of platelets. P-selectin 
on platelets or ECs upregulates the expression of TF on monocytes and mediates the 
binding of ECs with monocytes and neutrophils. The effect of P-selectin on monocytes in 
an area of vascular injury may be a component of a mechanism that initiates thrombosis 
(Celi et al., 1994). Moreover, platelet membrane aminophospholipids are exposed as a 
result of microparticle formation, which enhances the binding and assembly of the 
prothrombinase complex. 
 
The mechanisms of platelet activation during xenotransplantation still remain elusive. As 
previously mentioned, these processes could be a consequence of the immunological 
response to the xenograft and viewed as a component of rejection. For example, the 
expression of vWF on activated ECs in response to XNA and complement and/or the 
generation of thrombin due to the activation of ECs are a potent stimulator of platelets. 
Furthermore, vascular injury could be further exacerbated by the associated loss of 
vascular ATPDase/CD39. The insufficient elimination of adenosine nucleotides may 
exacerbate vascular inflammation. Platelets binding to the C1q component of activated  
complement  can result in the activation of the platelet fibrinogen receptor (GPIIbIIIa) 
with consequent expression of P-selectin, and development of procoagulant activity on 
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platelets(Peerschke et al., 1993). Nevertheless, non-immunologic factors, such as 
molecular incompatibilities, could also contribute to the activation of platelets and 
exacerbation of coagulation.  Such molecular barriers could persist even if the xenogeneic 
immune response was completely inhibited. 
  
The results in Chapter 3 showed that PAECs could activate platelets and monocytes to 
express TF activity without the requirement of Abs and complement and therefore 
independent of the humoral immune response. Understanding the interactions between 
these cells would be helpful in developing systemic pharmacological approaches, such as 
anti-platelet modalities. In this chapter, we attempt to dissect the molecular interactions 
between primate platelets and PAECs.  
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5.2 RESULTS  
 
5.2.1 Apoptosis of PAECs induced by platelets is associated with the quantity of 
platelets 
In order to dissect the interaction between PAECs and platelets, the in vitro culture 
system was optimized to avoid the apoptosis of PAECs during incubation without the 
presence of primate (baboon or human) plasma shown in Chapter 3 (Figure 3.2-5). The 
extent of apoptosis of PAECs induced by incubation with platelets was associated with 
the concentration of platelets (Figure 5.2-1A). In this culture system, when PAECs were 
incubated with 5×106/ml of (baboon or human) platelets, which was reduced from the 
initial 5×107/ml of platelets, the apoptosis of PAECs decreased to the same percentage as 
when PAECs were incubated with medium. At the same time, PAECs activated platelets 
to express human rather than porcine TF since anti-human TF Ab inhibited TF activity 
expressed on platelets (Figure 5.2-1). Furthermore, the recalcified clotting assay in FVII-
deficient plasma was optimized to be carried out with 3×106/ml of platelets instead of 
1×107/ml to minimize the demand of platelets. In the following study of this chapter, all 
in vitro experiments were at least 3 times performed by using human and baboon platelets 
respectively.   
  






















































Figure 5.2-1 PAECs activate primate platelets to express primate TF. 
A. PAECs were isolated after co-incubation with various concentrations of platelets 
(incubated with medium as control). Apoptosis was measured by flow cytometry, 
double-staining with annexin V-FTIC and PI-PE defined apoptotic cells. The 
percentages of cells double-positive for TF and annexin V or single-positive for 
annexin V are indicated. (*, P<0.05)  
B. Platelets were incubated with PAECs in the absence of human plasma for 8 hours. 
Platelets were harvested for analysis of TF activity by the recalcified clotting assay. 
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Platelets were incubated with anti-human TF Ab for 30 minutes prior to clotting assay 
(grey bar). (*, P<0.05 compared to not pretreated with anti-TF Ab) 
 
5.2.2 PAECs activates primate PBMCs and platelets to express TF activity 
independent of cell-to-cell contact 
To investigate the molecular interaction between PAECs and platelets, a transwell culture 
system (pore size: 0.4µm) was used to determine the importance of cell contact. The 
experiments were carried out with the two cell types in a transwell system. The PAECs 
were cultured and adhesive in the lower chamber in all cases, and platelets or PBMCs 
were incubated in the upper chamber. In this system, PAECs still activated PBMCs and 
















































Figure 5.2-2 PAECs activate PBMCs and platelets to express TF independent of cell-
to-cell contact.  
PBMCs (A) and platelets (B) were incubated with medium (control) and PAECs in an 
ordinary and a transwell culture system for 8 hours. TF activity on PBMCs and platelets 
was determined by recalcified clotting assay (grey: transwell system). 
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5.2.3 TF activity on platelets and PBMCs is unrelated to the presence of the Gal 
antigen and the expression of a complement regulator 
The generation of pigs that do not express Gal antigen or express a hCRP has overcome 
the challenge of HAR. To investigate lack of the expression of the Gal antigen or 
expression of a hCRP (CD46), PBMCs or platelets were incubated with PAECs from GT-
KO pigs or MCP transgenic pigs. GT-KO PAECs and MCP (+/+) PAECs also activated 
primate PBMCs or platelets to express TF activity, identical to WT PAECs (Figure 5.2-4 
A,B).  
 














































Figure 5.2-3 GT-KO or MCP (+/+) PAECs activate primate PBMCs and platelets to 
express TF activity identical to WT PAECs.  
A. PBMCs were incubated with medium (control) and various PAECs. TF activity on      
 PBMC was determined by recalcified clotting assay. 
B. The same experiments were carried out with platelets. 
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5.2.4 The molecular interaction between primate platelets and PAECs is associated 
with the receptor of GPIbα on platelets 
We went on to analyze the molecular interaction between primate platelets and PAECs by 
an Ab-neutralizing method. The receptors and ligands possibly involved in this 
interaction were tested, including anti-SLA I, ant-SLA-II, anti-CD106, anti-CD42b, anti-
P-selectin (clone 1.2B6), anti-CD154, and anti-PAR1 and anti-vWF Abs. TF activity on 
platelets was inhibited by the anti-CD42b (GPIbα), anti- vWF and anti- P selectin Abs, 
but not by other Abs (Figure 5.2-4).     
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Figure 5.2-4 The interactions between PAECs and primate platelets are inhibited by 
anti-GPIb, vWF and P-selectin antibodies.  
Both of primate platelets and PAECs were pre-treated with different neutralizing Abs for 
30 minutes at 4ºC. Thereafter, platelets were incubated with PAECs for 8 hours and 
harvested for analysis by the recalcified clotting assay (A, B, C, and D) and quantitative 
RT-PCR (E).  (*, P<0.005 compared to incubation with PAECs in each experiment. The 
cocnetration of isotope control was the same as the highest one of the Abs). 
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5.2.5 TF expression on primate platelets induced by PAECs is associated with the 
interaction between platelet P-selectin and PSGL-1  
Since both platelets and ECs express P-selectin, we further investigated that the inhibitory 
site of anti-P-selectin Ab locates in primate platelets or PAECs. The experiments were 
performed by either washing or not washing Abs 3 times before primate platelets were 
added. Moreover, 3 clones of anti-P-selectin Abs were used and the reactivity to human 
or pig was determined by flowcytometry analysis (Figure 5.2-5 ) 1) Clone 1.2B6 is 
reactive to human P-selectin and human and pig E-selectin (Goda et al., 1999; Keelan et 
al., 1994; Wellicome et al., 1990). 2) Clone AK4 is reactive to human P-selectin. 3) Clone 
12C5 is reactive to human and pig P-selectin (Stocker et al., 2000). TF expression on 
platelets after incubation with PAECs was inhibited by anti-human P-selectin Abs (1.2B6 
and AK4) and anti-human and pig P-selectin Ab (12C5). After washing prior to 
incubation with primate platelets, anti-vWF Ab still inhibited TF expression on primate 
platelets but 3 clones of anti-P-selectin Abs did not (Figure 5.2-6). Moreover, anti-PSGL-
1 Ab (CD162), the receptor of P-selectin on platelets, also prevented TF expression on 
platelets (Figure 5.2-7). These results indicated that anti-vWF Ab functioned on the 
surface of PAECs; in contrast, anti-P-selectin Abs acted on platelets.  
 
 











Figure 5.2-5  The reactivity to human or pig of 3 clones of anti-P-selectin antibodies. 
 Platelets and PAECs were activated by thrombin (1 U/ml) for 30 minutes or TNF-α 
(10ng/ml) for 2 hours respectively. The phenotypes were determined by flowcytometry. 
The clones of 1.2B6 and 12C5 are cross-reactive to both pig and primate but clone AK4 
only is reactive to primate (Grey: isotype control).  
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Figure 5.2-6 Anti-vWF and anti-P-selectin antibodies act on different sites to inhibit 
TF expression on primate platelets after incubation with PAECs. 
PAECs were pre-treated with anti-vWF Ab or anti-P-selectin for 30 minutes; then primate 
platelets were co-incubated for another 8 hours. TF expression on platelets was analyzed 
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by recalcified clotting assay. (Filled: Abs were washed out before platelets were co-
incubated, * P<0.05 compared to without neutralizing Ab).  
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Figure 5.2-7 TF expression on platelets is inhibited by anti-PSGL-1 antibody.  
Primate platelets and PAECs were pre-treated with different neutralizing Abs for 30 minutes at 4ºC. 
TF activity on platelets was analysed by recalcified clotting assay. (*, P<0.005 compared to 
incubation with PAECs. The cocnetration of isotope control was the same as the highest 
one of the Ab). 
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5.3 DISCUSSION  
The origin of TF on platelets still remains controversial. Stimulated human platelets seem 
to express preformed TF which derives from the α-granules and the open canalicular 
system of resting platelets and is exposed on the cell surface after platelet activation 
(Muller et al., 2003).  Platelet-leucocyte interactions seem necessary for its expression and 
TF is transferred to platelets by monocyte-derived microparticles (Morrissey, 2001). 
Recently, platelets have been demonstrated to synthesize de novo proteins via the splicing 
process of constitutive pre-mRNA (Denis et al., 2005). TF is also constitutively 
synthesized as well. This process is controlled by CLK1, and interruption of CLK1 
signaling prevents TF from accumulating in activated platelets.  In the present study, the 
TF activity of platelets after incubation with PAECs was dose-dependently inhibited by 
anti-CLK1 Ab. This result suggests TF expression on activated platelets is de novo 
synthesized and via splicing of pre-mRNA.  
 
The interesting question regarding the interactions between primate platelets and PAECs 
is to determine the molecular interactions, by which we can target and develop new 
pharmaceutical approaches. In this present study, the data show that platelets were 
activated by PAECs to express TF activity without the requirement of cell-to-cell contact. 
The Ab neutralizing study indicates TF expression on platelets is inhibited by anti-GPIb 
(CD42b) and anti-vWF Abs. Although both PAECs and primate platelets express vWF, 
TF expression on platelets was not only inhibited in the presence of anti-vWF Ab, but 
also when Ab was washed out before platelets were co-incubated. Therefore, these 
observations suggest that PAECs secrete soluble vWF to activate primate platelets to 
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express TF via GPIb receptor on platelets. This result is compatible with other group’s 
previous findings (Schulte Am Esch et al., 2005). Their studies indicated that purified 
porcine vWF spontaneously aggregates human platelets, which was inhibited by anti-
human GPIb Ab. By transiently  transfecting recombinant human or porcine vWF A1-
domains in COS-7 cells, Schulte et al. reported that platelets were activated through 
aberrant interaction between the O-glycosylated A1 domain and platelet glycoprotein Ib 
in the absence of shear stress .  This effect probably has in vivo significance, particularly 
after lung xenotransplantation.  For instance, in an ex vivo pig-to-human pulmonary 
xenotransplantation model (Kim et al., 2008), pre-treatment of porcine lungs with 
desmopressin, which can reduce the content of vWF, attenuated platelet activation and 
systemic intravascular coagulation. Furthermore, if pulmonary intravascular macrophages 
were depleted in the recipients, baboons survived longer after receiving a lung transplant 
from a vWF-deficient pig than from a CD46-transgenic pig (Cantu et al., 2007). 
 
P-selectin is an adhesion molecule expressed on activated platelets and ECs and plays an 
important role in atherosclerosis. P-selectin also circulates in plasma in a soluble form 
(sP-selectin), which induces procoagulant microparticle formation. However, that the 
thrombotic effects of P-selectin result from platelets or ECs still remains controversial.  
When monitored by intravital microscopy, platelets, like leucocytes, were found to roll on 
activated endothelium in the mesenteric venules and this process is supported by either 
vWF or P-selectin, dependent on shear rate (Andre et al., 2000; Frenette et al., 
1995) .Furthermore,  GPIb was shown to be the counter-receptor not only for vWF, but 
for P-selectin (Andre et al., 2000). Therefore, P-selectin on ECs is inferred to play a more 
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important role in thrombosis. On the other hand, P-selectin of platelets was found to 
stabilize platelet aggregates (Merten and Thiagarajan, 2000).  In an in vivo model of 
transluminal endothelial injury of the femoral artery, the platelet layer in P-selectin-
deficient mice was less compact and did not recruit leucocytes as it did in WT mice 
(Smyth et al., 2001). These results indicated that P-selectin might support platelet–platelet 
or platelet-leucocyte interactions to promote fibrin deposition. 
  
In this present study, TF expression on primate platelets induced by PAECs is inhibited 
by anti-human P-selectin Abs (clone 1.2B6, AK4 and 12C5). Contrary to anti-vWF Ab, 
which still inhibit TF expression on platelets when Abs are washed out before platelets 
are co-incubated,   anti-porcine P-selectin Abs (clone 12C5) fail to inhibit TF expression 
on platelets. TF expression on platelets was inhibited by Ab for the receptor of P-selectin, 
PSGL-1. Hence, we conclude that this inhibitory effect of TF expression on platelets is 
attributed to P-selectin on platelet, but not on PAEC. Interestingly, in this system, the 
platelets were essential free of leucocytes, evidenced by flow cytometry, so the effect of 
anti-P-selectin Ab is irrelevant to the existence of leucocytes. Furthermore, a recent study 
indicates that platelets also have the receptor of P-selectin ligand (PSGL-1) (Frenette et 
al., 2000), the present study suggested that like ADP or GPIIbIIIa, expression of P-
selectin on platelets may create positive feedback to activate platelets further via P-
selectin and PSGL-1 pathway and contribute the activity of TF. This finding provides an 
alternative to inhibit TF expression in xenotransplantation by pharmaceutical inhibition of 
P-selectin ligand. On the other hand, what triggers resting PAECs to secrete vWF 
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emerges as an important entity to prevent TF expression on platelets and remains under 
investigation.  
 
The generation of pigs that lack the expression of Gal epitopes reduces the immunologic 
response and increase interest in investigating the prevention of coagulopathy in 
xenotransplantation. During laminar flow, monocyte adhesion to PAECs is dependent on 
Gal-mediated monocyte activation (Peterson et al., 2005). Recruitment of human 
monocytes to non-activated xenogeneic ECs requires both α4 and β2 integrins on the 
monocyte; binding of Gal to monocytes results in rapid activation of β2 integrins. 
Therefore, PAECs from GT-KO pigs would be expected to have a beneficial effect in 
preventing TF expression on monocytes. However, in the present study, PAECs that lack 
Gal epitopes did not have a protective effect and still activated primate PBMCs to express 
TF. Similarly, primate platelets were activated to express TF activity by GT-KO PAECS 
as well.  
 
PBMCs are activated to express TF activity by PAECs through soluble molecule(s) in the 
present study. This finding is compatible with the early experiments.   IL-1 mediated the 
increases of TF-associated procoagulant activity on ECs cocultured with allogeneic 
monocytes and stimulated with lipopolysaccharide and/or IgG (Wharram et al., 1991). 
Nevertheless, adhesion interactions in the induction of TF on monocytes which involves 
ligation with both E-selectin (Lo et al., 1995) and P-selectin (Celi et al., 1994) have been 
recognized. 
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Genetic deletion of Gal epitopes and the expression of a hCRP failed to attenuate the TF 
expression on platelets, which are activated by PAECs. These results were confirmed by 
in vivo studies (see Chapter 7). Platelet aggregation occurred early after 
xenotransplantation when the liver or kidney grafts from GT-KO/ MCP (+/+) pigs were 
transplanted into baboons. The severity of platelet aggregation was similar to those using 
WT organs. The identification of molecular interaction between primate platelets and 
PAECs as mentioned above is mandatory to facilitate further genetic manipulation or 
pharmaceutical approach.    
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CHAPTER 6  
PHARMACEUTICAL APPROACHES TO 
PREVENT CONSUMPTIVE 
COAGULOPATHY IN ACUTE HUMORAL 
XENOGRAFT REJECTION: STATINS AND 
ANTI-PLATELET AGENTS 
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6.1 INTRODUCTION 
In addition to genetic modification of organ donors, pharmaceutical intervention has been 
attempted to solve the procoagulant challenge. Interest is focused on platelet aggregation 
and thrombi because they may contribute to graft dysfunction by decreasing local blood 
flow. Activated platelets also promote leucocyte infiltration and localized 
vasoconstriction by the expression of P-selectin and secretion of ADP and serotonin. The 
history of using nonselective anti-platelet agents with differing mechanisms of action in 
experimental xenotransplantation dates back to as early as 1974 by Shons and Najarian, 
but with limited success(Shons and Najarian, 1974). In the final decade of the last century, 
therapy with more specific agents, such as platelet-activating factor (PAF) antagonists 
and anti-P-selectin Abs resulted in modest prolongation of survival of discordant 
xenografts (Coughlan et al., 1993; Makowka et al., 1990). 
 
Statins are widely used to lower blood cholesterol levels and prevent ischemic heart 
disease. Clinical trials have demonstrated statins have pleiotropic effects, such as anti-
inflammatory, anticoagulant, and immunomodulatory effects (Mason, 2003). 
Observations in heart transplantation patients, together with several in vitro studies that 
have determined a potential mechanism for their immunosuppressive effect, have 
provided a principle for the use of statins in patients with organ allografts (Kobashigawa, 
2004).  
 
Although the exact reasons of xenograft failure in pig-to-primate xenotransplantation 
remain a mystery, depending on such factors as the type of source-pig (wild-type or 
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genetically modified), the immunosuppressive regimen, and the nature of the transplanted 
organ or cells, they are indispensably associated with the interactions of the immune 
response, inflammation and coagulation.  The pleiotropic effects of statins provide a 
promising opportunity to attenuate all the detrimental reactions at the same time. My 
colleagues have demonstrated that statin reduced in a dose-dependent manner the 
upregulation of swine leucocyte antigen (SLA) class II on PAECs, induced by IFN-γ 
(Ezzelarab and Cooper, 2007). Using mixed lymphocyte reaction, atorvastatin reduced 
the human PBMC proliferative response to unstimulated or stimulated PAECs from WT 
or GT-KO pigs (Ezzelarab et al., 2008). In this chapter, we investigated the anticoagulant 
and anti-inflammatory benefits of atorvastatin in xenotransplantation. 
 
The constant feature of platelet microthrombi in AHXR also convinced us to re-examine 
the application of a novel anti-platelet drug as an adjuvant therapeutic agent. The integrin 
GPIIbIIIa is crucial in the formation of platelet aggregates and potentiates adhesion to 
subendothelial matrices via fibrin(ogen), vWF, and vitronectin. Eptifibatide, a synthetic 
cyclic heptapeptide, is a selective high-affinity inhibitor of the platelet glycoprotein 
IIb/IIIa receptor. It has been demonstrated to be capable of inhibiting platelet-dependent 
prothrombinase activity in the acute coronary syndrome (Li et al., 2000). Another 
GPIIbIIIa antagonist, tirofiban, also inhibits thrombin generation during cardiopulmonary 
bypass in baboons (Rao et al., 1999).  ADP, which is secreted from ECs or activated 
platelets provides autocrine and paracrine function to augment the recruitment of platelets 
via the P2 receptor on platelets. More evidence showed that the ADP pathway is 
associated with the initiation and generation of thrombin. In P2Y1-deficient mice, the 
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ability of collagen to enhance the generation of thrombin was impaired (Leon et al., 2004). 
Herein, we also investigated the beneficial effect of anti-platelet agents on TF expression 
on primate platelets after incubation with PAECs. 
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6.2 RESULTS  
 
6.2.1 Atorvastatin inhibits TF activity on PAECs induced by anti-nonGal antibodies 
To investigate the anticoagulant effect of atorvastatin in xenotransplantation, WT PAECs 
were pre-treated with atorvastatin with or without mevalonic acid for 16 hours before 
being co-incubated with HI-sensitized baboon serum. Atorvastatin inhibited about 50% of 
TF activity of activated WT PAECs by the recalcified clotting assay. This effect was 
associated with the presence of atorvastation since the addition of mevalonic acid, which 
is a downstream product of HMG-CoA reductase, reversed the inhibitory effect of 
atorvastatin (Figure 6.2-1A). Consistently, atorvastatin also inhibited the RNA expression 
of TF in WT PAEC after incubation with HI-sensitized BS by quantitative RT-PCR 
(Figure 6.2-1B).   
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Figure 6.2-1 Atorvastatin inhibited TF expression on PAECs activated by heat-
inactivated sensitized baboon serum. 
PAECs were incubated with various concentrations of atorvastatin without or with 
mevolonic acid (MVA) (10µM) for 16 hours. Atorvastatin was reconstituted in dimethyl 
sulfoxide (DMSO).  Thereafter PAECs were activated by 10% HI-sensitized baboon 
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serum (SBS) for another 8 hours.  TF activity on the surface of PAECs was determined 
by the recalcified clotting assays (A) and quantitative RT-PCR (B).  
 
6.2.2 Atorvastatin inhibits TF expression on platelets activated by PAECs 
We went on to investigate the ability of atorvastatin to inhibit the activation of platelets 
after incubation with PAECs. Platelets were pre-incubated with atorvastatin (5µM) for 30 
minutes and 16 hours with/without mevalonic acid (10µM), and then were co-cultured 
with PAECs for 8 hours.  TF activity was analyzed by the recalcified clotting assay. TF 
activity on platelets was inhibited after incubation with PAECs when platelets or PAECs 
were pretreated with atorvastatin both for 30 minutes and 16 hours (Figure 6.2-2A). 
However, the inhibitory effect disappeared if atorvastatin was washed out before primate 
platelets were added. The effect of atorvastatin was also negative when simultaneously 
incubated with mevalonic acid. The experiments were repeated with 2 hour incubation 
when PAECs was preteated with atorvastatin for 16 hours for analysis of TF mRNA. The 
expression of mRNA was identical to the finding of the recalcified clotting assay (Figure 
6.2-2B).   
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Figure 6.2-2 Atorvastatin inhibits TF expression on platelets after incubated with 
PAECs. 
Primate platelets and PAECs were pre-treated with atorvastatin (ATS) for 16 hours or 30 
minutes in the presence or absence of mevalolic acid (MVA) for 30min. (filled: 
atorvastatin was washed out before platelets were co-cultured.) Thereafter, platelets were 
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incubated with PAECs and harvested for analysis by the recalcified clotting assay (A) and 
quantitative RT-PCR (B).  (*, p<0.05 compared to incubation with PAECs alone).  
 
6.2.3 PAECs induce the aggregation of platelets and PBMCs in vitro  
The number of CD42a-positive cells of PBMCs was significantly higher 8 hours after 
incubation with PAECs than after incubation with HAECs or medium alone. After 
incubation for 24 hours, the percentage of CD42a-positive cells was slightly higher after 
incubation with HAECs than with medium, but was significantly increased after 
incubation with PAECs. Therefore, in further experiments to examine the effects of drugs, 


























Figure 6.2-3 CD42a-positive PBMCs after incubation with platelets and PAECs. 
PBMCs and platelets from the same donors were incubated with medium (control, grey 
line), HAEC (dash line), PAECs (solid line) for variable periods. CD42a positive PBMCs 
were determined as PBMC-platelet aggregates by flowcytometry. (*, P<0.05; **, P< 0.01 
compared to incubation with medium) 
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6.2.4 Atorvastatin inhibits primate platelet-PBMC aggregates after incubation with 
PAECs  
The WT PAECs were pretreated with atorvastatin (5µM) for 30 minutes or 16 hours; 
without washing, primate platelets and PBMCs were added for another 8 hours co-
incubation. Only after pretreated for 16 hours, atorvastatin inhibited platelet and PBMC 
aggregation after incubation with PAECs. This effect was not seen after pretreatment with 
atorvastatin for only 30 minutes or when mevalonic acid was added at the same time 
(Figure 6.2-4). This demonstrated that the inhibitory effect resulted from the presence of 






















Figure 6.2-4 Atorvastatin inhibits primate platelet-PBMC aggregation after 
incubated with PAECs 
Primate platelets and PBMCs were pre-treated with atorvastatin (ATS) for 16 hours or 30 
minutes in the presence or absence of mevalolic acid (MVA) for 30min. Thereafter, 
platelets and PBMCs were incubated with PAECs for 8 hours and harvested for analysis 
  186 
of platelet-PBMC aggregation by flowcytometry.  (*, p<0.05 compared to incubation with 
PAECs alone). 
 
6.2.5 Anti-CD41 antibody inhibited TF expression on platelets  
We further investigated the role of membrane GPIIbIIIa (CD41) in this system, which 
contributes to the stabilization of thrombus after platelets are activated. The experiments 
were repeated with the addition of anti-human CD41 neutralizing Abs. Anti-CD41 Abs 
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Figure 6.2-5 TF expression on platelets after incubated with PAECs is inhibited by 
anti-CD41 antibody. 
Primate platelets and PAECs were pre-treated with a series of concentrations of 
neutralizing Abs for 30 minutes at 4ºC. Thereafter, platelets were incubated with PAECs 
and harvested for analysis by the recalcified clotting assay (A) and quantitative RT-PCR 
(B). (*: p<0.05 compared to incubation with PAECs) 
 
6.2.6 Eptifibatide and clopidogrel inhibit TF expression on platelets activated by 
PAECs 
We went on to examine the effect of the anti-platelet agents, eptifibatide (2µg/ml) and 
clopidogrel (0.1µg/ml) on TF expression of platelets. The platelets were pretreated with a 
series of concentrations of eptifibatide and clopidogrel for 30min. Then they were co-
incubated with PAECs without washing. The platelets were harvested for analysis of TF 
activity.  Both eptifibatide and clopidogrel inhibited TF expression on platelets after 
  188 
incubation with PAECs by recalcified clotting assay and quantitative RT-PCR (Figure 
6.2-6). 











































Figure 6.2-6 TF expression on platelets after incubation with PAECs is inhibited by 
anti-platelet agents.  
Primate platelets and PAECs were pre-treated with eptifibatide and clopidogrel for 30 
minutes at 4ºC. Thereafter, platelets were incubated with PAECs for analysis by the 
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recalcified clotting assay (A) and quantitative RT-PCR (B). (*: p<0.05 compared to 
incubation with PAECs) 
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6.3 DISCUSSION    
 Sensitized baboon serum with high titres of anti-nonGal Abs activated PAECs to express 
TF activity on PAECs independent of complement activation. This may contribute to the 
coagulopathy after transplantation of organs from GT-KO pigs with hCRP genes into 
baboons. By preventing TF expression, statins have anticoagulant effects. These results 
demonstrated that atorvastatin does not only inhibit functional TF activity but also the 
expression of TF mRNA when PAECs were activated with anti-nonGal Abs.  
 
Although statin inhibits TF expression in some types of cells, the reports of its inhibitory 
effect on TF expression on platelets are scarce. We also demonstrated atorvastatin 
inhibited TF expression on platelets after incubation with PAECs. Since statin remained 
in the incubation system, the benefit could result from two possibilities. First, statin 
indirectly prevents TF expression on platelets by interfering with interactions between 
PAECs and primate platelets. This indirect action is less likely because it needs a longer 
incubation time for atorvastatin to take effect on PAECs. The time course showed that 
atorvastatin needed 16 hours incubation to inhibit TF up regulation on PAECs after 
incubation with baboon serum and to prevent lymphocyte proliferation after incubation 
with PAECs (Ezzelarab et al., 2008). In the present study, pretreatment with atorvastatin 
for 30 minutes was long enough to inhibit TF expression on platelets. The effect seems to 
result from the direct inhibition on platelets themselves. Recently, a novel NO-releasing 
statin inhibited the aggregation of platelets induced by collagen (Rossiello et al., 2005). 
Moreover, it also inhibited collagen-induced platelet P-selectin expression in whole blood 
as well as platelet adhesion to collagen-coated cover slips under flow conditions. This 
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finding is compatible with the result that TF activity of platelets after incubation with 
PAECs is inhibited when neutralizing anti-human P-selectin Ab is present (Figure 5.2-6).  
 
My previous study showed that PAECs activated platelets and PBMCs to express TF 
activity. Similarly, PAECs also promoted the aggregation of platelets and leucocytes 
independent of XNA and complement. The aggregates play a central role in inducing a 
further burst of cellular interaction. This suggests that further manipulation of the immune 
response will not solve the coagulopathy completely. This study also showed atorvastatin 
was able to inhibit this aggregative reaction induced after incubation with PAECs. 
 
Extensive evidence has shown that the anti-platelet agents, such as eptifibatide and 
clopidogrel, inhibit platelet aggregation in arterial ischemia or xenotransplantation models. 
Therefore, they confer anti-thrombotic activity (Herault et al., 1999; Savi et al., 1994)). 
However, a recent study indicated that the effect of clopidogrel is beyond inhibiting 
platelet aggregation and reduces circulating TF-procoagulant levels in patients with 
peripheral arterial disease (Rao et al., 2006). At the same time, plasma P-selectin level 
also declined. The mechanism of clopidogrel inhibiting circulating TF is attributed to 
downregulation of expression of P-selectin on platelets, inhibition of platelet-leucocyte 
aggregation and subsequently reduction of TF expression on leucocytes (Evangelista et al., 
2005; Leon et al., 2004). Similarly, GPIIb/IIIa antagonists (tirofiban and eptifibatide) 
inhibit platelet aggregation and improve heart performance in an ex-vivo perfusion model 
by preventing intravascular thrombosis (Brandl et al., 2007) although direct evidence of 
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inhibition of TF-induced coagulation activation in humans with low-grade endotoxemia 
was not detected (Derhaschnig et al., 2003).   
  
In the present study, we clearly showed eptifibatide and clopidogrel prevented TF activity 
on platelets after incubation with PAECs, which was unrelated to the involvement of 
leucocytes. These effects result from the inhibition of the autocrine feedback pathway of 
ADP and GPIIbIIIa on platelets. These observations suggest eptifibatide and clopidogrel 
exert anti-thrombotic activity through a distinctive mechanism.  
 
Anti-platelet agents have been used to try to resolve coagulopathy during 
xenotransplantation. In a hCD46-transgenic pig-to-baboon cardiac transplantation model, 
warfarin and low-molecular weight heparin had no impact on graft survival, with no 
reduction in fibrin deposition and platelet thrombi. The combination of aspirin and 
clopidogrel neither prolonged graft survival nor inhibited thrombosis in cardiac 
xenografts (Schirmer et al., 2004). However, clopidogrel exerted some systemic 
inhibition on platelet aggregation. A high dosage of a GPIIbIIIa antagonist prolonged 
graft survival and decreased platelet aggregation in a rodent model (Candinas et al., 1996). 
Eptifibatide also effectively prevented platelet aggregation in a primate study (Alwayn et 
al., 2000).  Although the impact on graft survival has hitherto been disappointing, these 
observations suggest that anti-platelet agents are sufficient to prevent platelet aggregation 
in the circulation. Moreover, the effect of anti-platelet agents depends on the intensity of 
stimulation (Ciborowski et al., 2008), which implies that would inhibit the generation of 
thrombin and activation of ECs will allow these drugs to be more beneficial.  
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Although the mechanisms of statins in xenotransplantation are not well-defined, its 
pleiotropic effects offer the opportunity to tackle the complex problems seen in xenograft 
rejection. It will be noteworthy to examine the effect of atorvastatin in animal studies. 
The failure of anti-platelet drugs in previous studies may be because the immune response 
was not well-controlled at that time and the intensity was so strong to overshadow the 
benefit of anti-platelet agents. With progress in the genetic modification of pig donors, 
the immune response has been significantly alleviated by deleting antigen and expressing 
a hCRP. This pharmaceutical systemic approach may offer additional survival benefits by 
preventing platelet activation.  
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CHAPTER 7 
THE ROLE OF RECIPIENT TF IN PIG-TO-
BABOON ORGAN 
XENOTRANPLANTATION  
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7.1 INTRODUCTION  
Intravascular thrombosis or systemic coagulation disorders during AHXR has been a 
major hurdle to successful xenotransplantation. In the model of heterotopic cardiac 
xenotransplantation from GT-KO swine to baboons, all grafts failed due to the intragraft 
exhibition of TM with platelet-rich fibrin thrombi in the microvasculature, myocardial 
ischemia and necrosis, and focal interstitial hemorrhage. The development of TF was in 
parallel with the activation of ECs in the grafts, presented with the upregulation of TF and 
vWF and down-regulation of CD39. This implied TM is initiated by the expression of TF. 
Previous studies stressed that the origin of TF derived from the activation of ECs in 
response to XNA and complement activation. However, the coagulation disorder 
developed not only in the graft, several studies reported AHXR is associated with 
systemic coagulation cascade activation, consistent with non-physiologic DIC. 
 
This systemic consumptive disorder is compatible with DIC seen in varying underlying 
conditions, including endotoxemia, cardiac surgery and cancer (Langer F, 2008; 
Mackman N, 2007). The pathophysiology of DIC may be associated with liberation of 
constitutive TF into the blood and inducible TF expression on leucocytes and other cells. 
 
On the other hand, a similar situation occurs in islet transplantation by the method of 
portal vein infusion. Many transplanted islets are lost immediately after transplantation 
due to the instant blood-mediated inflammatory reaction (IBMIR). IBMIR is associated 
with the presence of TF expression on endocrine cells and subsequent contact with portal 
blood (Bennet et al., 2000, Johansson et al., 2005).  This observation was demonstrated in 
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an animal study. Berman et.al showed that interference with TF by using a humanized 
anti-TF Ab leads to prolonged and/or enhanced islet allograft function in an a non-human 
primate model (Berman et al., 2007). 
 
Furthermore, as demonstrated in Chapter 3, my in vitro study showed that PAECs can 
activate platelets and PBMCs to express TF activity. Therefore, we hypothesized that TF 
activity was not only expressed on ECs of the grafts. Recipient platelets and leucocytes 
also expressed TF activity in the systemic circulation. This presentation may be 
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7.2 RESULTS  
 
7.2.1 Survival of animals   
The survivals of all animal were describled in detail (Table 7.2-1). The liver allograft 
recipient survived for 28 days uneventfully and was euthanized by protocol. In the HAR 
group, the baboon receiving a kidney graft developed acute renal failure (rapidly 
increased serum creatinine level) within 24 hours; at euthanasia, the graft revealed gross 
thrombotic changes compatible with features of typical HAR. The liver xenograft was 
euthanized 5 hours after implantation, although the graft was not grossly thrombotic.  
 
In non-HAR kidney group, HAR was averted by either using the grafts from genetically-
modified pigs or by administering immunosuppressants to inhibit the humoral response. 
All 6 recipients of kidney grafts with immunosuppressants died of consumptive 
coagulopathy and survived 6 to 15 days (median: 10 days). The other two recipients 
without immunosuppressant died of transplant-unrelated causes 2 and 4 days after 
transplantation (iatrogenic fluid overload was suspected in B4407). At that time, 
hematological and biochemical profiles were within normal limits and there was no 
significant abnormal finding at autopsy. Platelet counts and serum creatinine levels in 
baboon recipients of pig kidney grafts were presented in Figure 7.2-1 . 
 
After liver xenotransplantation, coagulation disorder presented by severe 
thrombocytopenia and thrombin formation developed in all recipients of liver grafts 
within 5 hours. The platelet counts dropped from 270±60 to 50±20 ×103/µL and D-dimer 
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increased from 1.25 ±0.55 to 2.12±0.06 µg/ml with fibrin formation in the graft (Figure 
7.2-2). The four recipients of liver grafts died of consumptive coagulopathy and survived 
4 to 7 days (median: 6 days).  At euthanasia, the liver grafts grossly presented scattered 
thrombotic patches (necrotic part) in the liver surface.   
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 Group  Baboon 
No  
Organ  Type of pig Immunosuppressant  Survival (Days)  Cause of death  
Allograft  I (n=1) B3408 Liver  Baboon liver  FK based  28  Protocol euthanized  
HAR II (n=2) B3807 Kidney  WT  None <1 Graft necrosis  
B16907 Liver WT None <1 Protocol euthanized 
Non HAR III (n=8) 
 
B4407 Kidney GT-KO, MCP None 2 CC 
B4507 Kidney GT-KO, MCP None 4 Unknown  
B3907 Kidney  WT MMF based  6 Unknown  
B18308 Kidney GT-KO MMF based 7 CC 
B4207 Kidney GT-KO, MCP MMF based  10 CC 
B4307 Kidney GT-KO, MCP MMF based 10 CC 
B16307 Kidney GT-KO, MCP MMF based 10 CC 
B16007 Kidney GT-KO, MCP MMF based 15 CC 
IV (n=4) B3108 Liver  GT-KO  FK based  6 CC 
B3208  Liver  GT-KO, MCP FK based  4 CC 
B7708 Liver  GT-KO, MCP FK based 7 CC 
B7808 Liver  GT-KO, MCP FK based 6 CC 
 
Table 7.2-1 The graft types, immunosuppressants, survival time and causes of death in each group of animal studies. 
CC: consumptive coagulopathy 
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1 0 1 1 0 1 2 3 4
B3807 (HAR) B4407 
B3907 (CC) B18308 (CC)


































































































































Figure 7.2-1 Platelet counts and serum creatinine levels in baboon recipients of pig 
kidney grafts. 
B3807 developed HAR with a rapidly increasing creatinine level, but its platelet count 
remained unchanged.  Two baboons (B4407, B4507) died of causes unrelated to AHXR 
or CC.  The remaining 6 baboons developed features of CC (defined in the text). Arrows 
with numbers indicate the day on which CC was initially documented.  (The day of 
kidney Tx was designated as day 0).  HAR = hyperacute rejection; CC = consumptive 
coagulopathy, black line: platelet counts, gray line: serum creatinine level.  
 





































Figure 7.2-2  Consumptive coagulopathy developed immediately after liver 
xenotransplantation. 
A. Platelet counts decreased (left panel) and the level of D-dimer increased immediately 
after reperfusion (n=4). 
B. Immunofluorescence staining shows fibrin (green) deposits in the vessels of the graft. 
a. pre-perfusion, b. HAR in B16907, c. 2 hours after reperfusion in B7708 d. 7 days 
after transplantation in B7708. (Red: CD31 for ECs, arrow: fibrin deposition)  
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7.2.2 Platelets and PBMCs express baboon TF activity after xenograft 
transplantation  
Platelets and PBMC were isolated from the baboon’s peripheral blood before and after 
transplantation. TF activity on platelets and PBMC was determined by the recalcified 
clotting assays, quantitative RT-PCR and flowcytometry. Before operation, no TF activity 
was detected on platelets and PBMCs.  In the liver allograft group (n=1), TF activity was 
not detected on platelets and PBMCs throughout follow-up for 28 days after 
transplantation. 
7.2.2.1 HAR group  
TF activity was expressed on platelets and PBMCs after liver or kidney pig xenograft 
transplantation by the recalcified clotting assay. TF activity on platelets and PBMCs 
could be inhibited by anti-human TF Ab, so these TF activities were derived from baboon, 
but not porcine origin (Figure 7.2-3A).   The mRNA levels of TF were also higher in 
platelets and PBMCs after transplantation compared to pre-transplantation by quantitative 
RT-PCR (Figure 7.2-3B). Furthermore, the surface expression of TF was confirmed by 
flowcytometry (Figure 7.2-3C).  
 
Since TF acitivity on PBMCs was much larger than on platelets, evidenced by RT-PCR 
and clotting assay, TF expression was expressed on the surface of PBMCs, not from 
platelets, which aggregated with PBMCs.    











































































































                
Figure 7.2-3 Platelets and PBMCs expressed TF after xenotransplantation.  
A,B,C. The expression and activity of platelets and PBMCs were determined by the 
recalcified clotting assay in all recipients (A), quantitative RT-PCR in HAR baboon 
(B3807) (B) and flowcytometry in all baboons (representative by B4207) (C) before 
and after xenotransplantation. (Black bar: the cells were pre-incubated with anti-
human TF Ab for 30 minutes at 4ºC.) 
D. The time when PBMCs or platelets to express TF activity was measured by the 
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7.2.2.2 Non-HAR kidney group  
TF activity on platelets was detected on postoperative day (POD) 1 or 2 (n=8) by 
recalcified clotting assay and flowcytometry. In contrast, TF activity on PBMCs was not 
documented until POD 4 or 7 (median =5, n=6) exclusive of two baboons that died of 
unknown causes.  
7.2.2.3 Non-HAR liver group  
Similar to the HAR group, TF activity and expression on platelets and PBMCs were 
detected 5 hours after xenotransplantation. The days on which TF was expressed on 
platelets or PBMCs were summarized in Figure 7.2-3D.  
 
7.2.3 The expression of TF on PBMCs is associated with the onset of consumptive 
coagulopathy  
We further examined 7 baboons that developed consumptive coagulopathy to address the 
relationship between the expression of TF on PBMCs and the onset of consumptive 
coagulopathy.  TF activity on PBMCs was usually expressed 2 days before the onset of 
consumptive coagulopathy in 5 baboons of kidney graft group. The onset of consumptive 
coagulopathy was highly correlated with TF expression on PBMCs (Figure 7.2-4).  
 









0 1 2 3 4 5 6 7 8






















Figure 7.2-4 TF expression on PBMCs predicted the onset of consumptive 
coagulopathy. 
The relationship between TF activity on PBMCs. TF activity was detected by recalcified 
clotting assay. The onset of thrombocytopenia was defined as 30% drop in platelets 
counts (POD: post-operative day). 
 
7.2.4 Grafts remain functioning during consumptive coagulopathy 
When the recipient developed consumptive coagulopathy, the function of the graft usually 
remained functioning. On the date of onset of consumptive coagulopathy, the serum 
creatinine levels of baboons who died of consumptive coagulopathy was 0.8±0.4mg% 
(n=6) with adequate urine output. The serum creatinine level then increased, presumably 
due to bleeding and hypovolemia until they required euthanasia.  
 Similarly, the peak aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
levels were on POD1 after liver xenograft transplantation and gradually returned to a 
level of about 1000(U/L). At the same time, the level of total bilirubin still remained 
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about 2.3±1.4 mg% (n=4) until the day on which the baboons were critical. The 
parameters of the hematological and liver function tests are presented in Figure 7.2-5. 
Furthermore, the gross color of the kidney xenografts was pink unlike typical HAR, 
which were thrombotic and necrotic. Most of liver xenografts also showed non –necrotic 
appearance with patchy ischemic change.  The coagulation function and complement 



















































Figure 7.2-5 Hematological and liver function tests in baboons who underwent liver 
transplantation.  
The data were presented as mean of values in 4 baboons. PLT: Platelet, Hb: hemoglobin, 
T-bili: total bilirubin. BT: blood transfusion. 
   
7.2.5 Recipient TF expression in the grafts    
Baboon TF activity was assessed by quantitative RT-PCR. The kidney tissues were 
collected at the time of euthanasia; the liver tissues were collected at the time of 
reperfusion and euthanasia. Baboon TF mRNA was detected in the porcine grafts, which 
was even higher than in native baboon kidneys when normalized by β actin (Figure 
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7.2-6A). Baboon TF mRNA was detected in porcine liver xenografts and was 
significantly higher in tissues with thrombotic change compared to immediately after 
reperfusion but was not higher in the tissues without thrombotic change (Figure 7.2-6B). 
 
Immunofluorescence staining revealed that large numbers of platelets deposited in the 
thrombi and expressed TF when AHXR developed. At the same time, PBMCs also 
expressed TF on the surface (Figure 7.2-6C).  
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Figure 7.2-6 Baboon TF is expressed in porcine xenografts during consumptive 
coagulopathy.  
A. TF expression in the graft was determined by quantitative RT-PCR with baboon (white) 
and pig (gray) TF primers. During consumptive coagulopathy (CC), baboon but not 
porcine TF was significantly expressed in the kidney grafts (* p<0.05 compared to 
naïve baboon, CC: baboons who developed CC).  
 B. TF expression in the graft was determined by quantitative RT-PCR with porcine TF 
primer after liver xenotransplantation. At euthanasia, liver xenografts grossly 
appeared heterogenous demaceration including   thrombotic change (necrotic) and 
normal tissue (non-necrotic) (* p<0.05 compared to naïve baboon, CC: baboons who 
developed CC). 
C. Platelets (a,b) (CD41,red) plugged in the thrombi of graft and PBMCs (c,d) (CD45, red) 
expressed TF (green) after AHXR (a,c: pre-transplant, b,d: post-transplant in B18307).   
 
7.2.6 Recipient TF expression in the extra-graft organs  
Since circulating inflammatory cells (platelets and PBMCs) expressed TF after 
xenotransplantation, they would induce systemic TF expression not only in the grafts but 
also in the other organs. The native livers from the recipients for liver xenotransplantation 
and hearts from the donors for baboon liver allotransplantation were used as pre-operative 
control. After kidney xenotransplantation, the level of TF mRNA in the livers and hearts 
were significantly increased by quantitative RT-PCR (Figure 7.2-7).  
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Figure 7.2-7 TF expression is increased in extra-graft organs after kidney 
xenotransplantation. 
TF expression in the hearts (left) and liver (right) was measured by quantitative RT-PCR. 
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7.2.7  Histopathology in AHXR-kidney group 
The histopathological findings at the time of graft excision or recipient euthanasia of 5 
kidney graft recipients that developed HAR and consumptive coagulopathy are 
summarized in Table 7.2-2.   Of importance, 3 of 5 showed the features of minimal 
humoral response (Figure 7.2-8). There was only minimal IgM deposition without the 
deposition of IgG, C3, or infiltration of macrophages, B and T cells. Deposition of fibrin 
and platelets was indeed found.  
 
 IgM IgG Fibrin C3 MФ PMN B cells T cells 
B3807 (++) (++) (+++) (+++) (++) (++) (+) (+) 
B3907 (+) (+) (+++) (--) (--) (--) (--) (--) 
B18308 (+) (+) (+++) (--) (--) (--) (--) (--) 
B4207 (+/-) (--) (++) (--) (--) (--) (--) (--) 
B4307 (+/-) (--) (++) (--) (--) (--) (--) (--) 
B16307 (+/-) (--) (+++) (--) (--) (--) (--) (--) 
B16007 (++) (++) (+++) (++) (--) (--) (--) (--) 
 
Table 7.2-2 Histopathology of kidney grafts that developed hyperacute rejection and 
consumptive coagulopathy 
(--) none; (+/-): minimal; (+) mild; (++) moderate; (+++) severe.  
MΦ = macrophages; PMN = polymorphonuclear neutrophils 
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Figure 7.2-8 Histological features of kidney grafts showing minimal immune 
response. 
Deposition of IgM (brown in A), IgG (brown in B), C3 (brown in C) and fibrin (red in D) 
is presented in HAR kidney graft (B3807). In contrast, the grafts in AHXR group (B4207) 
are minimal deposition of IgM (E), negative for IgG (F), C3 (G), macrophage (CD68) (I), 
B cell (CD20) (J), CD4 (K) and CD8 (L) T lymphocytes with some fibrin deposition (H).     
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7.2.8 Clinical course in AHXR-kidney group 
In summary, the clinical courses of kidney graft recipients that developed consumptive 
coagulopathy, were associated with the expression of TF on recipient platelets and 
PBMCs (Figure 7.2-9A). TF expression on platelets occurred early after the kidney grafts 
were implanted. Thereafter, serum fibrinogens started to drop after TF expression on 
platelets but before on PBMCs. Then PBMCs were activated to express TF activity later 
after transplantation, which was associated with the development of consumptive 
coagulopathy that presented with severe thrombocytopenia, anemia, and exhaustion of 
coagulation factors. Meanwhile, the renal grafts were still functioning with adequate 
urination. In B16007 baboon, the serum creatinine remained in normal range for another 






















































































Figure 7.2-9  Clinical manifestations of kidney graft recipients who developed 
consumptive coagulopathy.   
A. The data are presented as mean, representative of 4 kidney graft recipients (B4207, 
B4307, B16307, and B18308). (Cr:creatinine, POD: post-operative day) 
B. The data is representative of B16007 with the longest survival.  
 
 
7.2.9 Platelet and leucocyte aggregates during consumptive coagulopathy    
We went on to investigate the interaction between platelets and leucocytes during the 
development of consumptive coagulopathy. Leucocytes and platelets were isolated from 
0.5 ml of peripheral blood with 5 ml ACK (ammonia chloride-potassium) buffer 
(Appendix 8) for lysis of red blood cells. The phenotype of leucocytes was confirmed by 
the marker of CD45 and dot plot in flowcytometry. Aggregation between platelets and 
leucocyte was determined by the percentage of CD42a expression in the leucocyte gate. 
The platelet and granulocyte, monocyte and lymphocyte aggregates were significantly 
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greater on post-operative day 2, on which TF was expressed on platelets after kidney 
xenotransplantation, compared to before transplantation. (Figure 7.2-10A,B). In addition, 
the platelet-leucocyte aggregation dramatically increased when leucocytes expressed TF 
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Figure 7.2-10  Platelet and leucocyte aggregation increases after kidney 
xenotransplantation. 
Leucocytes were isolated from baboon’s peripheral blood before and after kidney 
xenotransplantation. Thereafter, leucocytes were stained by CD42a as platelets marker. 
The phenotype of leucocytes was confirmed by the expression of CD45. Granulocytes, 
monocytes and lymphocytes were determined by dot plot of flowcytometry. CD45 and 
CD42a double positive cells were designated as platelet-leucocyte aggregates.   
A. In dot plot, there are 3 distinctive groups of cells including lymphocytes (L), 
monocytes (M) and granulocytes (G).   
B. The percentages of CD42a-positive cells  in the granulocyte gate (upper), the 
monocyte gate (middle) and the lymphocyte gate (lower) in pre-operative, POD2 (TF 
expression on platelets) and POD6 (the onset of thrombocytopenia). The percentage 
of cells in the quadrant is indicated. (POD: post-operative day)   
  220 
C. The clinical courses of platelet-leucocyte aggregation, TF expression and consumptive 
coagulopathy in B18308.   
 
7.2.10  Consumptive coagulopathy develops before the activation of PAECs after 
liver xenotransplantation  
To further investigate what cells (donor PAECs or recipient inflammatory cells) are the 
first to initiate the coagulation disorder in xenotransplantation, we examined the 
activation of PAECs by the expression of VCAM-1 (CD106) and TF. By 2 hours after 
reperfusion when consumptive coagulopathy was developing, the expression of VCAM-1 
and TF on PAECs of grafts was still minimal by immunofluorecence staining (Figure 
7.2-11).  




B                            
 
 
Figure 7.2-11 The expression of VCAM-1 and TF in liver xenografts is minimal 2 
hours after reperfusion. 
A.  The expression of VCAM-1 (red).   
B. The expression of TF (green) and CD31(red).  
   a: pre-perfusion, b: HAR in B16907, c: 2 hours after reperfusion in B7708; d: 7 days 
after transplantation in B7708.   
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7.3  DISCUSSION  
Although the survival of xenografts has been extended after the transplantation of hearts 
from GT-KO pigs into baboons, the results of kidney and liver transplantation are 
discouraging. In the present study, the median survivals of kidney and liver grafts from 
GT-KO/MCP pigs were 10 and 6 days respectively. Interestingly, they shared the 
common complication and causes of mortality despite the different time of onset. Most of 
them died of consumptive coagulopathy associated with severe thrombocytopenia, 
anemia and bleeding tendency although the organs still remained functional, evidenced by 
adequate urine amount and biochemistry parameters.  Importantly, the histology of the 
grafts showed only a minimal immune response without deposition of IgG and infiltration 
of macrophages, B and T cells (unlike that seen in typical AHXR) in kidney xenograft 
model. These observations suggest that the development of  consumptive coagulopathy 
was dissociated from the presence of an immune response.  
 
Extensive evidence demonstrated that coagulopathy in AHXR is initiated by the 
expression of TF. However, the sources of TF still remain elusive. One concept is that 
ECs of the graft, activated by the binding of XNA and/or activation by complement, 
express TF activity and trigger coagulation. The activated ECs and the generated 
thrombin subsequently activate platelets, leucocytes and other inflammatory cells to form 
a vicious circle. The other concept is that inflammatory cells, especially platelets and 
mononuclear cells, activated by soluble inflammatory mediators or other immune 
response-independent pathway in the grafts might stimulate coagulation via expression of 
TF (Blakely et al., 1994).  In the present study, we first demonstrated that baboon 
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platelets and PBMCs were activated to express TF activity in pig-to-primate 
xenotransplantation. TF activity on platelets was expressed early after the xenografts were 
implanted and the timing was unaffected by graft types and immunosuppressive regimens. 
  
Whether it is donor ECs or recipient platelets that are activated earlier to express TF after 
xenotransplantation still required investigation. We believe that TF expression on 
platelets precedes the activation of PAECs in the graft and results from humoral immune 
response-independent factors because of the following reasons. 1. Co-stimulatory 
blockade, anti-CD154 monoclonal Ab was routinely used in this series. The recipients 
were not sensitized immediately after transplantation. 2. Complement activity was 
regulated by the expression of MCP or eliminated by the administration of CVF 
(evidenced by the CH50 test). 3. Importantly, the histology of the grafts showed minimal 
evidence of an immune response, without deposition of IgG and infiltration of 
macrophages, B and T cells in kidney xenograft model. In addition, the kidney and liver 
xenografts were still functioning after the development of consumptive coagulopathy. For 
example, in the baboon (B16007) , the serum creatinine levels remained in normal range 
for 7 days after the onset of severe thrombocytopenia. 
 
More importantly, in liver xenograft model, platelets were activated to express TF before 
graft ECs expressed VCAM-1 and TF. These results indicate that activation of on 
platelets may not be associated with humoral rejection but initiated by other non-
immunological factors, such as molecular incompatibilities. These findings are 
compatible with my previous in vitro finding that PAECs can activate primate platelets 
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and monocytes to express TF independent of a humoral immune response (Chapter 3). 
These observations were also found in other models by transplanting guinea pig cardiac 
xenografts into rats treated (Blakely et al., 1994). In HAR model, activation of donor ECs 
developed immediately after transplantation. In contrast, in a delayed humoral rejection 
model by the use of CVF, the expression of TF on the recipient infiltrating mononuclear 
cells was detected 12 hr after transplantation, which was prior to the expression of TF on 
donor ECs.  
 
In addition to platelets, baboon PBMCs were activated to express TF activity. The onset 
of consumptive coagulopathy was associated with the development of TF expression on 
PBMCs in the non-HAR kidney and liver graft models. This coincidence is similar to the 
development of DIC in sepsis, in which inducible TF is predominantly expressed by 
monocytes and macrophages, as was shown in patients with severe bacterial infection 
(Schouten et al., 2008). Furthermore, a recent study indicated that leucocytes (dendritic 
cells) are the primary source and determine the extent of disseminated coagulation 
activation during exacerbation of inflammation (Niessen et al., 2008).   
 
The critical question is what factors activate PBMCs to express TF activity and induce 
consumptive coagulopathy. There are three possible explanations. First, it has been 
previously thought that activated PAECs activated PBMCs to express TF via P- and E- 
selectin or thrombin, which is formed during PAEC activation and is a potent stimulator 
of PBMCs. This process is mainly involved with the immune response and subsequent 
activation of PAECs. Second, like platelets, PBMCs are activated to express TF through a 
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humoral response-independent pathway. Circulating PBMCs are directly activated when 
in contact with graft ECs in the graft.  Third, TF expression of PBMCs is induced by 
activated platelets, which have been activated at earlier-time points after 
xenotransplantation. Activated platelets stimulate leucocytes to express TF activity via 
interaction between P-selectin and PSGL-1. Importantly, in the present study, we 
demonstrated that serum level of fibrinogen started to drop, concomitant with TF 
expression on recipient platelets. Moreover, platelets and PBMCs progressively 
aggregated until consumptive coagulopathy developed. In addition, the histopathological 
findings of grafts showed a minimal immune response with functioning. These 
observations suggest that TF expression on platelets plays an initial role to trigger the 
formation of thrombin. As a result, activated platelets and thrombin are potent stimulators 
to activate PBMCs or ECs, contributing to the development of consumptive coagulopathy 
during AHRX.   
 
In addition, we found that thrombocytopenia developed earlier than the activation of ECs 
(by the expression of TF, VCAM-1) in the grafts of liver xenotransplantation. The 
rapidity of development of thrombocytopenia was not alleviated by the transplantation of 
a liver from a pig that did not express Gal but did express a hCRP, nor by 
immunosuppressive therapy. These results suggest it is recipient TF that initiates the 
consumptive coagulopathy that develops after organ xenotransplantation and results from 
a non-immune response.  
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Although this study elucidates that TF expression on platelets and PBMCs is associated 
with the development of consumptive coagulopathy, whether TF expression on pro-
inflammatory cells in the circulation plays an exclusive role in this process requires 
further investigations. An in vivo study of using the infusion of anti-TF Ab or of pigs 
transgenic for TFPI to block the activity of TF would allow investigation of whether the 
survival of grafts will be extended or the development of consumptive coagulopathy will 
be attenuated.  
 
In summary, we are the first to clarify that TF expression on recipient platelets and 
PBMCs plays a pivotal role in the induction of coagulopathy in pig-to-baboon 
xenotransplantation. This TF expression and activity seem to be unrelated to the immune 
response since they occur even when the response of XNA and activity of complement 
are minimal.  This suggests that other non-immunological factors should be investigated. 
Hopefully, this can be manipulated either by genetic modification or systemic medication 
therapy. Moreover, further manipulation of the immune response, with the risk of 
infection and other complications, will not completely solve the challenge of xenograft 
coagulopathy.  
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CHAPTER 8 
GENERAL DISCUSSION AND FUTURE 
DIRECTIONS  
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Extensive evidence has supported the view that thrombosis leads to the loss of both whole 
organ and islet xenografts in the pig-to-primate model. The mechanisms of the 
coagulation disorders seen in xenotransplantation are involved with complex 
immunologic and non-immunological reactions. Many novel approaches have not been 
entirely successful to lead to a significant advance. An understanding of the mechanisms 
is mandatory for further manipulation, which would allow xenotransplantation to advance 
to clinical trials.  
  
8.1 IMMUNOLOGIC MECHANISMS CONTRIBUTING TO 
COAGULOPATHY DURING XENOTRANSPLANTATION  
The interactions between porcine ECs, platelets, and other blood cells are at the nexus of 
a complex network that contributes to coagulation during AHXR (Figure 8.1-1). 
According to the standard paradigm, the process is initiated by the immune response 
against the graft, such that activation of PAECs caused by XNA with complement leads 
to expression of donor TF that triggers the coagulation cascade. In the present study, we 
demonstrated that natural or elicited anti-nonGal Abs induce PAECs to express TF 
activity via a complement-independent pathway.   Together with loss of anticoagulant 
regulators, such as TFPI, thrombomodulin, or heparan sulfate, or through fgl-2 
conversion, thrombin and fibrin are deposited in the graft.  This detrimental process 
intrinsically involves potent platelet activation, which results from activated ECs or 
consequent formation of thrombin/fibrin.  At the same time, the loss of ecto -NTPDases 
and failure of enzymatic degradation of ADP aggravates the activation and aggregation of 
platelets. 
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Figure 8.1-1 Diagrammatic representation of procoagulant change of PAECs and 
activation of platelets in pig-to-primate organ xenotransplantation.  
(1) PAECs are activated by XNA with/without the involvement of complement to express 
TF and trigger the formation of thrombin, which is a potent activator of platelets. Fgl-2 
cleaves prothrombin to generate the formation of thrombin. (2) The ligands (vWF or 
others) on the PAECs activate platelet receptors probably independent of the humoral 
immune response. (3) PAECs lose expression of CD39 and CD73, and are unable to 
adequately catalyse ADP to adenosine, and therefore contribute to the activation of 
platelets. 
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8.2 NON-IMMUNOLOGIC MECHANISMS CONTRIBUTING TO 
COAGULOPATHY DURING XENOTRANSPLANTATION  
However, immune-independent factors, such as molecular incompatibilities, also 
contribute to the activation of platelets directly. The effect of porcine vWF has been 
mentioned already. In the present study, primate platelets and monocytes were activated 
to express TF when incubated with PAECs without the involvement of Abs and 
complement. This kind of activation of platelets and monocytes was confirmed in animal 
models of pig-to-primate kidney or liver xenotransplantation. In the kidney 
xenotransplantation model, baboon platelets and monocytes were activated to express TF 
after organ transplantation from GT-KO with/without MCP (+/+) pigs. The expression of 
TF on platelets and leucocytes was associated with the development of a consumptive 
coagulopathy. Importantly, although most recipients developed a severe systemic 
consumptive coagulopathy, the grafts were still functioning. Histological examination of 
grafts showed minimal features of immune injury, rather than AHXR or TM. In the liver 
xenotransplantation model, we clarified that the aggregation of platelets and formation of 
fibrin occurred even when the expression of VCAM-1 and TF on ECs in the grafts 
remained minimal. This dissociation suggests that this activation of platelets seems is 
unrelated immune response and is compatible with my in vitro findings.  Once activated, 
platelets contain many pro-inflammatory mediators and surface ligands that are expressed 
and/or released. Importantly, activated platelets bind avidly to leucocytes, forming 
platelet-leucocyte complexes and inducing TF expression on leucocytes through P-
selectin and its ligand on the leucocyte. TF expression on PBMCs continues to the 
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development of a systemic consumptive coagulopathy, which leads to irreversible graft 
failure.   
 
8.3 INTERACTIONS BETWEEN PRIMATE PLATELETS AND PAECS  
Since TF expression on platelets predicts the development of consumptive coagulopathy, 
the molecular interactions between primate platelets and PAECs will play a crucial role in 
resolving challenge. Compatible with other groups’ studies, we demonstrated that PAECs 
activated primate platelets through the interaction of vWF on ECs and GPIb on platelets.  
Interestingly, this activation of platelets is dependent of the interaction of P-selectin and 
PSLG-1 on platelets. Additionally, platelet TF expression was inhibited by anti-platelet 
agents, such as eptifibatide and clopidogrel.  
 
8.4 CONCLUSIONS 
The present study demonstrated that TF expression on recipient platelets and PBMCs 
plays an essential role in consumptive coagulopathy. The effects result from non-
immunological factors and lead to systemic complications. In contrast to the previous 
concepts, further manipulation of immune system and genetic modification of donor 
organs may not be sufficient to overcome this problem. Multiple modalities addressing 
different aspects of the problem are likely to be necessary for further advances.  
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8.5 FUTURE STUDIES TOWARDS TO SUCCESSFUL 
XENOTRANSPLANTATION   
The resolution of this coagulation disorder is critical to allow xenotransplantation to 
advance sufficiently to clinical trials. Current studies have revealed that the coagulation 
disorder involves not only activation in the graft, which may be related to AHXR, but 
also systemic changes that take place in the circulation; these may be initiated by factors 
unrelated to the immune response. A clearer understanding of the molecular interactions 
between PAECS and primate platelets may provide new targets for intervention. Ideally, 
genetic modification of the organ-source pig offers the optimal approach to avoid adverse 
systemic effects. The generation of GT-KO pigs transgenic for one or more 
‘anticoagulant’ or ‘anti-thrombotic’ genes is likely to confer additional benefit. However, 
the documented systemic coagulation disorders suggest the necessity of an additional 
pharmacological approach. We therefore propose that, in addition to genetic modification 
of the organ-source pig, systemic medication will be necessary. Hopefully, this combined 
approach will enable the adverse effects of coagulation disorders to be overcome.  
 
8.5.1 Multiple –gene transgenic pigs  
Although the introduction of GT-KO pigs as a source of organs has provided a significant 
advance, many unresolved problems have stimulated the necessity for additional genetic 
modifications of the organ-source pig.  GT-KO pigs that express a hCRP and one or more 
‘anticogulant’ or ‘anti-thrombotic’ genes are anticipated to inhibit the generation of 
thrombosis and subsequent platelet activation. With new cloning techniques, transgenic 
mice for CD55/hTFPI/hTM/CTLA4-Ig/hCD39 have been attempted (Fisicaro et al., 
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2007). The same technology is expected to be successfully applied to generate pigs with 
multiple gene modifications and will enable these pigs to become available in a shorter 
period of time than through conventional breeding.     
 
8.5.2 Systemic pharmaceutical approach  
The present study has demonstrated that atorvastatin is able to inhibit TF expression on 
PAECs activated by either primate serum or by complement-independent anti-nonGal 
Abs. Atorvastatin was also capable of preventing TF expression and subsequent platelet-
leucocyte aggregates after pre-incubation with PAECs. Furthermore, lovastatin enhanced 
ecto-NAPDases activity and membrane expression in ECs (Ledoux et al., 2002), 
consequently inhibiting platelet aggregation through the action of adenosine, which plays 
an important role in platelet aggregation during AHXR. These promising in vitro results 
encourage us to investigate the effects of statins in pig-to-primate transplantation models. 
 
Anti-platelet agents have been extensively used clinically to prevent or reduce the 
development of cardiovascular disease(Chan et al., 2003; Gurbel et al., 2005). Anti-
platelet agents, such as antagonists of P2Y12 or GPIIbIIIa receptors, would be expected 
to prevent aggregation when platelets are activated during AHXR. We also demonstrated 
that eptifibatide and clopidogrel inhibit platelet TF expression after incubation with 
PAECs. The failure of anti-platelet drugs in previous studies may be because the immune 
response was not well-controlled at that time and its intensity was so strong to 
overshadow the benefit of anti-platelet agents. In the combination with genetic 
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modification of pig donors, thrombosis in the graft may be prevented by anti-platelet 
agents, which may offer additional benefits by the prevention of systemic coagulopathy. 
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APPENDIXES  
 
Appendix 1: Protocol for PAECs culture medium  
 The stocking solution was prepared after sterilization using a filter system (Corning) and 
Stored at 4°C.   
Reagent  Company  Volume  
RPMI 1640 Gibco  450ml 
Anti-mycotic liquid ( penicillin, 
streptomycin, amphotericin B) 
Invitrogen  5ml 
HEPES buffer solution  Gibco  5ml  
Fetal bovine serum (HI)   Sigma  50ml 
Endothelial cell growth supplement  BD Biosciences  
  
 
Appendix 2 Protocol for PAECs washing medium 
The stocking solution was prepared after sterilization using a filter system and stored at 
4°C.   
Reagent  Company  Volume  
RPMI 1640 Gibco  450ml 
Penicillin+ streptomycin Invitrogen  5ml 
HEPES buffer solution  Gibco  5ml  
Bovine serum (HI)   Sigma  50ml 
 
Appendix 3 Protocol for 0.05% collagenase solution 
Reagent  Company  Volume  
Collagenase B  Sigma  10mg 
PBS Invitrogen  20ml 
 
Appendix 4 protocol for PAECs storage medium  
The stocking solution was prepared after sterilization using a filter system and stored at 
4°C. 
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Reagent  Company  Volume  
RPMI 1640 Gibco  400ml 
Fetal bovine serum (HI)   Sigma  100ml 
 
Appendix 5: Protocol for MACS buffer  
The stocking solution was stored at 4°C 
Reagent  Company  Volume  
PBS  Invitrogen 500ml 
0.5 M EDTA Sigma  2 ml 
Fetal bovine serum Sigma  2.5 gm 
 
Appendix 6: Protocol for FACS solution  
The stocking solution was stored at 4°C 
Reagent  Company  Volume  
PBS Invitrogen 1000ml 
Sodium Azide  Sigma  1 gm 
Bovine serum albumin  Sigma  1gm 
 
Appendix 7: Protocol for Tri base solution (TBS, 25 mM) 
The stocking solution was autoclaved and stored at room temperature  
Reagent  Company  Volume 
Tris  Sigma  8 mg 
NaCl Sigma  3 gm 
KCl2 Sigma 0.2 mg 
Milli Q water   1000ml 
 
Appendix 8:  Protocol for ACK lysis buffer   
The stocking solution was steriled by 0.22µm filter and stored at room temperature.  
Reagent  Company  Volume  
NH4Cl Sigma 4.1 gm 
KHCO3 Sigma  0.5 gm 
EDTA-Na2 Sigma  18.6 gm 
Milli Q water  500ml  
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